essenti
medicin
satisfi
prioriti
healthcar
need
popul
essenti
medicin
polici
crucial
promot
health
achiev
sustain
develop
sustain
develop
goal
specifi
calli
mention
import
access
safe
eff
ectiv
qualiti
aff
ordabl
essenti
medicin
vaccin
central
compon
univers
health
coverag
uhc
sustain
develop
goal
emphasis
need
develop
medicin
address
persist
treatment
gap
recognit
import
essenti
medicin
new
nairobi
confer
ration
use
drug
govern
present
stakehold
propos
comprehens
set
essenti
medicin
polici
year
later
lancet
commiss
essenti
medicin
polici
conven
explor
question
progress
achiev
challeng
remain
address
lesson
learn
inform
futur
approach
essenti
medicin
polici
har
promot
uhc
contribut
global
sustain
develop
ment
agenda
report
address
question
intent
reposit
essenti
medicin
polici
global
develop
agenda
commiss
identifi
ed
fi
area
crucial
essenti
medicin
polici
pay
basket
essenti
medicin
make
essenti
medicin
aff
ordabl
assur
qualiti
safeti
medicin
promot
qualiti
use
medicin
develop
miss
essenti
medicin
commiss
locat
essenti
medicin
polici
within
context
current
global
debat
balanc
trade
intellectu
properti
polici
human
right
assur
health
secur
strengthen
peoplecentr
health
system
advanc
access
essenti
technolog
polici
area
particular
attent
paid
further
equiti
access
strengthen
relev
institut
creat
account
polici
area
commiss
made
action
recommend
therebi
reaffi
rming
essenti
medicin
polici
central
pillar
global
health
develop
agenda
global
quarter
health
expenditur
medicin
mani
countri
main
sourc
fi
nanc
medicin
direct
payment
individu
householdsthi
sourc
highli
inequit
ineffi
cient
reduct
key
target
uhc
furthermor
commiss
found
avail
data
pharmaceut
expenditur
mani
countri
lack
suffi
cient
detail
type
medicin
procur
sold
public
privat
sector
spend
degre
access
key
popul
subgroup
report
commiss
develop
new
modelbas
global
estim
total
fi
nanc
would
need
achiev
univers
access
basic
packag
essenti
medicin
lowincom
middleincom
countri
lmic
cost
model
develop
basi
diseas
preval
current
project
consumpt
medicin
intern
refer
price
use
two
consumpt
scenario
commiss
estim
us
billion
per
capita
requir
fi
nanc
basic
packag
essenti
medicin
dosag
form
lmic
yet
major
lowincom
countri
lic
middleincom
countri
spent
less
per
capita
pharmaceut
thu
commiss
confi
rmed
mani
peopl
worldwid
access
even
limit
basket
essenti
medicin
countri
adapt
commiss
model
nation
context
creat
local
relev
estim
benchmark
measur
perform
essenti
medicin
commiss
recom
men
dation
fi
nanc
essenti
medicin
govern
nation
health
system
must
provid
adequ
fi
nanc
ensur
inclus
essenti
medicin
benefi
packag
provid
public
sector
health
insur
scheme
govern
nation
health
system
must
implement
polici
reduc
amount
outofpocket
spend
medicin
intern
commun
must
fulfi
l
human
right
oblig
support
govern
lic
fi
nanc
basic
packag
essenti
medicin
unabl
domest
govern
nation
health
system
must
invest
capac
accur
track
expenditur
medicin
especi
essenti
medicin
public
privat
sector
disaggreg
prepaid
outofpocket
expenditur
among
import
key
popul
aff
ordabl
essenti
medicin
core
challeng
health
system
work
achiev
uhc
therefor
featur
promin
global
agenda
complex
problem
aff
ordabl
illustr
urgent
need
comprehens
polici
solut
singl
polici
alon
solv
problem
lack
medicin
price
inform
make
diffi
cult
consumersboth
individu
health
systemsto
make
inform
decis
purchas
medicin
scarciti
data
also
imped
assess
whether
individu
household
face
fi
nancial
barrier
make
outofpocket
payment
medicin
creat
barrier
crossnat
comparison
could
inform
set
benchmark
establish
appropri
eff
ectiv
price
polici
medicin
benefi
packag
guid
procur
reimburs
aff
ordabl
essenti
medicin
compil
packag
necessit
build
capac
nation
level
translat
fi
nding
evid
includ
health
technolog
assess
local
context
use
fi
nding
input
decis
make
includ
interven
infl
uenc
price
govern
purchas
medicin
expand
transpar
share
inform
increas
effi
cienci
avoid
duplic
eff
ort
commiss
recommend
make
essenti
medicin
aff
ordabl
govern
health
system
must
creat
maintain
inform
system
routin
monitor
data
aff
ordabl
essenti
medicin
well
price
avail
public
privat
sector
govern
must
implement
comprehens
set
polici
achiev
aff
ordabl
price
essenti
medicin
govern
health
system
must
develop
nation
capac
creat
medicin
benefi
packag
guid
procur
reimburs
aff
ordabl
essenti
medicin
govern
nation
health
system
pharmaceut
industri
must
promot
transpar
share
health
medicin
inform
despit
impress
progress
seriou
problem
medicin
qualiti
safeti
remain
particularli
lmic
problem
threaten
health
peopl
wast
resourc
qualiti
safeti
medicin
compromis
manufactur
whether
accid
intent
produc
substandard
product
suppli
chain
allow
unsaf
sometim
dishonest
practic
transport
deliveri
current
regulatori
capac
enforc
insuffi
cient
lmic
global
nation
regulatori
structur
therefor
requir
consider
urgent
reform
assur
qualiti
safeti
medicin
larg
donor
programm
aid
tuberculosi
malaria
treatment
help
advanc
strategi
qualiti
procur
whoun
prequalifi
cation
programm
clear
trend
toward
intern
regulatori
collabor
electron
commun
emerg
trend
leverag
ensur
continu
progress
full
array
essenti
medicin
countri
commiss
recommend
assur
qualiti
safeti
essenti
medicin
global
eff
ort
must
made
promot
harmonis
qualiti
assur
eff
ort
use
intern
standard
regulatori
dossier
cover
format
content
evolv
whoun
prequalifi
cation
programm
maintain
move
focu
new
essenti
medicin
payer
procur
agenc
must
adopt
good
procur
practic
incorpor
eff
ectiv
transpar
qualiti
assur
mechan
govern
must
redirect
activ
nation
regulatori
agenc
toward
add
valu
reduc
duplic
eff
ort
engag
system
independ
public
assess
perform
nmra
regulatori
agenc
must
encourag
involv
stakehold
gener
public
promot
qualiti
safeti
essenti
medicin
nation
govern
must
establish
concret
target
public
account
mechan
perform
nation
regulatori
author
problem
inappropri
use
aris
singl
root
causethu
address
requir
complex
coordin
intervent
com
mission
recommend
focu
strategi
enabl
collabor
among
patient
healthcar
provid
insur
suppli
chain
manag
other
includ
pharmaceut
industri
incentivis
support
qualiti
medicin
use
strong
institut
capac
gener
evid
implement
evidenceinform
polici
crucial
benefi
ts
eff
ort
includ
improv
clinic
public
health
econom
ethic
outcom
commiss
recommend
improv
use
essenti
medicin
govern
main
public
privat
payer
establish
independ
pharmaceut
analyt
unit
equival
focu
gener
infor
mation
action
promot
qualiti
use
conjunct
object
pharmaceut
analyt
unit
must
collabor
multipl
stakehold
relev
system
increas
engag
account
qualiti
use
medicin
interven
jointli
medicin
use
problem
engag
stakehold
group
led
data
produc
pharmaceut
analyt
unit
identifi
prioritis
local
medicin
use
problem
identifi
contribut
factor
across
system
develop
implement
sustain
longterm
multifacet
intervent
global
research
develop
r
polici
framework
need
develop
miss
essenti
medicin
make
access
present
system
develop
medicin
crisi
larg
fail
produc
much
need
product
address
health
need
million
peopl
worldwid
price
new
essenti
medicin
develop
sometim
high
even
highincom
countri
face
fi
nanc
problem
pharmaceut
compani
sharehold
typic
reluct
invest
market
medicin
patient
popul
repres
profi
tabl
market
two
problem
relat
disproportion
aff
ect
peopl
lmic
current
patentbas
innov
system
feasibl
achiev
maintain
uhc
serious
risk
sever
notforprofi
initi
often
collabor
pharmaceut
industri
compens
problem
current
system
repres
longterm
solut
new
global
polici
framework
need
drastic
adapt
current
model
reduc
relianc
market
exclus
main
driver
innov
govern
need
defi
ne
list
miss
essenti
medicin
provid
uhc
scheme
govern
nongovernment
organis
industri
need
make
necessari
r
fi
nanc
mechan
avail
identifi
ed
need
price
new
essenti
medicin
delink
develop
cost
product
made
wide
avail
aff
ordabl
nonexclus
licens
agreement
result
decreas
price
provid
fi
nancial
space
directli
fi
nanc
identifi
ed
prioriti
r
commiss
recommend
develop
miss
essenti
medicin
govern
must
take
intern
public
leadership
prioriti
set
essenti
r
due
regard
public
health
need
lmic
govern
must
lead
process
toward
global
research
develop
polici
framework
agreement
includ
new
fi
nanc
mechan
ensur
miss
essenti
medicin
develop
made
aff
ordabl
intern
commun
must
creat
gener
essenti
medicin
patent
pool
govern
nation
stakehold
must
develop
implement
comprehens
nation
action
plan
guarante
equit
access
new
essenti
medicin
pharmaceut
industri
must
better
align
r
prioriti
set
global
health
need
develop
access
strategi
make
medic
import
innov
avail
need
commiss
recommend
repres
compil
proven
promis
practic
improv
nation
polici
assur
access
qualityassur
aff
ordabl
essenti
medicin
qualiti
use
central
compon
uhc
transform
recommend
realiti
requir
commit
part
govern
polici
maker
implement
pharmaceut
industri
donor
healthcar
provid
citizen
patient
well
intern
agenc
civil
societi
organis
commit
creat
part
deliber
step
document
eff
ort
demonstr
progress
thu
commiss
propos
set
core
indic
measur
progress
implement
comprehens
essenti
medicin
polici
togeth
propos
indic
track
progress
countri
global
commun
eff
ort
advanc
fi
prioriti
area
essenti
medicin
polici
fi
nanc
aff
ordabl
qualiti
safeti
use
develop
new
medicin
commiss
intend
indic
serv
start
point
continu
develop
account
mecha
nism
incorpor
independ
review
correct
action
set
appropri
target
indic
crucial
compon
process
requir
activ
involv
relev
stakehold
nation
leadership
promot
nation
ownership
result
prioriti
essenti
medicin
central
promot
health
ensur
sustain
develop
sustain
develop
goal
sdg
adopt
septemb
member
state
un
recognis
equit
access
aff
ordabl
qualityassur
essenti
medicin
crucial
step
achiev
key
develop
target
panel
countri
agre
move
toward
univers
health
coverag
uhc
aim
uhc
ensur
peopl
obtain
health
servic
need
without
suff
ere
fi
nancial
hardship
pay
sdg
specifi
calli
mention
import
access
safe
eff
ectiv
qualiti
aff
ordabl
essenti
medicin
vaccin
throughout
report
phrase
access
essenti
medicin
denot
broad
defi
nition
also
use
sdg
encompass
qualiti
safeti
effi
caci
medicin
vaccin
well
avail
aff
ordabl
appropri
use
assur
access
essenti
medicin
crucial
move
toward
uhc
report
present
fi
nding
lancet
commiss
essenti
medicin
polici
examin
fi
core
challeng
everi
countri
must
address
secur
access
essenti
medicin
adequ
fi
nanc
pay
appropri
set
essenti
medicin
fi
rst
key
challeng
medicin
repres
larg
proport
household
expenditur
health
lowincom
middleincom
countri
lmic
accord
world
health
survey
total
expenditur
poorer
household
lmic
spent
medicin
far
higher
expend
poorer
household
highincom
countri
hic
statist
particularli
true
countri
inadequ
public
fi
nanc
health
care
result
high
outofpocket
expenditur
littl
evid
exist
indic
much
fi
nanc
would
requir
pay
essenti
medicin
focu
second
challeng
aff
ordabl
essenti
medicin
determin
compar
price
product
amount
buyer
aff
ord
high
price
medicin
often
associ
period
monopoli
patent
protect
howev
even
lowerpr
medicin
becom
unaff
ordabl
household
lowincom
countri
lic
aff
ordabl
becom
particularli
seriou
problem
medicin
need
chronic
condit
includ
noncommunic
diseas
ncd
aff
ordabl
medicin
becom
key
issu
govern
well
public
privat
payer
health
care
regardless
countri
incom
level
european
countri
aff
ect
global
fi
nancial
crisi
report
restrict
access
essenti
medicin
usa
statefund
healthcar
institut
respons
prison
su
poor
access
new
highpric
essenti
medicin
hepat
c
third
key
challeng
assur
qualiti
safeti
essenti
medicin
poorqual
medicin
serious
undermin
eff
ectiv
health
care
well
public
confi
denc
health
system
mani
incid
harm
substandard
falsifi
ed
medicin
record
exampl
poorqual
antimalari
medicin
respons
estim
death
per
year
children
year
subsaharan
african
countri
contamin
medicin
product
respons
death
children
panama
patient
pakistan
medicin
posit
impact
health
unless
use
appropri
nomin
health
coverag
popul
suffi
cient
ensur
qualiti
use
medicin
multipl
factor
contribut
problem
overus
underus
incorrect
use
unnecessari
market
new
treatment
hepat
c
viru
infect
past
year
current
global
debat
equit
access
treatment
place
eff
ectiv
polici
essenti
medicin
centr
stage
global
health
detail
case
succinctli
illustr
fi
key
challeng
essenti
medicin
polici
present
report
pay
essenti
medicin
make
treatment
aff
ordabl
assur
qualiti
safeti
promot
qualiti
use
develop
new
essenti
medicin
case
also
illustr
fi
challeng
interconnect
equal
relev
highincom
lowincom
countri
alik
million
peopl
global
live
hepat
c
viru
infect
newli
develop
medicin
known
directact
antivir
medicin
daa
dramat
improv
effi
caci
safeti
hepat
c
treatment
ere
substanti
improv
qualiti
life
longev
develop
global
strategi
treatment
elimin
viral
hepat
ad
four
daasdaclatasvir
dasabuvir
simeprevir
sofosbuvirto
model
list
essenti
medicin
overal
respons
rate
substanti
higher
previous
use
fi
rstline
regimen
although
effi
caci
daa
vari
viral
genotyp
nation
govern
healthcar
payer
worldwid
work
scale
access
medicin
peopl
live
hepat
c
viru
infect
promin
question
debat
pay
daa
extrem
costli
directli
relat
question
need
estim
much
treatment
cost
specifi
c
popul
estim
major
challeng
sinc
price
new
daa
vari
wide
among
countri
also
sometim
within
countri
exampl
estim
treat
elig
patient
usa
daa
would
requir
addit
us
billion
cours
year
us
insur
plan
er
treatment
mani
restrict
access
particular
subset
patient
hepat
c
viru
infect
base
exampl
sever
ill
likelihood
benefi
ting
treatment
high
price
sofosbuvir
list
price
full
cours
treatment
prompt
investig
us
senat
committe
financ
reveal
even
though
medicar
spent
billion
medicin
less
patient
hepat
c
viru
infect
enrol
medicar
receiv
treatment
budget
implic
pay
daa
part
basic
healthcar
packag
tremend
highincom
countri
budget
implic
health
system
far
fewer
resourc
even
daunt
aff
ordabl
daa
major
global
challeng
also
wide
debat
exampl
sofosbuvir
licens
malaysia
hepat
c
viru
infect
preval
estim
peopl
age
year
mostli
among
men
howev
sofosbuvir
remain
unaff
ordabl
patient
govern
alik
price
set
cours
malaysia
consid
uppermiddleincom
countri
gross
domest
product
per
capita
less
cost
singl
treatment
cours
price
littl
product
cost
sofosbuvir
product
estim
cost
treatment
cours
medicin
sold
india
egypt
introduc
local
product
medicin
price
drop
thu
ampl
scope
price
reduct
malaysia
elsewher
achiev
requir
concert
eff
ort
implement
rang
polici
promot
aff
ordabl
price
expect
fall
product
sofosbuvir
ledipasvirsofosbuvir
combin
tablet
recent
regist
tablet
sofosbuvirvelpatasvir
sale
lowincom
middleincom
countri
follow
gilead
scienc
inc
sign
voluntari
licenc
agreement
indian
gener
compani
medicin
patent
pool
also
er
licenc
daclatasvir
sale
lowincom
middleincom
countri
assur
qualiti
safeti
daa
mitig
risk
substandard
falsifi
ed
daa
enter
suppli
chain
reach
patient
necessari
qualiti
safeti
concern
highlight
need
aff
ordabl
qualityassur
treatment
march
nongovernment
organis
myanmar
report
identifi
ed
two
falsifi
ed
product
one
claim
contain
mg
sofosbuvir
mg
ledipasvir
mg
daclatasvir
manufactur
list
packag
never
produc
combin
current
produc
mg
daclatasvir
lack
access
treatment
attract
crimin
entiti
exploit
peopl
health
need
falsifi
ed
daa
found
israel
pakistan
regulatori
author
identifi
ed
factori
make
counterfeit
version
falsifi
ed
medicin
endang
patient
health
undermin
trust
legitim
medicin
manufactur
best
way
counter
suppli
falsifi
ed
substandard
medicin
ensur
avail
aff
ordabl
qualityassur
essenti
medicin
substanti
risk
also
result
inappropri
use
daa
lead
oper
challeng
expand
access
daa
appropri
select
daacontain
regimen
requir
previou
identifi
cation
viral
genotyp
inappropri
use
daa
lead
unnecessari
cost
furthermor
high
price
daa
might
lead
partial
cours
treatment
form
underus
patient
tri
cut
expens
testandtreat
strategi
shortcours
fi
xeddos
combin
pangenotyp
regimen
promot
qualiti
use
continu
next
page
consumpt
expens
medicin
mani
countri
inject
antibiot
heavili
overprescrib
survey
countri
outsid
organis
econom
cooper
develop
ment
oecd
peopl
hyper
tension
given
countri
take
appropri
medic
final
certain
essenti
medicin
miss
note
sdg
patentdriven
research
develop
r
model
develop
mani
miss
essenti
medicin
import
unmet
public
health
need
includ
heatstabl
insulin
oxytocin
shorter
treatment
latent
activ
tuberculosi
singleday
treatment
malaria
treatment
multidrugresist
tuberculosi
beyond
neglect
diseas
r
new
medicin
align
exist
emerg
burden
diseas
around
world
fi
core
challeng
essenti
medicin
polici
new
inde
past
decad
global
health
commun
sought
address
level
howev
fi
nding
longlast
sustain
solut
prove
diffi
cult
nation
global
econom
polit
interest
strongli
infl
uenc
develop
implement
essenti
medicin
polici
implic
public
health
econom
develop
trade
result
essenti
medicin
polici
often
highli
contest
nation
global
level
simultan
although
polic
aff
ect
prevent
treatment
mani
diseas
essenti
medicin
rare
present
centr
global
health
agenda
instead
often
essenti
medicin
polici
incorrectli
regard
technic
side
issu
answer
known
easili
appli
report
commiss
argu
essenti
medicin
pose
central
challeng
sustain
develop
agenda
demand
creativ
bold
action
exampl
commiss
present
case
new
essenti
medicin
treat
hepat
c
panel
case
illustr
essenti
medicin
polici
relev
countri
regardless
incom
level
fi
challeng
close
relat
report
discuss
eff
ectiv
essenti
medicin
polici
develop
impl
ment
describ
approach
contend
remain
emerg
challeng
introduct
place
argument
context
histor
evolut
essenti
medicin
within
broader
movement
global
health
underscor
crucial
essenti
medicin
everi
health
system
subsequ
section
delv
fi
key
challeng
analys
achiev
past
three
decad
identifi
lesson
learnt
make
action
evidenceinform
recommend
best
practic
promis
new
approach
final
report
propos
set
indic
track
progress
implement
recommend
indic
provid
scaff
old
build
nation
global
account
framework
support
propel
countri
toward
eff
ectiv
essenti
medicin
polici
implement
term
essenti
medicin
defi
ned
satisfi
prioriti
health
care
need
popul
concept
essenti
medicin
emerg
global
part
movement
primari
health
care
publish
fi
rst
model
list
essenti
medicin
year
alma
ata
confer
health
fi
rst
intern
confer
essenti
medicin
polici
nairobi
confer
ration
use
drug
panel
held
result
world
health
assembl
resolut
revis
drug
strategi
unpublish
repres
major
mileston
laid
foundat
mani
subsequ
intern
polici
relat
essenti
medicin
includ
procur
suppli
prescrib
dispens
medicin
regul
promot
practic
year
nairobi
essenti
medicin
becom
wide
accept
public
polici
concept
anniversari
nairobi
confer
provid
opportun
moment
take
stock
transpir
interven
year
sinc
lancet
commiss
essenti
medicin
polici
establish
juli
explor
progress
achiev
challeng
remain
lesson
learnt
detail
commiss
mandat
oper
provid
appendix
panel
continu
previou
page
concept
essenti
medicin
propos
immedi
drew
mix
reaction
lancet
call
select
desertisland
drug
recommend
appli
similar
approach
develop
countri
consum
activist
support
concept
way
reduc
unbridl
promot
unnecessari
harm
medicin
pharmaceut
industri
argu
restrict
prescrib
free
choic
medicin
would
lead
deterior
health
care
action
programm
essenti
drug
establish
pharmaceut
industri
fear
pressur
consum
group
would
develop
intern
code
pharmaceut
market
world
health
assembl
wha
led
nordic
countri
netherland
ask
directorgener
halfdan
mahler
organis
global
meet
discuss
ration
use
medicin
term
ration
use
refl
ect
view
medicinerel
problem
went
beyond
logist
also
driven
uncontrol
pharmaceut
market
kept
particip
list
secret
meet
prevent
lobbi
ask
particip
divulg
background
paper
open
mahler
remind
particip
invit
expert
stakehold
repres
central
theme
confer
need
restrict
market
medicin
essenti
meet
state
nation
medicin
polici
ensur
medicin
accept
qualiti
safeti
effi
caci
avail
aff
ordabl
cost
need
charg
dissemin
guidelin
develop
implement
nation
medicin
polici
much
discuss
focus
make
medicin
inform
object
access
confer
agre
govern
respons
regul
pharmaceut
market
advertis
sharp
disagr
univers
rationalis
whether
appli
public
privat
sector
interest
public
health
sum
confer
mahler
conclud
expert
invit
take
leadership
role
without
becom
supran
manipul
govern
suggest
establish
expert
committe
produc
guidelin
ethic
advertis
develop
nation
medicin
polici
wha
subsequ
adopt
revis
drug
strategi
basi
mahler
summari
neither
industri
consum
could
oppos
sinc
expert
accept
mahler
conclus
nairobi
yet
wha
meet
highli
politicis
industri
exhibit
press
centr
problem
drug
pack
issu
health
action
intern
usa
activ
lobbi
propos
role
regul
oper
pharmaceut
industri
develop
countri
usa
fail
pay
assess
contribut
larg
dissatisfact
activ
pharmaceut
area
follow
nairobi
revis
drug
strategi
guid
work
sinc
global
confer
essenti
medicin
held
two
decad
nairobi
intern
donor
particularli
netherland
nordic
countri
gave
extens
fi
nancial
polit
support
action
programm
mahler
complet
term
offi
ce
issu
ethic
criteria
medicin
drug
promot
initi
seen
weak
compromis
public
stood
test
time
year
also
publish
fi
rst
guidelin
develop
nation
drug
polici
updat
version
remain
wide
use
sinc
strengthen
standard
format
exchang
regulatori
inform
intensifi
ed
support
nation
regulatori
agenc
ultim
lead
whoun
prequalifi
cation
programm
ration
use
activ
start
develop
drug
use
indic
publish
guid
good
prescrib
mani
intern
train
cours
instrument
prepar
new
gener
intern
expert
follow
nairobi
confer
extens
support
lowincom
middleincom
countri
develop
implement
nation
medicin
polici
lowincom
middleincom
countri
formul
fi
rst
list
essenti
medicin
publish
nation
medicin
polici
fi
gure
year
nairobi
essenti
medicin
becom
wide
accept
concept
argu
year
encourag
support
increasingli
profession
consum
movement
consist
advoc
decis
action
sinc
use
term
essenti
medicin
rather
essenti
drug
prevent
confus
drug
abus
report
term
medicin
use
unless
cite
origin
document
structur
use
former
terminolog
develop
implement
essenti
medicin
polici
evolv
three
broad
era
fi
rst
era
characteris
establish
essenti
medicin
key
element
primari
health
care
global
intervent
era
focus
provid
technic
assist
countri
help
develop
essenti
medicin
list
nation
medicin
polici
predominantli
public
sector
second
era
essenti
medicin
polici
fundament
shape
global
investmentsfi
nancial
politicalin
expand
access
medicin
select
communic
diseas
particular
aid
tuberculosi
malaria
public
health
principl
underpin
concept
essenti
medicin
establish
central
element
right
health
health
system
respons
three
diseas
third
era
characteris
refram
essenti
medicin
polici
light
global
sdg
uhc
era
previou
focu
major
infecti
diseas
broaden
encompass
chronic
ncd
increas
equit
sustain
access
essenti
medicin
move
toward
uhc
emphasis
fi
rst
era
essenti
medicin
polici
coincid
emerg
primari
healthcar
movement
alma
ata
confer
essenti
medicin
concept
articul
fi
rst
model
list
essenti
medicin
publish
fi
rst
model
list
elicit
strong
support
strong
opposit
support
argu
list
essenti
medicin
establish
standard
enabl
stakehold
work
toward
common
aim
provid
advoc
baselin
healthcar
deliveri
howev
mani
health
profession
pharmaceut
industri
oppos
concern
select
list
essenti
medicin
would
limit
healthcar
deliveri
constrain
profession
autonomi
interfer
pharmaceut
market
reduc
health
benefi
ts
patient
despit
controversi
around
concept
essenti
medicin
throughout
govern
health
system
around
worldespeci
lmicsdevelop
essenti
medicin
list
larg
public
sector
mani
multilater
bilater
agenc
support
nation
public
sector
essenti
medicin
programm
notabl
exampl
includ
programm
bolivia
ecuador
kenya
malawi
sudan
tanzania
uganda
yemen
zimbabw
later
south
africa
nongovernment
health
organis
faithbas
organis
also
appli
strategi
across
africa
via
ecumen
pharmaceut
network
among
other
nation
essenti
medicin
list
fi
rst
era
focus
patent
lowerpr
gener
medicin
treat
prevent
common
acut
condit
exampl
includ
antiinfect
mebendazol
ivermectin
ampicillin
doxycyclin
analges
aspirin
paracetamol
anti
malari
chloroquin
primaquin
oral
rehydr
solut
childhood
vaccin
emphasi
align
movement
select
primari
health
care
strongli
champion
movement
emerg
respons
problem
face
enorm
unmet
medic
need
limit
resourc
select
primari
health
care
focus
deliv
restrict
rang
fi
rstcontact
servic
high
costeff
ectiv
lmic
emphasis
matern
child
health
servic
directli
address
health
system
structur
need
chronic
communic
noncommunic
condit
particularli
emerg
burden
hiv
instead
emphasi
essenti
medicin
polici
era
effi
cienci
prioritis
lowcost
costeff
ectiv
treatment
equiti
emphasis
treatm
ent
diseas
associ
poverti
fi
rst
era
also
saw
global
econom
crisi
imposit
econom
structur
adjust
programm
mani
donordepend
lmic
programm
reduc
fi
scal
space
public
sector
literatur
search
search
use
googl
websit
essenti
medicin
programm
specifi
c
call
edrug
listserv
case
contradictori
inform
especi
regard
date
public
origin
document
identifi
ed
studi
possibl
dataset
includ
countri
least
one
nation
essenti
medicin
list
could
identifi
ed
exclud
institut
region
nation
reimburs
list
countri
year
fi
rst
nation
essenti
medicin
list
gdp
per
capita
year
accord
world
bank
identifi
ed
fi
gure
show
nation
gdp
express
us
year
public
fi
rst
nation
essenti
medicin
list
everi
dot
repres
one
countri
fi
rst
nation
essenti
medicin
list
gdpgross
domest
product
increas
user
fee
health
servic
relianc
revolv
drug
fund
becam
common
featur
health
polici
set
result
essenti
medicin
larg
fi
nanc
individu
pay
pocket
often
privat
sector
two
indic
frequent
cite
demonstr
progress
fi
rst
era
number
lmic
establish
nation
list
essenti
medicin
number
countri
adopt
nation
medicin
polici
describ
principl
select
qualiti
appropri
use
although
use
structur
indic
demonstr
spread
concept
essenti
medicin
exist
polici
list
guarante
aff
ordabl
access
qualityassur
essenti
medicin
neither
necessarili
result
qualiti
use
furthermor
reduct
public
budget
countri
regularli
updat
essenti
medicin
polici
list
leav
larg
gap
polici
develop
implement
note
hospit
healthcar
organis
highincom
set
also
use
restrict
list
medicin
formulari
eff
ectiv
appli
similar
principl
determin
alloc
resourc
despit
gener
impress
develop
fi
rst
era
essenti
medicin
lmic
model
list
essenti
medicin
present
minimum
set
medicin
relev
resourceconstrain
set
howev
impress
mistaken
group
includ
mani
hic
well
fi
gure
part
impress
aros
focu
guidanc
develop
nation
medicin
polici
countri
medicin
suppli
system
domin
public
sector
second
era
expand
access
essenti
medicin
global
programm
second
era
essenti
medicin
polici
began
late
global
moral
outrag
toll
aid
epidem
era
outset
eff
ectiv
human
right
principl
reinforc
argument
use
fi
rst
aid
activist
polit
leader
support
greater
access
treatment
aid
rais
awar
global
dispar
access
essenti
medicin
concept
human
right
health
fi
rst
articul
un
appoint
fi
rst
un
special
rapporteur
right
everyon
enjoy
highest
attain
standard
physic
mental
health
subsequ
access
essenti
medicin
highlight
elabor
concret
element
right
health
make
process
select
essenti
medicin
model
list
evidenceinform
transpar
major
chang
introduc
coincid
call
activist
advocaci
group
san
chang
defi
nition
essenti
medicin
utmost
import
basic
indispens
necessari
health
need
popul
satisfi
prioriti
health
care
need
popul
ad
clarifi
cation
hey
select
due
regard
public
health
relev
evid
effi
caci
safeti
compar
costeff
ectiv
key
chang
new
emphasi
costeff
ectiv
high
cost
medicin
longer
automat
exclud
model
list
chang
twelv
wide
patent
antiretrovir
medicin
price
us
per
patient
per
year
classifi
ed
essenti
model
list
chang
bolster
moral
argument
polici
progress
realis
access
treatment
previous
aff
ordabl
one
condit
select
select
becam
part
pressur
ensur
aff
ordabl
follow
decad
due
concert
global
action
patient
activist
group
donor
govern
gener
manufactur
absenc
product
patent
medicin
india
elsewher
cost
antiretrovir
medicin
fell
less
per
person
per
year
enabl
million
patient
gain
access
lifesav
treatment
second
era
also
infl
uenc
grow
polici
attent
health
system
medicin
key
compon
health
system
face
profoundli
diffi
cult
decis
relat
alloc
scarc
resourc
new
initi
good
govern
medicin
programm
medicin
transpar
allianc
promot
link
essenti
medicin
initi
health
system
compon
second
era
also
coincid
set
millennium
develop
goal
mdg
goal
emphasis
reduc
mortal
due
aid
tuberculosi
malaria
promot
newborn
babi
child
matern
health
essenti
medicin
integr
compon
intervent
achiev
mdg
target
reduc
mortal
pneumonia
diarrhoea
measl
respons
half
million
fewer
death
fi
year
record
also
million
person
live
hiv
receiv
lifesav
antiretrovir
global
malaria
mortal
fell
million
death
avert
part
increas
access
antimalari
medicin
global
diseas
programm
institut
rang
mechan
address
price
select
qualiti
assur
costeff
ectiv
procur
medicin
howev
intervent
rare
identifi
ed
essenti
medicin
polici
although
concept
support
public
health
approach
gfatm
requir
qualiti
assur
gener
antiretrovir
medicin
procur
possibl
pool
procur
product
use
exert
downward
pressur
price
addit
gfatm
requir
public
report
procur
price
polici
contribut
improv
transpar
set
import
preced
major
donor
procur
programm
second
era
also
gener
coordin
advocaci
develop
new
essenti
medicin
present
global
survey
therapeut
area
lack
essenti
treatment
creat
concept
miss
essenti
medicin
call
public
health
approach
innov
key
group
miss
essenti
medicin
children
parallel
american
european
regulatori
eff
ort
world
health
assembl
resolut
better
medicin
children
highlight
need
paediatr
dose
form
mani
essenti
medicin
respons
publish
fi
rst
model
list
essenti
medicin
children
although
import
success
achiev
relat
mdg
gener
target
relat
access
medicin
mdg
cooper
pharmaceut
compani
provid
access
aff
ordabl
essenti
drug
develop
countri
prove
diffi
cult
measur
certainti
report
un
point
obviou
health
worker
patient
around
world
mani
poor
household
remain
unabl
obtain
need
medicin
either
poor
avail
poor
aff
ordabl
controversi
around
essenti
medicin
characteris
fi
rst
era
continu
throughout
second
era
mani
persist
current
period
howev
second
era
also
brought
concert
eff
ort
mobilis
stakehold
includ
pharmaceut
industri
work
toward
improv
health
secur
access
aff
ordabl
qualiti
assur
medicin
human
right
guidelin
pharmaceut
compani
relat
access
medicin
publish
follow
un
guid
principl
busi
human
right
past
decad
health
partnership
lmic
report
wherein
pharmaceut
industri
alon
collabor
stakehold
invest
improv
health
develop
progress
initi
document
access
medicin
atm
index
rigor
evalu
eff
ect
initi
remain
key
challeng
final
mobilis
implic
stakehold
meant
larger
role
organis
declin
role
provid
stewardship
global
polici
make
medicin
access
confront
continu
problem
gross
underfund
includ
essenti
medicin
programm
global
govern
health
medicin
came
involv
expand
set
stakehold
privat
foundat
eg
bill
melinda
gate
foundat
publicpriv
initi
eg
global
vaccin
allianc
gavi
increasingli
occur
outsid
plurilater
initi
intern
council
harmonis
ich
also
began
expand
constitu
third
era
uhc
demand
essenti
medicin
present
third
era
essenti
medicin
polici
driven
chang
diseas
burden
mark
transform
health
system
particular
push
uhc
world
health
report
acknowledg
medicin
centr
health
care
howev
mani
countri
commit
uhc
struggl
fulfi
l
vision
sinc
medicin
repres
substanti
proport
total
expenditur
health
everi
health
system
pressur
increas
maintain
appropri
pharmaceut
benefi
ts
coverag
also
balanc
qualiti
care
effi
cienci
spend
reduc
outofpocket
expenditur
move
toward
uhc
trigger
fundament
chang
medicin
fi
nanc
seek
shift
away
individu
outofpocket
payment
favour
prepay
pool
fi
nanc
mechan
commiss
argu
eff
ectiv
polici
essenti
medicin
central
fi
nancial
sustain
uhc
polici
support
essenti
medicin
must
support
increasingli
comprehens
health
servic
deliv
pluralist
system
includ
public
privat
sector
eff
ectiv
mobilis
engag
civil
societi
demograph
epidemiolog
transit
accompani
social
econom
developmentnam
age
popul
emerg
focu
ncdsgener
major
challeng
essenti
medicin
polici
public
fi
nanc
provis
essenti
medicin
fi
rst
second
era
tradit
gave
prioriti
medicin
treat
prevent
communic
diseas
un
high
level
meet
ncd
recognis
address
noncommunic
condit
necessari
countri
global
ncd
action
plan
set
one
target
avail
aff
ordabl
basic
technolog
essenti
medicin
includ
gener
requir
treat
major
ncd
public
privat
facil
countri
need
adopt
implement
polici
ensur
equit
access
aff
ordabl
essenti
medicin
mani
contextu
chang
aff
ect
evolut
essenti
medicin
polici
includ
increasingli
interdepend
pharmaceut
market
prioriti
set
increasingli
inform
econom
evalu
new
health
technolog
faster
exchang
larg
amount
healthcar
data
includ
pharmaceut
usag
data
global
regul
trade
particularli
intellectu
properti
rule
infl
uenc
competit
price
new
essenti
medicin
climat
chang
human
mobil
reshap
spread
diseas
demonstr
sever
acut
respiratori
syndrom
zika
viru
emerg
communic
diseas
might
aff
ect
countri
resourc
address
vari
consider
final
advanc
develop
new
medicin
includ
increas
target
therapi
particularli
oncolog
new
molecular
entiti
expect
come
market
cancer
medicin
target
medicin
target
therapi
eff
ectiv
small
subgroup
popul
requir
sophist
diagnost
test
infra
structur
fi
nancial
human
resourc
often
scarc
mani
health
system
also
struggl
tradeoff
invest
target
therapi
small
sub
group
provid
treatment
larger
popul
group
ad
sever
highpric
new
medicinesfor
treatment
hepat
c
tuberculosi
cancersto
model
list
essenti
medicin
move
refl
ect
import
product
health
system
abil
meet
popul
need
also
underscor
need
essenti
medicin
polici
countri
incom
level
confront
limit
budgetari
capac
ethic
principl
human
right
oblig
necessari
polici
institut
stakehold
engag
contribut
address
challeng
eff
ectiv
commiss
recognis
develop
essenti
medicin
polici
diffi
cult
eff
ectiv
implement
pose
substanti
challeng
health
system
much
room
improv
essenti
medicin
polici
countri
around
world
also
mani
opportun
implement
rang
proven
eff
ectiv
strategi
well
test
innov
emphasis
throughout
report
essenti
medicin
key
compon
health
system
commiss
assert
improv
access
qualityassur
essenti
medicin
end
rather
mean
improv
perform
equiti
health
system
variou
framework
exist
analysi
health
system
includ
specifi
calli
develop
locat
medicin
pharmaceut
polici
within
health
system
framework
emphasis
diff
erent
aspect
medicin
place
within
health
system
show
essenti
medicin
key
impact
health
system
level
effi
cienci
qualiti
access
intermedi
outcom
furthermor
essenti
medicin
indispens
achiev
ultim
health
system
goal
improv
health
statu
system
respons
ness
fi
nancial
protect
commiss
select
singl
framework
analys
fi
main
challeng
although
sever
refer
throughout
report
instead
section
present
area
opportun
strengthen
health
system
improv
access
essenti
medicin
identifi
polici
lever
fi
nanc
organis
regul
persuas
among
other
section
also
describ
three
crosscut
theme
link
core
health
system
goal
function
name
increas
equiti
strengthen
institut
promot
account
polici
implement
eff
ort
must
emphasis
increas
equiti
strengthen
institut
requir
implement
evalu
essenti
medicin
polici
promot
account
requir
concret
eff
ort
gener
inform
increas
transpar
foster
involv
civil
societi
decis
make
essenti
medicin
select
qualiti
assur
improv
use
prioriti
set
r
account
also
requir
independ
review
data
system
correct
action
improv
health
system
perform
requir
three
type
analysi
technic
ethic
polit
implement
eff
ectiv
essenti
medicin
polici
requir
understand
polit
economi
polici
develop
implement
evalu
report
suggest
concret
step
countri
health
system
take
also
consid
wider
polit
context
final
sixth
section
introduc
account
framework
compris
set
indic
combin
address
fi
specifi
c
challeng
three
crosscut
concern
advanc
essenti
medicin
polici
worldwid
despit
breadth
commiss
approach
essenti
medicin
relev
issu
could
fulli
address
report
includ
suppli
chain
manag
sourc
raw
materi
deliveri
fi
nal
product
consum
role
local
product
pharmaceut
problem
falsifi
ed
medicin
promot
adher
prevent
medic
error
sinc
global
eff
ort
address
issu
commiss
decid
analys
depth
howev
decis
taken
mean
deserv
less
attent
possibl
remedi
action
alreadi
place
particularli
achiev
uhc
requir
substanti
invest
strengthen
suppli
chain
health
commod
includ
essenti
medicin
eff
ectiv
integr
suppli
chain
medicin
demand
good
data
visibl
willing
learn
leverag
privat
sector
strong
nation
stewardship
commit
support
workforc
focu
continu
improv
ment
proactiv
risk
manag
final
gener
commiss
primarili
approach
essenti
medicin
polici
polici
academ
viewpoint
independ
expert
basi
analysi
best
avail
evid
commiss
seek
repres
possibl
viewpoint
stakehold
commiss
fi
rmli
believ
incorpor
strong
strateg
essenti
medicin
polici
enabl
countri
health
system
global
institut
take
major
stride
toward
achiev
highest
attain
standard
health
uhc
part
sustain
develop
fi
nding
present
report
seek
renew
global
debat
eff
ectiv
essenti
medicin
polici
implement
advanc
global
welfar
centuri
priti
age
year
treat
asthma
sinc
childhood
famili
health
insur
use
public
hospit
charg
outpati
consult
medicin
howev
present
prescript
new
inhal
told
hospit
stock
pharmacist
tell
stockout
happen
frequent
time
year
sinc
hospit
annual
medicin
budget
govern
exhaust
advis
buy
inhal
privat
pharmaci
instead
howev
famili
enough
money
buy
financ
encompass
fund
rais
resourc
alloc
health
fi
nanc
provid
govern
fi
scal
revenu
prepaid
insur
plan
form
employ
employe
contribut
subscript
outofpocket
expenditur
patient
famili
point
care
either
user
fee
pay
servic
cover
purchas
medicin
donat
also
use
fi
nanc
medicin
commod
repres
shortterm
strategi
address
resourc
gap
local
typic
use
temporari
support
emerg
lowresourc
set
central
aspir
uhc
protect
household
catastroph
health
expenditur
uhc
aim
provid
fi
nancial
risk
protect
increas
prepaid
coverag
whether
fi
scu
health
insur
fund
thu
decreas
relianc
outofpocket
expenditur
extent
prepaid
benefi
ts
includ
pharmaceut
expenditur
crucial
measur
adequaci
benefi
packag
ere
uhc
likewis
extent
health
system
deliv
suffi
cient
quantiti
essenti
medicin
determin
larg
fi
nanc
capac
implement
capac
system
effi
cienci
diseasespecifi
c
demand
forecast
develop
solicit
fund
prioriti
area
hiv
tuberculosi
malaria
howev
evidencebas
estim
much
would
cost
pay
basket
essenti
medicin
need
lmic
miss
make
diffi
cult
assess
use
resourc
eff
ectiv
advoc
adequ
fund
section
present
fi
rst
estim
total
cost
provid
basket
essenti
medicin
primari
secondari
level
care
entir
popul
lmic
model
develop
commiss
describ
along
result
estim
estim
contextualis
provid
overview
pharmaceut
expenditur
household
govern
donor
countri
level
final
action
recom
mendat
made
ensur
adequ
fi
nanc
basket
essenti
medicin
countri
topic
relat
fi
nanc
essenti
medicin
discuss
section
name
price
aff
ordabl
payer
section
payment
provid
improv
use
essenti
medicin
section
fi
nanc
r
medicin
section
strategi
countri
use
rais
fund
fi
nanc
basket
essenti
medicin
beyond
scope
report
describ
elsewher
new
model
develop
commiss
report
estim
cost
provid
basket
essenti
medicin
popul
lmic
treat
prioriti
diseas
primari
secondari
care
level
estim
base
diseas
preval
current
project
consumpt
medicin
adher
treatment
guidelin
medicin
price
includ
procur
suppli
chain
qualiti
assur
cost
estim
compris
overal
envelop
fi
nanc
need
provid
univers
access
basic
packag
essenti
medicin
lmic
margin
increas
exist
expenditur
new
cost
estim
use
inform
develop
fi
nanc
strategi
set
minimum
target
resourc
mobilis
countri
implement
uhc
one
innov
model
includ
larg
number
medicin
multipl
diseas
previou
cost
exercis
cover
smaller
set
medicin
focus
singl
therapeut
group
diseas
group
detail
cost
nation
level
still
necessari
incorpor
detail
nation
data
local
caseload
price
treatment
guidelin
method
present
could
adapt
use
nation
govern
organis
ideal
data
sourc
highqual
systemat
collect
inform
pharmaceut
utilis
data
avail
model
could
enabl
countri
develop
estim
minimum
futur
fi
nanc
need
essenti
medicin
model
also
provid
exampl
altern
data
sourc
use
estim
basic
need
essenti
medicin
histor
local
consumpt
data
accur
enough
model
includ
molecul
uniqu
dose
form
strength
list
medicin
use
model
exercis
present
appendix
essenti
medicin
administ
health
system
restrict
resourc
without
specialis
care
includ
medicin
mainli
list
core
model
list
essenti
medicin
categoris
use
primari
secondari
care
level
addit
medicin
relev
lmic
set
ad
basi
commission
knowledg
list
essenti
medicin
iran
south
africa
medicin
use
tertiari
care
set
exclud
data
limit
medicin
treatment
cancer
advanc
cardiovascular
care
also
exclud
similarli
medicin
preval
demand
data
avail
use
either
set
use
estim
consumpt
name
kwazulunat
denmark
explain
exclud
analysi
similar
approach
use
model
exercis
exampl
distinguish
basic
limit
enhanc
maxim
provis
packag
medicin
care
patient
breast
cancer
detail
explan
method
use
model
exercis
provid
appendic
brief
three
method
use
estim
quantiti
medicin
requir
year
lmic
first
medicin
singl
indic
data
global
burden
diseas
use
project
demand
data
obtain
global
burden
diseas
project
scientifi
c
literatur
scale
estim
mani
patient
given
condit
would
receiv
treatment
known
treatment
coverag
appendix
addit
standard
treatment
guidelin
fi
nding
literatur
use
model
mani
peopl
treatment
condit
would
receiv
medicin
known
medicin
coverag
appendix
second
exist
demand
forecast
use
whenev
avail
hiv
malaria
extent
tuberculosi
forecast
case
treatment
scaleup
plan
develop
specialis
agenc
clinton
health
access
initi
aid
medicin
diagnost
servic
unitaid
act
forecast
project
reproduct
health
suppli
coalit
stop
tb
partnership
case
forecast
includ
diff
erent
scenario
treatment
diagnosi
constraint
cascad
care
provis
final
estim
particularli
essenti
medicin
one
indic
base
pharmaceut
consumpt
data
ideal
data
sourc
demand
estim
highqual
local
measur
pharmaceut
consumpt
circumst
good
adher
diagnost
treatment
guidelin
case
model
data
came
denmark
kwazulunat
provinc
south
africa
locat
chosen
denmark
kwazulunat
implement
polici
promot
effi
cient
safe
use
medicin
therefor
pharmaceut
consumpt
health
system
refl
ect
servic
provis
scenario
would
reason
countri
emul
select
two
locat
suggest
either
pattern
consumpt
repres
lmic
absolut
ideal
rather
select
repres
reason
attain
level
consumpt
could
applic
countri
danish
dataset
cover
public
privat
sector
refl
ect
use
entir
popul
kwazulunat
dataset
cover
medicin
suppli
public
sector
assum
servic
popul
provinc
model
run
diff
erent
scenario
scenario
incorpor
consumpt
data
denmark
scenario
incorpor
data
kwazulunat
neither
denmark
kwazulunat
consid
fulli
repres
lmic
set
two
addit
scenario
test
assess
robust
model
result
scenario
basi
scenario
respect
consumpt
paramet
medicin
address
diseas
highest
global
burden
sub
stitut
data
middleincom
countri
mic
provid
im
health
input
held
constant
medicin
price
obtain
primarili
intern
drug
price
indic
guid
use
median
supplier
price
whenev
possibl
supplement
data
public
sector
price
sourc
kwazulunat
iran
price
convert
us
dollar
basi
averag
yearli
exchang
rate
unit
price
subject
proport
markup
repres
addit
qualiti
assur
suppli
chain
cost
deriv
literatur
sensit
analys
done
follow
chang
unit
price
input
data
median
price
either
highest
lowest
price
list
intern
drug
price
indic
guid
price
markup
qualiti
assur
suppli
chain
cost
switch
midpoint
limit
demand
forecast
publish
rang
preval
data
use
limit
confi
denc
interv
lower
higher
forecast
rang
treatment
medicin
coverag
estim
avail
model
estim
base
global
burden
diseas
data
account
either
futur
epidemiolog
chang
success
prevent
measur
might
chang
diseas
burden
model
includ
direct
medicinerel
cost
although
commiss
recognis
diagnost
test
consum
wider
health
system
cost
requir
deliveri
medicin
importantli
model
distinguish
adult
children
could
result
overestim
need
relat
certain
diseas
diabet
howev
enabl
model
reli
defi
ned
daili
dose
base
common
dose
main
indic
medicin
adult
final
static
model
account
relationship
suppli
demand
increas
use
might
aff
ect
price
dynam
model
far
complex
would
probabl
requir
larger
dataset
given
enorm
gap
data
avail
pharmaceut
sector
number
assumpt
dynam
model
would
also
increas
construct
dynam
model
beyond
scope
particular
analysi
seen
start
point
futur
estim
essenti
medicin
cost
individu
lmic
tabl
show
result
full
packag
medicin
scenario
well
subset
medicin
clinic
area
tabl
show
result
sensit
analys
overal
model
result
fairli
robust
strongli
infl
uenc
chang
data
input
except
relat
medicin
price
chang
median
price
lowest
list
price
intern
drug
price
indic
guid
chang
per
capita
estim
per
capita
wherea
chang
highest
list
price
chang
estim
per
capita
scenario
correspond
estim
scenario
chang
median
price
lowest
list
price
per
capita
chang
highest
list
price
previou
estim
cost
provid
essenti
medicin
gener
focus
medicin
specifi
c
subgroup
patient
exampl
report
estim
scale
combin
therapi
peopl
heart
diseas
would
cost
approxim
per
person
heart
diseas
lic
per
person
lowerm
per
person
upperm
manag
hiv
commiss
model
estim
total
cost
antiretrovir
lmic
approxim
billion
annual
far
greater
approxim
billion
report
procur
annual
global
fund
fight
aid
tuberculosi
malaria
presid
emerg
plan
aid
relief
pepfar
howev
combin
global
fund
pepfar
amount
includ
medicin
fund
countri
necessarili
includ
distribut
cost
commiss
estim
compar
howev
clinton
health
access
initi
estim
meet
target
lmic
would
cost
billion
purchas
cost
antiretrovir
likewis
tuberculosi
commiss
model
estim
total
cost
medicin
approxim
million
million
fi
rstline
treatment
million
secondlin
treatment
accord
unitaid
tb
medicin
landscap
report
total
valu
global
tuberculosi
medicin
market
combin
public
privat
sector
approxim
million
includ
million
fi
rstline
treatment
adult
million
treatment
multidrugresist
tuber
culosi
adult
similar
among
commiss
model
result
exist
estim
medicin
cost
global
treatment
hiv
tuberculosi
provid
corrobor
commiss
estim
commiss
estim
billion
per
year
total
cost
provid
basket
essenti
medicin
popul
lmic
need
assess
context
pharmaceut
expenditur
total
global
pharmaceut
sale
project
reach
trillion
accord
avail
data
per
capita
cost
consider
higher
estim
scenario
model
includ
select
set
medicin
appli
price
like
lower
actual
paid
denmark
similarli
kwazulunat
total
public
sector
expenditur
medicin
amount
per
capita
doubl
estim
scenario
basket
medicin
use
scenario
repres
subset
medicin
actual
procur
kwazulunat
global
refer
price
use
model
may
lower
actual
paid
pharmaceut
expenditur
repres
substanti
proport
total
health
expenditur
accord
commiss
analysi
use
nation
health
account
data
report
health
dollar
spent
medicin
lic
lowerm
health
dollar
spent
medicin
upperm
pharmaceut
expenditur
rang
hic
lowerm
lic
measur
lmic
pay
proport
pharmaceut
per
capita
hic
sourc
fi
nanc
medicin
also
vari
nation
health
account
data
show
public
expenditur
repres
pharmaceut
spend
hic
situat
revers
lmic
pharmaceut
expenditur
privat
sector
absenc
univers
access
health
insur
impli
signifi
cantli
outofpocket
expenditur
lmic
proport
resourc
avail
nation
level
spent
health
pharmaceut
indi
cate
countri
potenti
increas
alloc
pharmaceut
global
countri
spent
gross
domest
product
gdp
health
appendix
includ
gdp
pharmaceut
less
half
expend
public
fi
nanc
sourc
proport
gdp
spent
pharmaceut
across
countri
incom
group
consider
vari
lower
proport
gdp
spent
pharmaceut
hic
lmic
net
eff
ect
higher
per
capita
pharmaceut
expenditur
hic
countri
repres
twothird
global
pharmaceut
expenditur
despit
make
world
popul
fi
gure
convers
lic
repres
fi
fth
world
popul
account
total
global
pharmaceut
expenditur
dispar
also
stark
case
lowerm
third
world
popul
resid
account
pharmaceut
spend
expenditur
product
price
volum
variabl
contribut
hic
higher
expenditur
comparison
analysi
show
volum
medicin
consumpt
per
capita
signifi
cantli
lower
lowresourc
set
pepfar
global
fund
stoptb
global
drug
facil
gavi
bilater
multilater
intern
fund
mechan
express
intent
address
diseasespecifi
c
fund
dispar
hic
lmic
combin
total
budget
billion
incept
key
donor
provid
fund
wide
rang
activ
includ
procur
pharmaceut
health
commod
howev
fund
mechan
guarante
persist
support
frequent
predic
recipi
countri
gradual
shift
donor
support
selfreli
feasibl
transit
evid
scenario
kwazulunat
commiss
consid
model
estim
bare
minimum
amount
need
essenti
medicin
lmic
assum
effi
cient
procur
use
pharmaceut
resourc
prescrib
accord
standard
treatment
guid
line
minim
wast
commiss
note
lic
spend
less
medicin
estim
absolut
minimum
per
capita
half
pharmaceut
expenditur
lmic
privat
sourc
name
pocket
fi
nding
import
implica
tion
countri
move
toward
uhc
first
mani
lic
lowerm
need
increas
domest
fi
nanc
provid
basket
essenti
medicin
part
progress
realis
right
health
second
access
insur
fund
public
sector
health
fi
nanc
must
substanti
increas
seek
reduc
high
level
outofpocket
expenditur
final
govern
gener
suffi
cient
fund
basic
packag
support
short
term
intern
fund
mechan
support
would
contribut
ensur
peopl
access
essenti
medicin
includ
intern
human
right
treati
fulfi
l
govern
oblig
realis
human
right
even
beyond
border
support
would
also
help
lic
develop
health
servic
deliveri
infrastructur
work
identifi
adequ
domest
fi
nanc
mani
lowerm
spend
per
capita
necessari
fund
basic
packag
exist
case
promot
equiti
fair
access
essenti
medicin
prime
import
necessit
process
redistribut
within
countri
process
might
also
requir
redirect
nation
resourc
lower
price
elimin
ineffi
cienci
wast
see
section
furthermor
provid
access
essenti
medicin
benefi
packag
go
beyond
basic
list
includ
model
requir
addit
invest
commiss
expect
cost
model
use
adapt
countri
estim
nation
need
essenti
medicin
govern
move
toward
uhc
guarante
access
essenti
medicin
prerequisit
applic
model
local
data
input
includ
medicin
price
distribut
cost
diseas
preval
modifi
cation
model
input
would
crucial
individu
countri
seek
creat
benchmark
fi
nanc
access
essenti
medicin
absenc
high
qualiti
data
might
substanti
hamper
accur
estim
fi
nancial
envelop
need
notabl
accur
medicin
price
data
often
diffi
cult
obtain
section
distribut
cost
frequent
report
either
detail
local
diseas
preval
data
might
also
easili
avail
similarli
although
data
past
expenditur
pharmaceut
crucial
decis
make
futur
spend
nation
health
account
data
repositori
adequ
updat
global
level
hamper
transpar
comparison
present
section
base
recent
avail
data
datapoint
time
comparison
diffi
cult
assess
qualiti
data
submit
countri
includ
rel
contribut
public
versu
privat
sector
share
privat
prepaid
outofpocket
expenditur
final
commiss
acknowledg
even
nationallevel
analys
done
might
provid
insuffi
cient
evid
equiti
access
medicin
aggreg
globallevel
data
suggest
pharmaceut
expenditur
adequ
provid
essenti
medicin
nation
per
capita
expenditur
measur
might
obscur
inequ
diff
erent
region
subpopul
nation
repres
data
must
collect
way
allow
disaggreg
key
popul
public
expenditur
data
us
percentag
parenthes
tpe
total
pharmaceut
expenditur
thetot
health
expenditur
essenti
medicin
expenditur
subcompon
tpe
data
sourc
allow
diff
erenti
expenditur
essenti
nonessenti
medicin
data
nation
health
account
commiss
analysi
show
cost
provid
essenti
medicin
peopl
lmic
surmount
challeng
commiss
er
follow
recommend
relat
provid
suffi
cient
equit
fi
nanc
essenti
medicin
govern
nation
health
system
must
provid
adequ
fi
nanc
ensur
inclus
essenti
medicin
benefi
packag
provid
public
sector
health
insur
scheme
commiss
model
exercis
serv
start
point
determin
fi
nanc
need
essenti
medicin
particular
countri
exercis
adapt
nation
context
includ
diseas
burden
standard
treatment
guidelin
health
prioriti
cost
deliv
care
particular
system
nation
cost
exercis
particular
attent
must
paid
specifi
c
need
underserv
commun
promot
equiti
assur
progress
realis
right
access
healthcar
servic
aim
must
achiev
benefi
ts
packag
address
popul
health
need
way
sustain
fi
nanc
diff
erent
sourc
fair
transpar
manner
govern
nation
health
system
must
implement
polici
reduc
amount
outofpocket
spend
medicin
half
spend
medicin
lmic
come
outofpocket
expenditur
highli
inequit
move
toward
uhc
requir
countri
reduc
medicin
fi
nanc
via
direct
payment
increas
fi
nanc
requir
prepay
mechan
govern
alloc
intern
commun
must
fulfi
l
human
right
oblig
support
govern
lic
fi
nanc
basic
packag
essenti
medicin
unabl
domest
support
come
addit
similar
support
programm
alreadi
oper
essenti
medicin
specifi
c
diseas
hiv
tuberculosi
malaria
neglect
diseas
commiss
urg
countri
review
innov
fi
nanc
mechan
determin
whether
extend
appli
essenti
medicin
gener
govern
nation
health
system
must
invest
capac
accur
track
expenditur
medicin
especi
essenti
medicin
public
privat
sector
data
disaggreg
prepaid
outofpocket
expenditur
among
import
key
popul
inform
decis
make
invest
purchas
essenti
medicin
requir
qualiti
data
current
spend
sinc
nationallevel
data
obscur
import
inequ
data
need
disaggreg
import
key
popul
chosen
particular
nation
situat
mind
design
monitor
system
attent
must
also
paid
enabl
maxim
involv
stakehold
principl
transpar
includ
access
data
use
polici
analyst
academ
transpar
facilit
public
buyin
support
decisionmak
process
use
data
section
make
essenti
medicin
aff
ordabl
aff
ordabl
essenti
medicin
core
challeng
health
system
work
achiev
uhc
appropri
benefi
packag
includ
care
select
essenti
medicin
key
compon
uhc
aff
ordabl
essenti
medicin
one
press
problem
face
health
system
requir
comprehens
polici
solut
promot
equiti
maintain
fi
nancial
sustain
section
commiss
argu
concert
eff
ort
across
rang
polici
intervent
ensur
aff
ordabl
essenti
medicin
uhc
provid
opportun
revisit
recommend
intervent
underus
multipl
strategi
policiesinclud
price
polici
pool
fund
leverag
buy
power
manag
intellectu
properti
singlesourc
medicin
care
select
medicin
benefi
packagear
need
address
aff
ordabl
singlesourc
multisourc
medicin
term
aff
ordabl
use
describ
abil
purchas
necessari
quantiti
product
level
servic
without
suff
ere
undu
fi
nancial
hardship
agreement
exist
fi
nancial
hardship
mean
best
assess
common
way
measur
aff
ordabl
individu
household
level
compar
amount
payment
treatment
cours
household
avail
resourc
good
larg
aff
ordabl
highincom
household
could
remain
reach
lowincom
individu
household
collect
level
public
thirdparti
payer
aff
ordabl
depend
price
product
servic
avail
budget
fi
scal
space
defi
ned
heller
capac
govern
provid
addit
budgetari
resourc
desir
purpos
without
prejudic
sustain
fi
nancial
posit
avail
fi
nanc
essenti
medicin
rel
therefor
key
determin
aff
ordabl
aff
ordabl
also
distinct
valu
product
servic
thu
essenti
medicin
might
er
larg
health
benefi
high
valu
determin
exampl
costeff
ectiv
analysi
still
might
aff
ordabl
limit
resourc
high
price
new
treatment
hepat
c
panel
cancer
case
medicin
might
aff
ordabl
er
littl
addit
health
valu
exist
option
commonli
use
essenti
medicin
unaff
ordabl
mani
set
despit
avail
multipl
sourc
especi
true
individu
pay
pocket
medicin
unavail
public
sector
patient
forc
purchas
privat
sector
use
outofpocket
resourc
gener
medicin
avail
averag
public
health
facil
lic
lowerm
avail
rang
aff
ordabl
particularli
problemat
medicin
must
taken
continu
basi
manag
chronic
communic
noncommunic
condit
unlik
aid
tuberculosi
malaria
ncd
target
new
global
fund
facil
diff
erenc
aff
ordabl
also
exist
within
ncd
group
essenti
medicin
cancer
diabet
often
less
aff
ordabl
treatment
hypertens
nonetheless
studi
privat
pharmaci
price
four
commonli
use
cardiovascular
medicin
countri
show
potenti
unaff
ordabl
least
patient
everi
countri
result
includ
household
hic
upperm
lowerm
much
lic
exclud
india
india
result
review
whohealth
action
intern
hai
price
data
lmic
show
month
treatment
three
common
chronic
ncd
gastric
ulcer
asthma
type
diabet
aff
ordabl
larg
segment
popul
purchas
privat
sector
whohai
method
use
defi
nition
aff
ordabl
base
number
day
minimum
public
sector
wage
unskil
govern
worker
requir
purchas
month
treatment
similarli
consider
challeng
document
aff
ordabl
insulin
treat
diabet
public
sector
data
lmic
show
mean
public
sector
price
human
insulin
iu
isophaneregular
repres
day
minimum
public
sector
wage
month
treatment
privat
sector
across
lmic
medicin
repres
twice
burden
day
wage
mdg
gap
task
forc
report
state
ccess
essenti
medicin
aff
ordabl
price
remain
highli
problemat
mani
household
squeez
market
due
high
price
limit
avail
also
note
seriou
lack
data
adequ
track
progress
data
price
need
analys
understood
design
intervent
improv
aff
ordabl
howev
sub
stantial
gap
avail
qualiti
systemat
gather
analys
data
price
aff
ordabl
medicin
exist
global
level
world
health
statist
report
also
emphasis
ata
avail
medicin
poor
develop
countri
also
emphasis
reliabl
sourc
data
medicin
price
survey
done
use
whohai
method
howev
data
limit
rapidli
becom
date
world
health
statist
report
countri
survey
result
gener
datapoint
report
minimum
median
maximum
valu
avail
gener
medicin
median
consum
price
ratio
compar
intern
refer
price
select
gener
medicin
public
privat
sector
although
whohai
crosssect
survey
method
valid
remain
subject
limit
term
sampl
facil
basket
medicin
assess
countri
done
repeat
price
survey
data
aff
ordabl
incom
strata
avail
routin
data
easier
collect
singlepay
stateoper
system
data
obtain
distributor
retail
limit
data
often
date
price
fl
uctuat
refl
ect
undisclos
discount
clawback
type
price
reduct
routin
collect
data
actual
price
paid
patient
medicin
rare
occur
especi
set
outofpocket
payment
common
price
paid
highli
variabl
intern
drug
price
indic
guid
issu
manag
scienc
health
address
gap
certain
extent
report
seller
buyer
price
govern
agenc
pharmaceut
supplier
intern
develop
organis
price
report
mechan
develop
specifi
c
medicin
antiretrovir
tuberculosi
treatment
lack
reliabl
price
inform
barrier
crossnat
comparison
imped
develop
respons
price
polici
furthermor
aff
ordabl
relat
total
expenditur
determin
price
volum
data
use
medicin
see
section
consid
well
develop
evidenceinform
polici
commiss
conclud
new
system
need
routin
collect
analys
respond
price
data
real
time
particularli
lmic
system
requir
invest
strengthen
capac
institut
gener
analys
inform
implement
uhc
benefi
packag
must
design
includ
evidenceinform
list
medicin
provid
reimburs
commiss
identifi
ed
sever
strategi
beyond
develop
essenti
medicin
list
improv
access
aff
ordabl
essenti
medicin
individu
collect
level
panel
commiss
believ
aff
ordabl
price
essenti
medicin
compat
sustain
pharmaceut
industri
includ
detail
section
research
innov
develop
miss
essenti
medicin
countri
need
select
polici
option
appropri
particular
health
system
nation
prioriti
avail
resourc
human
right
consider
mani
factor
aff
ect
polici
appli
particularli
countri
medicin
suppli
chain
structur
exampl
health
care
might
deliv
predominantli
public
sector
involv
wider
rang
public
privat
sector
actor
pool
procur
use
limit
competit
bid
tender
pool
procur
use
monopsoni
power
price
negoti
base
volum
procur
inclus
reimburs
list
parallel
import
progener
polici
note
polici
also
reli
eff
ectiv
medicin
regulatori
author
assur
qualiti
product
local
market
intern
nonproprietari
name
prescrib
mandatori
er
gener
substitut
enabl
gener
substitut
pharmacist
dispens
reduct
remov
import
tax
sale
tax
intern
refer
price
note
type
price
also
progener
polici
depend
abil
set
reimburs
limit
refer
price
select
gener
option
extern
refer
price
regul
distribut
chain
markup
regul
profession
fee
regul
annual
factoryg
price
increas
patentrel
intervent
encourag
voluntari
licens
patent
pool
evidenceinform
standard
treatment
guidelin
essenti
medicin
list
reimburs
list
feedback
prescrib
behaviour
peer
review
intervent
reimburs
base
adher
guidelin
use
medicin
target
reimburs
cap
limit
patient
copay
disincent
overus
grant
enforc
medicin
patent
test
data
protect
leastdevelop
countri
use
parallel
import
compulsori
licens
govern
use
licens
applic
strict
patent
criteria
base
exist
guidanc
assess
relev
pharmaceut
polici
lowincom
middleincom
countri
factor
consid
includ
degre
establish
local
pharmaceut
market
relianc
import
medicin
exist
extent
medicin
patent
extent
relianc
donor
fund
purchas
essenti
medicin
er
guidanc
countri
wide
rang
medicin
price
polici
option
avail
govern
health
system
topic
includ
intern
extern
refer
price
reimburs
limit
reason
copay
remov
sale
tax
tariff
medicin
regul
increas
factoryg
price
set
distribut
chain
price
control
regul
profession
fee
although
mani
polici
option
relev
countri
public
sector
provis
health
care
predomin
other
becom
avail
countri
implement
purchaserprovid
split
uhc
impli
either
complet
relianc
public
sector
servic
provis
pluralist
system
involv
public
privat
provid
howev
system
enabl
larg
purchas
nation
health
insur
fund
public
health
sector
use
monopsoni
one
buyer
power
competit
bid
price
negoti
exert
downward
pressur
price
pool
procur
multipl
payer
within
countri
across
countri
negoti
price
togeth
also
use
increas
monopsoni
power
practic
wide
use
conjunct
measur
overcom
patent
barrier
suppli
gener
antiretrovir
global
fi
nanc
initi
transform
landscap
antiretrovir
price
transpar
price
major
featur
global
fi
nanc
system
mark
contrast
situat
pertain
pharmaceut
price
set
although
littl
conclus
evid
exist
transpar
alon
result
price
reduct
possibl
rais
price
transpar
could
enabl
collus
anticompetit
behaviour
compani
attempt
limit
price
reduct
howev
case
antiretrovir
shown
transpar
also
accompani
drastic
price
reduct
ineff
ectiv
ineffi
cient
nation
procur
institut
process
also
contribut
higher
necessari
price
payer
aff
ect
avail
medicin
least
past
decad
collect
procur
strategi
promot
global
particularli
intern
agenc
exampl
manufactur
reduc
price
etonogestrel
levonorgestrel
roughli
per
unit
etonogestrel
per
unit
levonorgestrel
thank
minimum
volum
guarante
consortium
global
health
partner
price
reduct
result
neardoubl
order
buyer
ultim
improv
access
women
global
donor
technic
partner
manufactur
also
join
forc
help
reshap
health
product
market
reduc
product
cost
pharmaceut
exampl
gavi
cultiv
competit
marketplac
penta
valent
vaccin
result
price
reduct
per
dose
low
reduct
project
save
gavi
million
cours
year
polici
promot
aff
ordabl
vari
depend
type
essenti
medicin
consid
singlesourc
medicin
includ
still
patent
multisourc
medicin
requir
diff
erent
approach
progener
polici
enabl
consider
cost
save
whenev
gener
altern
exist
exampl
estim
chines
hospit
purchas
could
save
total
billion
us
switch
origin
brand
antihypertens
antidiabet
domest
avail
gener
equival
progener
polici
includ
prescript
intern
nonproprietari
name
allow
requir
gener
substitut
pharmacist
use
procur
reimburs
decis
promot
gener
use
tabl
polici
depend
trust
held
prescrib
dispens
patient
carer
qualiti
avail
gener
product
section
past
year
price
increas
medicin
avail
gener
product
come
intens
scrutini
north
america
europ
manufactur
older
gener
medicin
point
larger
compani
littl
interest
product
low
profi
tabil
littl
competit
remain
produc
remov
downward
pressur
price
enabl
inordin
price
hike
manufactur
argu
price
refl
ect
valu
medic
other
interpret
unscrupul
price
goug
call
polici
solut
moral
ground
intervent
increas
use
gener
diffi
cult
medicin
question
patent
gener
equival
produc
world
trade
organ
agreement
traderel
aspect
intellectu
properti
right
trip
oblig
member
countri
provid
patent
technolog
includ
pharmaceut
minimum
durat
year
exempt
least
develop
countri
ldc
time
limit
trip
also
includ
rang
fl
exibl
provid
govern
option
allow
protect
public
health
includ
access
aff
ordabl
medicin
section
widespread
use
fl
exibl
key
exampl
suppli
gener
antiretrovir
howev
fl
exibl
continu
threat
tripsplu
oblig
includ
bilater
region
trade
agreement
exampl
data
exclus
provis
requir
manufactur
gener
biosimilar
medicin
gener
data
applic
regulatori
author
market
authorisationfor
mani
requir
becom
insurmount
barrier
furthermor
rais
ethic
concern
standard
care
alreadi
establish
countri
use
trip
fl
exibl
also
risk
trade
pressur
includ
annual
watch
list
like
special
report
issu
annual
us
trade
repres
system
respons
challeng
intellectu
properti
barrier
provid
medicin
patent
pool
mpp
describ
detail
section
patent
licenc
avail
mpp
certain
patenthold
compani
provid
legal
mean
reduc
neg
eff
ect
patent
monopoli
avail
gener
medicin
lead
greater
avail
aff
ordabl
price
use
licenc
might
requir
payment
royalti
subject
restrict
term
geograph
scope
compani
make
gener
medicin
mpp
licenc
certain
compani
licenc
nevertheless
suppli
countri
outsid
scope
licenc
provid
countri
issu
compulsori
licenc
enabl
govern
use
patent
suppli
otherwis
infring
grant
patent
countri
local
product
promot
strategi
expand
access
aff
ordabl
gener
medicin
exampl
mozambiqu
receiv
support
govern
brazil
promot
domest
pharmaceut
product
wherea
european
union
fund
larg
project
foster
technolog
transfer
region
earli
nation
hiv
treatment
programm
brazil
thailand
larg
depend
local
produc
lowcost
antiretrovir
two
earlier
literatur
review
conclud
promot
domest
product
often
polit
econom
motiv
meaning
assess
impact
miss
evid
exist
impact
domest
product
price
contradictori
perhap
partli
caus
confl
ict
public
health
industri
polici
agenda
weak
regulatori
author
dearth
human
resourc
among
econom
institut
barrier
imped
domest
product
mani
set
problem
aff
ordabl
singlesourc
medicin
patent
protect
might
well
acut
mic
exclud
voluntari
licens
agreement
countri
oblig
grant
patent
protect
pharmaceut
vulner
polit
pressur
attempt
appli
trip
fl
exibl
might
also
exclud
receiv
donor
support
regard
south
africa
except
case
basi
high
hiv
preval
includ
mani
voluntari
licenc
nonenforc
agreement
antiretrovir
drug
howev
south
africa
subject
full
forc
trip
agreement
yet
amend
patent
law
take
full
advantag
avail
fl
exibl
commiss
argu
countri
need
use
full
rang
price
polici
includ
trip
fl
exibl
promot
aff
ordabl
essenti
medicin
individu
collect
level
high
price
medicin
pose
problem
lmic
hic
alik
threaten
sustain
health
system
rais
seriou
ethic
question
equiti
coverag
price
new
medicin
typic
set
manufactur
maximis
profi
ts
period
monopoli
suppli
patent
tier
price
scheme
promot
strategi
protect
aff
ordabl
howev
practic
artifi
cialli
segment
market
result
shortterm
price
reduct
particularli
compar
longterm
impact
competit
larg
volum
high
price
combin
contribut
make
essenti
medicin
unaff
ordabl
whenev
larg
amount
medicin
requir
larg
patient
pool
exist
health
system
fi
nancial
capac
stress
price
wide
use
medicin
entir
class
medicin
increas
budgetari
impact
devast
antiretrovir
drug
exemplifi
ed
challeng
access
treatment
expand
special
report
see
http
ustrgovissuearea
treat
hepat
c
describ
panel
expens
medicin
urgent
need
million
peopl
worldwid
expir
primari
patent
product
expect
biolog
medicin
base
larg
complex
molecul
protein
antibodi
oppos
simpler
smaller
molecul
incorpor
chemic
medicin
monoclon
antibodi
use
treat
cancer
anoth
exampl
medicin
whose
price
present
aff
ordabl
challeng
countri
regardless
incom
level
usa
averag
acquisit
price
price
charg
patient
insur
health
system
newer
cancer
treatment
rang
per
month
biolog
medicin
project
compris
approxim
valu
global
pharmaceut
market
contribut
largest
percentag
increas
pharmaceut
expenditur
hic
fi
gure
high
price
led
call
place
emphasi
assess
valu
new
medicin
help
physician
payer
better
choic
use
uhc
extend
crucial
need
tool
assess
valu
new
medicin
particularli
highli
price
american
societi
clinic
oncolog
exampl
propos
valu
analysi
framework
assess
valu
new
medicin
howev
necessarili
lead
aff
ordabl
price
usa
larg
laissezfair
approach
medicin
price
eff
ect
mani
year
call
chang
system
price
link
valu
product
us
presid
barack
obama
issu
call
transpar
report
product
develop
cost
increas
rebat
manufactur
pay
medicin
receiv
certain
group
benefi
ciari
medicar
medicaid
grant
govern
author
negoti
price
certain
highpric
medicin
develop
repres
complet
chang
attitud
new
medicin
cost
usa
pay
averag
highest
price
medicin
global
term
newer
better
newer
need
longer
consid
appropri
defens
justifi
cation
similar
challeng
face
health
system
decid
whether
includ
new
medicin
essenti
medicin
reimburs
list
health
technolog
assess
hta
method
one
approach
assess
valu
new
medicin
hta
goe
far
beyond
costeff
ectiv
analysi
multidisciplinari
activ
systemat
examin
safeti
clinic
effi
caci
eff
ectiv
cost
costeff
ectiv
organis
implic
social
consequ
legal
ethic
consider
applic
health
technologyusu
drug
medic
devic
clinicalsurg
procedur
similar
process
describ
prioriti
set
cite
essenti
achiev
uhc
hta
programm
establish
number
hic
nation
health
insur
system
sever
transit
mic
poland
colombia
malaysia
also
establish
hta
agenc
survey
countri
latin
america
caribbean
countri
central
eastern
europ
show
numer
countri
set
institut
framework
develop
procedur
standard
establish
polici
support
hta
world
health
assembl
resolut
note
prerequisit
necessari
implement
hta
begin
independ
bodi
free
polit
pressur
vest
interest
medicin
polici
engag
stakehold
academ
institut
profession
associ
also
need
hta
often
requir
creation
new
capac
nation
level
final
substanti
sustain
fi
nancial
invest
need
provid
resourc
need
undertak
hta
exampl
korean
nation
evidencebas
healthcar
collabor
agenc
around
staff
budget
million
complet
hta
done
inhous
panel
review
prerequisit
use
exampl
health
intervent
technolog
assess
program
nation
agenc
perform
support
hta
thailand
commiss
acknowledg
hta
alon
make
essenti
medicin
aff
ordabl
howev
hta
substanti
contribut
evid
base
select
reimburs
decis
relat
medicin
moreov
result
hta
use
govern
agenc
input
price
negoti
new
essenti
medicin
exampl
thailand
panel
illustr
hta
use
support
reimburs
decis
trigger
price
intervent
medicin
sever
exampl
shown
ad
hoc
solut
creat
specifi
c
earmark
fund
particular
medicin
diseas
patient
group
often
tempt
polit
expedi
howev
ad
hoc
solut
rare
sustain
risk
undermin
well
design
eff
ectiv
decisionmak
process
health
system
overal
panel
hta
requir
invest
capac
assess
clinic
evid
consid
local
cost
servic
input
project
potenti
budget
impact
compet
option
budget
impact
assess
trigger
urgent
discuss
accept
price
new
essenti
medicin
activ
essenti
medicin
polici
could
improv
aff
ordabl
expand
access
ensur
sustain
health
gain
budget
impact
assess
alreadi
formal
requir
reimburs
decis
make
numer
countri
includ
australia
norway
canada
itali
bulfon
colleagu
comment
role
econom
evalu
part
whole
end
game
commiss
recognis
hta
one
tool
still
rais
mani
unresolv
challeng
among
type
technolog
consid
thailand
experi
demonstr
health
technolog
assess
hta
success
use
tool
develop
implement
polici
reduc
price
essenti
medicin
technolog
ministri
public
health
thailand
establish
hitap
gener
evid
inform
decis
make
medicin
health
technolog
would
cover
public
health
system
use
price
quotat
input
hta
trigger
price
intervent
hta
thailand
go
beyond
consider
exist
price
product
local
market
manufactur
market
medicin
hta
consider
might
submit
price
quotat
refl
ect
economi
scale
would
follow
product
deem
reimburs
addit
hta
show
increment
cost
eff
ectiv
ratio
exce
certain
thresholdapproxim
us
thai
baht
per
qualityadjust
lifeyear
disabilityadjust
lifeyearthen
price
negoti
ensu
reach
price
accept
parti
thu
thai
hta
process
led
activ
price
intervent
aim
ensur
aff
ordabl
essenti
medicin
see
also
panel
use
hta
input
budgetari
impact
consider
health
system
unlimit
budget
alway
tension
ensur
avail
costeff
ectiv
essenti
medicin
secur
mean
meet
cost
medicin
demonstr
costeff
ectiv
even
basi
locallyrelev
threshold
valu
prefer
suffi
cient
ensur
medicin
aff
ordabl
either
health
system
patient
exampl
thai
hta
conclud
reimburs
screeningplustreat
osteoporosi
age
costeff
ectiv
even
acquisit
price
medicin
assess
alendron
reduc
project
would
compris
almost
uhc
scheme
budget
includ
valu
assign
health
statu
select
metric
use
costeff
ectiv
comparison
cost
hta
risk
duplic
eff
ort
impact
diseasespecifi
c
approach
risk
game
system
comment
argu
hta
method
promot
donor
agenc
inadequ
adapt
use
nation
govern
decis
maker
therefor
warn
hta
appli
great
caution
given
limit
challeng
seem
crucial
identifi
area
hta
make
greatest
contribut
decis
make
need
exist
innov
tool
hta
requir
commit
transpar
stakehold
data
use
assess
avail
review
health
profession
consum
kind
transpar
could
implic
agenc
use
commerci
inconfi
denc
evid
provid
pharmaceut
compani
howev
medicin
regulatori
structur
deliber
polici
maxim
transpar
help
engend
trust
procedur
outcom
assess
region
global
collabor
hta
agenc
promot
effi
cienci
analys
especi
capac
poor
cooper
reli
transfer
extent
hta
done
one
set
use
adapt
anoth
set
cooper
requir
commit
share
inform
evid
compar
eff
ectiv
estim
costeff
ectiv
result
budget
impact
assess
outcom
price
intervent
howev
reli
assess
done
elsewher
inform
local
decisionmak
process
hta
includ
crucial
examin
applic
evid
use
local
condit
societ
valu
price
ere
medicin
consider
sever
network
establish
procedur
inform
share
hta
core
model
develop
eunethta
exist
network
fi
eld
list
appendix
htaor
assess
processalso
requir
transpar
respect
process
valu
appli
otherwis
becom
imposs
assess
exampl
prioriti
set
specifi
c
subpopul
fulfi
lment
right
highest
attain
standard
health
event
process
progress
realis
take
resourc
limit
account
exampl
mere
fact
diseas
rare
provid
humanrightsbas
justifi
cation
immedi
reimburs
treatment
lessfavour
margin
costeff
ectiv
treatment
diseas
propos
new
expens
treatment
ad
reimburs
packag
basi
margin
costeff
ectiv
criteria
cost
per
qualiti
adjust
lifeyear
gain
medicin
howev
commiss
note
societi
might
choos
appli
diff
erent
norm
particular
circumst
relat
endoflif
care
instanc
review
reimburs
decis
oecd
countri
found
sever
rariti
condit
use
justifi
higher
increment
costeff
ectiv
ratio
higher
price
would
norm
balanc
variou
consider
justifi
cation
could
use
decis
highlight
necess
explicitli
defi
ning
ethic
principl
guid
use
econom
analys
select
medicin
final
htaor
similar
approachrequir
commit
meaning
involv
public
stakehold
throughout
assess
process
analysi
valu
involv
applic
socal
valu
judgment
refl
ect
social
valu
prefer
patient
carer
addit
data
cost
rel
eff
ectiv
patient
public
particip
increasingli
recognis
import
valid
medicin
regulatori
decis
involv
medicin
thai
hta
trigger
intervent
reduc
price
medicin
consider
inclus
nation
list
essenti
medicin
nlem
price
negoti
oxaliplatin
ad
thai
nlem
treatment
metastat
colorect
cancer
part
folfox
adjuv
chemotherapi
regimen
folin
acid
also
known
leucovorin
uorouracil
initi
hta
shown
folfox
would
consid
costeff
ectiv
compar
altern
adjuv
therapi
folin
acid
uoruoracil
capecitabin
price
oxaliplatin
reduc
least
fi
nal
price
reduct
negoti
save
thai
health
system
approxim
us
million
million
thai
baht
per
year
label
use
thai
nlem
confi
rmed
decis
includ
intravitr
bevacizumab
rather
ranibizumab
treatment
agerel
macular
degener
although
bevcizumab
use
label
concern
rais
use
challeng
uk
hta
done
health
intervent
technolog
assess
program
conclud
two
medicin
equival
term
eff
ectiv
note
safeti
data
insuffi
cientli
robust
multistakehold
process
includ
ophthalmologist
academ
repres
thai
food
drug
administr
pharmaceut
industri
recommend
negoti
commenc
produc
ranibizumab
reduc
price
event
price
negoti
fail
bevacizumab
includ
nlem
develop
system
monitor
seriou
advers
eff
ect
costshar
arrang
although
hta
imigluceras
treatment
type
gaucher
diseas
show
product
costeff
ectiv
costshar
model
negoti
allow
product
includ
nlem
fi
rst
fi
patient
newli
identifi
ed
year
cost
share
equal
manufactur
govern
eff
ectiv
price
reduct
subsequ
patient
identifi
ed
year
manufactur
would
cover
entir
cost
treatment
select
especi
decis
restrict
access
medicin
health
technolog
aff
ordabl
essenti
medicin
market
year
new
newli
attain
essenti
statu
fundament
challeng
lmic
hic
aff
ordabl
high
prioriti
countri
move
toward
uhc
design
equit
implement
eff
ectiv
polici
achiev
concert
eff
ort
govern
health
system
concert
pharmaceut
industri
commiss
maintain
everi
avail
regulatori
manag
intervent
could
improv
aff
ordabl
medicin
must
consid
suit
polici
instrument
includ
price
intervent
progener
polici
use
trip
fl
exibl
patent
barrier
prevent
access
lowerpr
altern
avoid
tripsplu
provis
bilater
trade
agreement
consider
evid
support
use
polici
support
aff
ordabl
essenti
medicin
option
regard
tabl
polit
reason
exampl
remov
tax
tariff
well
within
power
govern
even
might
unpopular
certain
stakehold
moreov
commit
uhc
provid
countri
new
opportun
eff
ectiv
implement
polici
leverag
newli
creat
buyer
power
fi
nancial
pool
address
high
price
medicin
ultim
object
mere
costcontain
instead
previous
note
uhc
aim
longterm
sustain
health
system
abil
develop
provid
proven
eff
ectiv
medicin
peopl
need
includ
disadvantag
group
improv
health
statu
person
satisfact
fi
nancial
protect
ere
citizen
hta
one
method
gener
evid
support
decis
make
select
essenti
medicin
procur
reimburs
ment
input
price
negoti
especi
new
essenti
medicin
hta
end
necessarili
best
method
priorityset
everi
context
hta
method
assess
valu
budget
impact
assess
use
combin
polici
instrument
deliv
aff
ordabl
medicin
note
p
riorityset
solv
challeng
barrier
associ
health
resourc
alloc
howev
support
transpar
account
abil
factor
enhanc
good
govern
commiss
er
follow
key
recommend
promot
aff
ordabl
essenti
medicin
govern
health
system
must
creat
maintain
inform
system
routin
monitor
data
aff
ordabl
essenti
medicin
well
price
avail
public
privat
sector
countri
move
toward
uhc
opportun
respond
need
payer
qualiti
price
inform
procur
reimburs
decis
simultan
countri
measur
progress
provid
aff
ordabl
medicin
monitor
system
inform
decis
make
need
intervent
medicin
price
aff
ordabl
monitor
system
also
need
includ
regular
survey
obtain
data
disaggreg
econom
statu
rural
urban
set
sex
key
popul
group
govern
must
implement
comprehens
set
polici
achiev
aff
ordabl
price
essenti
medicin
countri
move
toward
uhc
consid
use
price
polici
leverag
larg
buyer
power
set
reimburs
limit
refer
creat
incent
prescrib
patient
reimburs
cap
copay
appropri
polici
address
high
price
gener
essenti
medicin
might
requir
diff
erent
set
polici
essenti
medicin
patent
protect
full
rang
medicin
price
polici
intervent
must
employ
ensur
aff
ordabl
essenti
medicin
individu
popul
includ
outcom
health
technolog
assess
decis
deni
coverag
medicin
social
unaccept
politician
might
ask
seek
shortterm
solut
trastuzumab
pose
existenti
challeng
health
technolog
assess
process
england
wale
face
initi
reject
nation
institut
health
care
excel
uk
health
secretari
interven
forc
reimburs
primari
care
trust
cancer
drug
fund
form
specifi
calli
help
patient
get
access
innov
new
cancer
drug
followon
formul
trastuzumab
emtansin
sold
kadcyla
roch
treatment
local
advanc
unresect
metastat
stage
iv
breast
cancer
initi
fund
cancer
drug
fund
schedul
withdrawn
novemb
revers
provok
fi
erc
respons
cancer
group
includ
request
uk
govern
issu
compulsori
licenc
allow
lower
price
version
product
product
remain
avail
cancer
drug
fund
agreement
manufactur
nation
health
servic
england
reach
howev
cancer
drug
fund
consid
longterm
solut
replac
manag
access
fund
sustain
lie
lower
price
medicin
consid
essenti
polit
respons
pharmaceut
benefi
ts
advisori
committe
reject
trastuzumab
also
result
creation
uniqu
fund
programm
australia
trastuzumab
ad
model
list
essenti
medicin
togeth
sever
expens
cancer
treatment
current
avail
directact
antivir
hepat
c
viru
infect
step
fi
rst
process
ensur
equit
access
need
essenti
medicin
exempt
medicin
tax
tariff
progener
polici
case
multisourc
product
use
trip
fl
exibl
case
singlesourc
product
protect
wide
rang
polici
option
countri
abstain
demand
agre
tripsplu
provis
trade
agreement
govern
health
system
must
develop
nation
capac
creat
medicin
benefi
packag
guid
procur
reimburs
aff
ordabl
essenti
medicin
develop
requir
build
capac
identifi
health
technolog
assess
make
greatest
contribut
decis
make
translat
fi
nding
assess
local
context
use
fi
nding
input
decis
make
includ
help
identifi
instanc
govern
interven
relat
medicin
price
govern
nation
health
system
pharmaceut
industri
must
promot
transpar
share
health
medicin
inform
global
region
countri
health
system
must
particip
transpar
share
inform
price
evid
compar
eff
ectiv
costeff
ectiv
estim
econom
assess
ment
technolog
budget
impact
assess
outcom
price
intervent
share
promot
effi
cienci
avoid
duplic
enabl
countri
lower
resourc
use
adapt
assess
medicin
health
technolog
accord
need
adwoa
girl
age
year
rural
villag
feverish
day
mother
grace
fear
daughter
malaria
district
hospit
far
away
grace
went
local
shop
sold
loos
tablet
shopkeep
told
give
adwoa
halftablet
immedi
rest
divid
day
day
later
adwoa
develop
high
fever
experienc
seizur
famili
borrow
money
take
hospit
admit
immedi
treat
cerebr
malaria
although
adwoa
surviv
might
suff
ere
perman
brain
damag
grace
worri
done
someth
wrong
medic
fact
medicin
poorli
manu
factur
contain
enough
activ
ingredi
medicin
complex
product
power
eff
ect
enorm
help
disastr
harm
likewis
medicin
safeti
complex
cover
three
dimens
moleculebas
link
activ
ingredi
productbas
link
qualiti
product
usebas
link
prescriptioneg
right
dosag
right
diseas
section
focus
productbas
qualiti
safeti
usebas
safeti
discuss
section
medic
devic
invitro
diagnost
specifi
calli
consid
medicin
qualiti
safeti
reliabl
assess
consum
even
profession
need
specialis
train
equip
inform
govern
therefor
posit
oblig
protect
health
public
assur
qualiti
safeti
medicin
regul
r
manufactur
market
distribut
use
govern
action
enabl
health
profession
patient
trust
qualiti
safeti
product
market
multiprong
process
becom
even
challeng
biolog
medicin
complex
structur
manufactur
process
includ
biosimilar
poorqual
medicin
also
refer
substandard
spuriou
fals
label
falsifi
ed
counterfeit
panel
caus
seriou
even
fatal
harm
patient
money
spent
poorqual
medicin
wast
least
often
addit
cost
incur
counteract
harm
popul
level
poorqual
medicin
reduc
health
outcom
endang
public
health
exampl
contribut
develop
antimicrobi
resist
loss
public
trust
health
system
commiss
believ
achiev
sustain
develop
requir
concert
eff
ort
improv
qualiti
safeti
essenti
medicin
build
appropri
regulatori
system
part
health
system
new
concept
approach
emerg
recent
decad
section
identifi
es
fi
crucial
area
opportun
improv
qualiti
safeti
essenti
medicin
regulatori
harmonis
pre
qualifi
cation
improv
procur
enhanc
surveil
account
low
qualiti
medicin
continu
pervas
poorli
understood
problem
exampl
survey
found
antimalari
medicin
sampl
cameroon
ethiopia
ghana
kenya
nigeria
tanzania
substandard
consider
diff
erenc
exist
countri
lowest
failur
rate
ethiopia
kenya
highest
nigeria
antituberculosi
medicin
armenia
azerbaijan
belaru
kazakhstan
ukrain
uzbekistan
meet
qualiti
specifi
cation
rifampicin
capsul
failur
rate
result
systemat
review
studi
countri
primarili
lic
lowerm
show
median
preval
substandard
medicin
rang
true
extent
problem
howev
remain
unknown
studi
substandard
falsifi
ed
medicin
focu
infecti
diseas
treatment
especi
malaria
much
less
inform
avail
medicin
ncd
studi
crosssect
survey
provid
inform
one
point
time
studi
design
necessari
enabl
examin
longitudin
chang
impact
poorqual
product
devast
benign
poorqual
medicin
treatment
eff
ect
worst
caus
human
disast
estim
death
children
year
subsaharan
african
countri
attribut
consumpt
poorqual
antimalari
medicin
true
caus
death
rare
note
children
assum
die
malaria
dramat
incid
gener
public
outcri
inclus
toxic
diethylen
glycol
paracetamol
oral
liquid
dosag
form
led
death
children
panama
ingredi
import
china
via
european
broker
disclos
origin
true
content
similar
case
haiti
product
came
dutch
broker
addit
incorrect
activ
ingredi
tablet
cardiovascular
diseas
result
estim
death
pakistan
appendix
case
caus
seriou
neglig
manufactur
subsequ
failur
qualiti
assur
process
includ
failur
proper
regulatori
oversight
survey
hall
p
concept
foundat
unpublish
assess
capac
manufactur
oral
contracept
produc
goodqual
product
gener
manufactur
lmic
survey
declar
complianc
nation
good
manufactur
practic
gmp
standard
yet
less
third
manufactur
plant
met
global
gmp
requir
set
either
pharmaceut
inspect
convent
pharmaceut
inspect
cooper
scheme
jointli
abbrevi
pic
local
gmp
requir
might
distinct
pic
requir
nonglob
gmp
requir
mean
default
product
poor
qualiti
howev
pic
set
global
standard
aim
ensur
qualiti
safeti
anoth
survey
qualiti
misoprostol
mic
show
product
contain
correct
quantiti
activ
ingredi
contain
probabl
falsifi
ed
panel
falsifi
ed
medicin
deliber
fraudul
mislabel
respect
ident
sourc
falsifi
ed
product
often
carri
fake
logo
purport
recognis
innov
gener
brand
might
contain
correct
ingredi
inappropri
amount
wrong
ingredi
activ
ingredi
key
factor
absenc
document
trace
back
legitim
manufactur
suppli
falsifi
ed
medicin
crimin
act
problem
falsifi
cation
distinct
qualiti
problem
product
meet
relev
qualiti
standard
address
involv
wide
array
stakehold
politician
custom
law
enforc
judiciari
sophist
falsifi
ed
medicin
seem
increas
appendix
number
although
clear
extent
better
report
fi
gure
intern
agreement
exist
exact
definit
variou
type
poor
qualiti
product
follow
approach
use
institut
medicin
report
distinct
made
substandard
medicin
genuin
product
fail
meet
nation
standard
set
falsifi
product
spuriou
fals
label
falsifi
medicin
medicin
intent
fake
product
ident
actual
maker
establish
term
counterfeit
use
describ
trademark
infring
problem
primari
concern
public
health
organ
product
may
fall
one
categori
time
exampl
falsifi
product
definit
also
substandard
activ
ingredi
misoprostol
tablet
tend
degrad
rapidli
make
technic
demand
produc
qualityassur
product
concept
foundat
test
sampl
misoprostol
acquir
licens
seller
argentina
bangladesh
egypt
cambodia
kenya
india
indonesia
kazakhstan
mexico
nigeria
nepal
pakistan
peru
philippin
vietnam
fi
gure
product
level
activ
ingredi
within
specifi
cation
horizont
line
fi
gure
less
product
fail
longer
store
product
state
content
found
perhap
compens
advanc
degrad
time
importantli
product
includ
singl
manufactur
contain
neither
misoprostol
princip
degrad
product
classifi
ed
falsifi
ed
diamond
symbol
fi
gure
disguis
brand
product
therefor
counterfeit
well
gener
misoprostol
product
claim
shelf
life
year
innov
product
shelf
life
year
figur
clearli
show
year
product
packag
plasticaluminium
blister
red
circl
fi
gure
fail
failur
rate
full
aluminium
blister
green
circl
fi
gure
lower
still
unaccept
aluminium
blister
guarante
good
qualiti
manufactur
environ
also
need
control
despit
manufactur
challeng
qualityassur
misoprostol
productsal
pack
plasticaluminium
blister
green
squar
box
fi
gure
manufactur
product
approv
stringent
regulatori
author
sra
prequalifi
cation
global
fund
expert
review
panel
squar
box
fi
gure
fail
test
outcom
contrast
nonsra
approv
gener
product
circl
fi
gure
regulatori
oversight
sra
essenti
lifesav
product
pic
see
http
wwwpicschemeorg
sinc
encourag
report
substandard
falsifi
ed
medicin
nation
medicin
regulatori
agenc
nmra
larg
procur
agenc
use
standard
form
data
analys
rapid
alert
system
initi
identifi
cation
problem
reli
voluntari
report
healthcar
profession
nongovernment
organis
pharmaceut
industri
custom
polic
patient
caregiv
august
rapid
alert
system
databas
contain
report
fi
gure
antiinfect
antiparasit
frequent
report
class
falsifi
ed
medicin
although
outcom
might
refl
ect
substanti
resourc
avail
higher
volum
medicin
hiv
tb
malaria
remain
worri
fi
nding
potenti
develop
antimicrobi
resist
databas
reveal
contrari
common
belief
gener
medicin
also
frequent
falsifi
ed
fi
gure
falsifi
ed
vaccin
diagnost
also
emerg
howev
individu
case
report
aggreg
data
publicli
avail
hamper
assess
extent
problem
number
falsifi
ed
medicin
proport
substandard
product
diffi
cult
estim
publish
studi
might
make
distinct
qualiti
problem
use
diff
erent
defi
nition
suff
er
sampl
bia
eg
check
qualiti
suspect
sampl
depend
spontan
report
review
san
suggest
falsifi
ed
product
constitut
small
proport
substandard
product
conclud
nation
intern
action
therefor
focu
prevent
substandard
product
without
specifi
c
focu
falsifi
ed
product
notabl
problem
falsifi
ed
counterfeit
medicin
current
address
memberst
mechan
coordin
replac
earlier
programm
perceiv
parti
industri
driven
review
avail
evid
show
mani
problem
exist
medicin
qualiti
product
safeti
worldwid
action
urgent
need
substandard
medicin
symptom
underli
structur
problem
ensur
complianc
regulatori
standard
gmp
despit
limit
capac
regulatori
system
mani
countri
grow
number
product
facil
product
market
progress
madebut
data
eff
ectiv
regulatori
agenc
need
assur
qualiti
safeti
essenti
medicin
set
commiss
believ
import
opportun
ensur
progress
exist
level
follow
section
identifi
es
opportun
promot
eff
ectiv
regulatori
oversight
involv
multipl
stakehold
suppli
chain
improv
medicin
qualiti
safeti
fi
nal
respons
qualiti
product
rest
manufactur
liabl
case
noncompli
howev
topic
qualiti
product
address
report
govern
respons
creat
enforc
qualiti
safeti
standard
medicin
health
technolog
key
area
discuss
follow
intern
regulatori
harmonis
broaden
prequalifi
cation
programm
good
procur
practic
qualiti
safeti
surveil
commit
advanc
account
nmra
vari
abil
eff
ectiv
regulatori
activ
depend
access
fund
avail
technic
capac
among
factor
past
year
clear
trend
toward
increas
regulatori
harmonis
creat
new
opportun
bolster
nation
eff
ort
intern
resourc
ich
previous
known
intern
confer
harmon
technic
requir
registr
pharmaceut
human
use
also
abbrevi
ich
brought
togeth
regul
pharmaceut
industri
associ
europ
usa
japan
ich
develop
harmonis
guidelin
aim
elimin
dupli
cation
registr
includ
common
technic
document
regulatori
applic
although
initi
perceiv
industri
driven
focus
hic
ich
open
broader
global
perspect
includ
addit
nmra
region
regulatori
harmonis
initi
industri
group
thu
ich
potenti
becom
relev
lmic
intern
confer
drug
regulatori
author
icdra
largest
global
regul
forum
particip
nation
icdra
host
brazil
dedic
separ
meet
regul
similar
biotherapeut
product
biosimilar
issu
use
recommend
countri
view
progress
african
regulatori
system
icdra
fi
rst
time
host
african
nation
south
africa
icdra
forum
especi
valuabl
small
medium
size
regul
forum
ich
past
rare
address
specifi
c
need
pic
provid
activ
construct
forum
cooper
fi
eld
gmp
inspect
mission
pic
promot
cooper
nmra
inspector
lead
develop
harmonis
gmp
standard
pic
establish
rigor
assess
process
inspector
meet
standard
allow
join
scheme
nmra
member
pic
member
hic
upperm
argentina
indonesia
malaysia
south
africa
ukrain
china
brazil
appli
membership
region
harmonis
programm
america
asia
africa
provid
opportun
simplifi
regulatori
process
focu
nmra
activ
add
valu
harmonis
medicin
registr
system
set
east
african
commun
eac
fi
rst
joint
whoeac
product
assess
exercis
organis
un
prequalifi
cation
programm
result
prompt
associ
southeast
asian
nation
asean
develop
asean
common
technic
dossier
asean
common
technic
requir
allow
implement
common
standard
elimin
unnecessari
countryspecifi
c
regulatori
requir
accept
bioequival
report
asean
member
instanc
facilit
faster
market
entri
gener
product
mutual
recognit
arrang
gmp
inspect
report
also
prepar
inform
increasingli
avail
stringent
regulatori
agenc
usa
eu
canada
switzerland
japan
australia
region
author
recognis
refer
author
nmra
especi
resourceconstrain
set
expand
use
inform
instead
emphasis
nation
sovereignti
regulatori
decis
countri
join
collabor
registr
procedur
product
approv
way
short
timelin
increas
share
electron
applic
market
authoris
standard
electron
common
technic
document
format
provid
anoth
oppor
tuniti
speed
approv
process
creat
effi
cienci
pharmaceut
industri
allow
wider
market
essenti
medicin
smaller
market
harmonis
intern
level
need
clear
decis
whether
dossier
alreadi
review
stringent
regulatori
author
follow
intern
agreedupon
standard
requir
reevalu
sever
hic
canada
switzerland
singapor
new
zealand
decid
repeat
assess
resourceconstrain
nmra
also
adopt
approach
rather
invest
repeat
assess
activ
add
consider
valu
continu
relianc
premarket
qualiti
control
test
nmra
also
need
reconsider
action
could
improv
effi
cienci
nmra
activ
enabl
faster
market
entri
import
new
essenti
medicin
qualityassur
gener
face
weak
nation
regulatori
system
mani
countri
reli
verifi
whether
specifi
c
select
medicin
vaccin
invitro
diagnost
product
meet
intern
qualiti
standard
substanti
opportun
strengthen
expand
exist
programm
process
prequalifi
cation
particip
intern
tender
un
procur
began
childhood
vaccin
prequalifi
cation
medicin
start
initi
small
number
aff
ordabl
product
avail
procur
largescal
hiv
treatment
programm
global
fund
august
product
prequalifi
ed
includ
hiv
tuberculosi
malaria
condit
pre
qualifi
cation
diagnost
product
also
expand
focus
mainli
invitro
diagnost
hiv
malaria
hepat
c
august
medicin
qualiti
control
laboratori
prequalifi
ed
procedur
establish
rapidli
assess
product
alreadi
approv
stringent
regulatori
agenc
medicin
urgent
need
prequalifi
ed
product
avail
product
emerg
use
diagnost
test
investig
product
ebola
viru
eff
ect
prequalifi
cation
programm
farreach
exampl
prequalifi
ed
vaccin
immunis
infant
worldwid
without
prequalifi
ed
product
larg
indian
gener
manufactur
widespread
aff
ordabl
access
antiretrovir
would
possibl
qualiti
standard
use
prequalifi
cation
also
adopt
institut
includ
nmra
donor
global
fund
unitaid
mpp
prequalifi
cation
programm
concret
applic
global
norm
standard
medicin
qualiti
safeti
panel
posit
global
regulatori
agenc
greatli
shape
world
gener
market
drive
cost
ensur
qualiti
product
also
becom
import
train
ground
regul
inspector
pave
way
region
harmonis
commiss
believ
whoun
prequalifi
cation
programm
evolv
address
wider
rang
essenti
medicin
least
intern
standard
establish
global
gener
market
develop
suffi
cient
capac
produc
distribut
adequ
suppli
qualiti
safe
medicin
exampl
assess
new
gener
version
fi
rstline
antiretrovir
left
stringent
nation
author
region
network
focu
programm
shift
prioriti
medicin
gener
insulin
biosimilar
newli
develop
essenti
medicin
still
pose
challeng
nmra
programm
qualiti
standard
public
report
use
basi
regulatori
converg
reciproc
recognit
public
assess
report
public
inspect
report
serv
exampl
nmra
transpar
initi
european
australian
regul
also
serv
exemplar
regard
multilater
fi
nanc
mechan
would
enabl
prequalifi
cation
programm
evolv
waynot
mere
increas
exist
activ
move
toward
analysi
select
new
essenti
medicin
independ
individu
donor
manufactur
alik
good
procur
practic
crucial
tool
assur
product
qualiti
safeti
protect
variou
problem
includ
corrupt
mani
intern
organis
global
fund
unitaid
us
pepfar
un
popul
fund
stoptb
global
drug
facil
san
intern
committe
red
cross
implement
strict
guidelin
requir
procur
product
stringent
regulatori
agenc
approv
prequalifi
cation
interim
approv
eg
expert
review
panel
mani
lmic
centralis
medicin
procur
agenc
provid
opportun
appli
good
procur
practic
increas
number
nation
procur
agenc
appli
similar
polici
insist
product
meet
prespecifi
ed
qualiti
standard
mission
essenti
drug
suppli
kenya
pioneer
regard
panel
describ
strict
qualiti
requir
frequent
control
reduc
percentag
qualiti
failur
mani
procur
guidelin
exist
major
challeng
remain
implement
qualiti
procur
complex
costli
corrupt
procur
ment
repres
major
obstacl
nation
intern
agenc
contribut
problem
qualiti
safeti
well
effi
cienci
commiss
believ
countri
move
toward
uhc
must
invest
improv
procur
process
qualityassur
essenti
medicin
use
pool
procur
contribut
improv
aff
ordabl
qualiti
assur
mechan
describ
previous
help
attain
ultim
goal
coordin
intern
nation
eff
ort
requir
achiev
systemwid
sustain
improv
procur
practic
pharmacovigil
continu
monitor
medicin
follow
releas
embrac
overal
concept
patient
safeti
includ
document
advers
reaction
substandard
qualiti
inadequ
use
larg
number
newli
establish
nation
pharmacovigil
programm
lmic
join
programm
intern
drug
monitor
past
year
appendix
lmic
repres
countri
contribut
global
programm
pharmacovigil
although
particip
programm
grow
frequenc
qualiti
report
need
substanti
improv
analysi
socal
safeti
signalsind
emerg
problem
medicin
safetyrequir
sophist
algorithm
might
beyond
capac
lmic
howev
global
databas
vigibas
uppsala
monitor
centr
establish
allow
analysi
aggreg
data
countri
particip
global
programm
vigibas
contain
million
individu
case
safeti
report
fi
gure
although
report
submit
lmic
contribut
increas
contribut
uppsala
monitor
centr
databas
lmic
regul
pharmacovigil
programm
gener
safeti
signal
detect
potenti
medicationrel
safeti
problem
relev
set
use
particular
medicin
concentr
lmic
contribut
safeti
report
substanti
exampl
extrapyramid
disord
artesunateamodiaquin
malaria
treatment
identifi
ed
basi
vigibas
case
report
submit
eight
nation
africa
lmic
new
medicin
tropic
diseas
often
develop
public
health
initi
wide
introduc
without
previou
experi
countri
well
develop
pharmacovigil
system
rather
wait
spontan
report
launch
accompani
activ
surveil
cohort
expos
subject
tropic
diseas
activ
surveil
mechan
establish
safeti
profi
le
new
product
typic
use
condit
region
regu
latori
network
also
harmonis
pharmacovigil
system
adapt
ich
pharmacovigil
requir
situat
member
new
mobil
telephon
technolog
creat
opportun
make
spontan
report
easier
healthcar
profession
patient
method
current
develop
ethic
analys
social
media
inform
earli
identifi
cation
possibl
problem
widespread
introduct
electron
health
record
also
enabl
rapid
access
inform
patient
outcom
expos
popul
earli
experi
suggest
data
mine
technolog
also
use
sinc
found
establish
global
norm
standard
qualiti
assur
cover
stage
product
life
cycl
essenti
medicin
use
global
expertis
well
resourc
resourceconstrain
countri
expert
committe
report
publish
technic
report
seri
set
gener
productspecif
qualiti
safeti
efficaci
standard
medicin
includ
vaccin
blood
product
biosimilar
norm
standard
develop
wide
use
essenti
tool
standardis
qualiti
control
pharmaceut
includ
assign
intern
nonproprietari
gener
name
standard
good
manufactur
practic
manufactur
guidelin
blood
product
regulatori
guidelin
assess
similar
biotherapeut
product
intern
pharmacopoeia
recent
year
major
nation
region
pharmacopoeia
work
toward
converg
harmonis
identifi
substandard
falsifi
ed
productseg
nation
centr
handl
report
quickli
transmit
detail
inform
product
distribut
channel
contact
primari
report
inform
laboratori
capac
test
suspect
product
nmra
invest
develop
capabl
medicin
qualiti
surveil
could
also
advanc
new
tool
requir
analysi
laboratori
thu
new
technolog
could
also
allow
stakehold
gener
public
involv
qualiti
assur
medicin
januari
six
countri
africa
six
countri
asia
prequalifi
ed
medicin
qualiti
control
laboratori
inexpens
mobil
thinlay
chromatographi
techno
logi
becam
avail
known
minilab
global
pharma
health
fund
minilab
detect
markedli
substandard
falsifi
ed
pharmaceut
product
outsid
laboratori
environmentfor
exampl
custom
offi
cesand
requir
specialis
skill
interpret
result
minilab
oper
least
lmic
studi
antimalari
six
african
countri
sampl
test
minilab
sampl
laboratori
minilab
result
cotrimoxazol
larg
compar
classic
test
diagnost
accuraci
medicin
evalu
major
drawback
outcom
depend
visual
acuiti
observ
resolv
smartphon
app
method
especi
use
detect
gross
lack
activ
ingredi
past
decad
varieti
portabl
batterypow
nondestruct
chemic
analys
requir
sampl
prepar
consum
also
develop
techniqu
done
blister
pack
bottl
although
rel
capit
expens
inexpens
run
suitcases
micro
fl
uidic
devic
rapid
chemic
analysi
medicin
develop
us
food
drug
administr
develop
cd
handheld
tool
visual
examin
packag
comparison
refer
imag
devic
laboratorybas
evalu
singl
system
medicin
done
diagnost
accuraci
eas
use
costeff
ectiv
especi
coformul
medicin
assess
handheld
tool
alway
accur
detect
substandard
medicin
use
detect
falsifi
ed
medicin
contain
activ
ingredi
trackandtrac
technolog
also
develop
enabl
suppli
chain
oper
patient
check
true
ident
product
wide
array
technolog
propos
uniqu
serial
number
radio
frequenc
identifi
cation
tag
miniatur
edibl
tablet
tag
short
messag
servic
verifi
cation
usa
medicin
packag
requir
bear
uniqu
serial
number
track
product
suppli
chain
eu
direct
requir
facil
import
buy
sell
medic
product
track
mani
product
twodimension
barcod
ministri
health
malaysia
invest
meditag
hologram
system
crimin
fake
registr
number
ministri
suppli
decod
licens
pharmaci
pharmaceut
enforc
branch
mobil
telephon
technolog
empow
consum
check
authent
product
purchaseeg
scratch
panel
packet
reveal
uniqu
singleus
code
techniqu
increasingli
use
wealthier
countri
asia
africa
implement
system
howev
face
substanti
obstacl
exampl
attempt
falsifi
system
alreadi
uncov
nigeria
conclus
new
technolog
great
potenti
creat
system
prevent
falsifi
ed
product
enter
legal
suppli
chain
requir
constant
mission
essenti
drug
suppli
med
collect
medicin
procur
agenc
faithbas
health
organis
kenya
establish
mani
year
med
strict
qualiti
assur
polici
oper
medicin
qualiti
control
laboratori
prequalifi
ed
buyer
price
charg
invest
qualiti
assur
figur
show
reduct
qualiti
failur
upgrad
strengthen
avoid
infi
ltration
falsifi
er
verifi
cation
system
like
expand
becom
norm
although
diffi
cult
establish
oper
eff
ectiv
mani
lmic
evidenceinform
polici
qualiti
safeti
medicin
propos
commiss
success
concert
consist
polit
pressur
two
world
health
assembl
resolut
call
member
state
strengthen
regulatori
system
medic
product
biotherapeut
polit
leadership
legal
polici
action
adequ
fund
tran
parent
decis
make
collabor
infor
mation
share
resolut
also
charg
support
assess
perform
nmra
indepth
uptod
studi
exist
perform
nmra
two
assess
done
sever
year
ago
found
regulatori
capac
vari
greatli
worldwid
consider
number
nmra
fell
far
short
desir
standard
second
survey
show
progress
number
regulatori
websit
defi
ned
type
qualiti
inform
doubl
anoth
studi
identifi
ed
function
regulatori
websit
updat
pharmacovigil
inform
guidanc
applic
also
becom
frequent
howev
mani
nmra
remain
unabl
minimum
rang
regulatori
function
defi
ned
appendix
commiss
note
perform
data
public
lack
transpar
hinder
eff
ort
creat
greater
account
eff
ectiv
nmra
exampl
studi
african
regulatori
author
identifi
countri
discuss
latin
america
identifi
ed
six
nation
author
refer
neither
criteria
assess
result
public
proactiv
champion
support
public
assess
perform
nmra
make
data
countri
name
assess
avail
public
procedur
limit
independ
entiti
establish
carri
crucial
task
assur
public
account
nmra
sever
condit
must
place
ensur
eff
ectiv
nmra
clear
mission
statement
adequ
medicin
legisl
regul
appropri
organis
structur
facil
clearli
defi
ned
role
respons
adequ
fi
nancial
resourc
develop
retain
staff
ensur
oper
effi
cienci
eff
ectiv
guidelin
procedur
intern
qualiti
assur
system
commiss
believ
polit
attent
deliv
result
specifi
c
target
defi
ned
improv
perform
nmra
timelin
process
outcom
measur
mean
make
assess
publicli
access
commiss
identifi
ed
number
key
area
nmra
great
potenti
progress
panel
key
area
formul
also
serv
indic
regulatori
perform
use
nation
intern
assess
eff
ectiv
mechan
continu
monitor
report
correct
action
need
develop
section
commiss
conclud
despit
impress
progress
sever
area
seriou
problem
remain
medicin
qualiti
safeti
particularli
lmic
mani
manufactur
produc
substandard
product
uppsala
monitor
centr
see
http
wwwwhoumcorg
current
global
suppli
chain
allow
mani
unsaf
dishonest
practic
complex
product
biolog
medicin
also
pose
challeng
regul
regulatori
capac
enforc
insuffi
cient
mani
countri
especi
lmic
limit
threaten
health
peopl
describ
case
adwoa
result
wast
resourc
global
nation
regulatori
system
requir
consider
urgent
reform
strengthen
ing
assur
qualiti
safeti
medicin
contribut
sustain
health
system
achiev
uhc
commiss
argu
qualiti
assur
strategi
establish
larg
donor
programm
aid
tuberculosi
malaria
leverag
ensur
futur
progress
implement
recommend
requir
involv
multipl
stakehold
level
includ
manufactur
govern
procur
end
user
commiss
recommend
specifi
main
actor
involv
implement
global
eff
ort
must
made
promot
harmonis
qualiti
assur
eff
ort
use
intern
standard
regulatori
dossier
cover
format
content
implement
ectd
global
promot
facilit
rapid
exchang
product
assess
site
inspect
report
among
agenc
intens
intern
collabor
electron
exchang
inform
could
simplifi
process
prevent
unnecessari
duplic
eff
ort
dossier
assess
site
inspect
facilit
innov
shorten
approv
time
programm
maintain
move
focu
new
essenti
medicin
evolut
move
attent
matur
product
toward
prioriti
essenti
medicin
pose
special
challeng
regul
human
insulin
biosimilar
newli
develop
essenti
medicin
standard
public
assess
report
form
basi
regulatori
converg
mutual
recognit
lead
rapid
regulatori
approv
sustain
fi
nancial
base
must
creat
maintain
full
independ
donor
manufactur
payer
procur
agenc
must
adopt
good
procur
practic
incorpor
eff
ectiv
transpar
qualiti
assur
qualiti
assur
mechan
must
exist
point
suppli
chain
appropri
qualiti
assur
system
requir
invest
share
test
result
fi
nding
inspect
avoid
duplic
increas
effi
cienci
govern
must
redirect
activ
nation
regulatori
agenc
toward
add
valu
reduc
duplic
eff
ort
engag
system
independ
public
assess
perform
nmra
activ
aim
address
effi
cienci
eff
ectiv
cover
basic
compon
nation
medicin
regulatori
author
special
focu
intern
harmonis
prevent
duplic
eff
ort
mainten
singl
central
nmra
within
countri
inspect
enforc
regul
assess
new
essenti
medicin
neglect
diseas
jurisdict
regul
medicin
promot
transpar
report
preval
substandard
medicin
market
pharma
co
vigil
collabor
domest
manufactur
promot
gmp
abstent
patent
linkag
extend
period
data
exclus
regulatori
agenc
must
encourag
involv
stakehold
gener
public
promot
qualiti
safeti
essenti
medicin
action
achiev
exampl
involv
stakehold
present
regulatori
decis
use
product
qualiti
verifi
cation
test
point
sale
involv
uniqu
barcod
portabl
lowcost
qualitycontrol
equip
technic
devic
link
via
smartphon
internet
nation
govern
must
establish
concret
target
public
account
mechan
assess
perform
nation
regulatori
author
goal
encompass
basic
compon
nation
regulatori
author
list
appendix
recommend
panel
jomkwan
obes
man
age
year
attend
primari
care
clinic
affi
liat
nation
health
insur
scheme
present
symptom
uncontrol
diabet
consult
patient
medic
record
provid
duti
see
patient
prescrib
glibenclamid
mg
daili
last
came
clinic
month
ago
also
diagnos
hypertens
hypercholesterolaemia
upon
question
jomkwan
mention
late
feel
well
state
somewhat
shaki
heart
pound
like
gain
weight
despit
skip
meal
decid
stop
take
glibenclamid
sinc
heard
make
gain
weight
doctor
explain
diabet
medicin
must
taken
everi
day
import
regular
meal
physic
activ
add
new
antidiabet
medicin
sitagliptin
medicin
includ
nation
insur
benefi
packag
jomkwan
regimen
instruct
come
back
checkup
month
jomkwan
return
month
worsen
symptom
see
diff
erent
doctor
tell
accord
standard
treatment
guidelin
metformin
sitagliptin
glibenclamid
use
condit
chang
prescript
metformin
next
checkup
report
feel
much
better
medicin
enorm
potenti
prevent
prematur
death
allevi
suff
ere
contribut
human
wellbeingbut
use
appropri
medicin
benefi
cial
patient
prescrib
clinic
correct
aff
ordabl
medicin
treat
condit
medicin
taken
time
way
recommend
durat
yet
inappropri
use
medicin
continu
despit
decad
eff
ort
improv
clinic
public
health
social
econom
ethic
reason
qualiti
use
medicin
must
becom
need
exist
independ
public
assess
perform
nation
medicin
regulatori
agenc
nmra
follow
key
area
use
suggest
indic
websit
present
full
inform
applic
legisl
regist
product
public
assess
report
approv
product
inform
licens
facil
public
inspect
report
result
riskbas
sampl
qualiti
test
perform
modul
safeti
report
public
websit
essenti
condit
transpar
account
inform
supplement
inform
mean
process
time
applic
consum
might
awar
product
regul
mani
lowincom
middleincom
countri
qualiti
safeti
medic
devic
includ
invitro
diagnost
certain
biolog
product
particularli
blood
blood
product
subject
weak
even
regulatori
oversight
inform
also
contribut
enhanc
transpar
mani
countri
gener
public
patient
involv
regulatori
assess
decis
although
civil
societi
involv
support
adher
human
right
principl
even
polici
exist
paper
mani
countri
struggl
enforc
inspect
mani
agenc
therefor
de
facto
control
market
hold
variou
stakehold
manufactur
import
wholesal
consum
hospit
retail
pharmaci
account
inspect
point
sale
also
inconsist
allow
unregist
untrac
product
suppli
chain
market
sever
countri
includ
usa
china
india
pakistan
regulatori
power
regard
suppli
chain
deleg
state
provinc
lead
discrep
enforc
lack
central
oversight
appendix
data
promot
account
basic
respons
qualiti
safeti
product
lie
manufactur
govern
respons
ensur
manufactur
standard
exist
enforc
yet
collabor
nmra
manufactur
promot
gmp
present
import
opportun
stepwis
approach
toward
obtain
gmp
develop
nigeria
small
increment
step
incentivis
compani
aspir
goal
manufactur
qualityassur
medicin
ghana
ethiopia
similar
phasein
approach
toward
full
gmp
complianc
place
gmp
qualifi
cation
manufactur
facil
unit
motiv
work
toward
productbas
prequalifi
cation
cost
new
rapid
qualiti
assess
tool
drop
potenti
increas
number
qualiti
assess
studi
facilit
accur
determin
preval
substandard
falsifi
ed
product
comparison
across
set
particular
need
exist
studi
qualiti
medicin
noncommunic
diseas
biolog
product
number
report
lowincom
middleincom
countri
still
insuffi
cient
track
inform
could
motiv
nmra
collabor
intern
might
includ
spontan
report
cohort
event
monitor
nation
diseas
control
programm
especi
medicin
neglect
tropic
diseas
releas
countri
includ
highincom
countri
seriou
gap
regul
qualiti
safeti
product
export
bilater
region
trade
agreement
impos
patent
linkag
test
data
exclus
norm
requir
traderel
aspect
intellectu
properti
right
agreement
socal
tripsplu
requir
see
also
section
appendix
explicit
intermedi
perform
goal
health
system
work
toward
uhc
inde
commiss
contend
uhc
necessit
facilit
chang
toward
qualiti
use
medicin
healthcar
deliveri
fi
nanc
system
focu
qualiti
use
medicinesinclud
use
less
expens
equival
product
availablea
core
system
object
wast
resourc
inappropri
use
medicin
short
measur
taken
move
toward
uhc
also
increas
inappropri
use
medicin
ghana
earli
experi
expand
coverag
show
failur
address
medicin
use
threaten
system
sustain
usa
substitut
gener
product
brandnam
counterpart
save
health
system
trillion
estim
common
medicin
sold
lowestpric
gener
rather
origin
brand
cost
could
save
across
countri
mostli
mic
inappropri
use
medicin
longstand
challeng
becom
increasingli
problemat
pharmacotherapi
evolv
prescrib
secondlin
thirdlin
treatment
higher
price
older
safer
fi
rstline
therapi
lower
price
indic
avail
inappropri
exampl
use
insulin
analogu
increas
among
privat
insur
patient
type
diabet
treat
patient
must
take
medicin
clinic
appropri
ill
right
dose
dosag
form
right
time
recommend
durat
patient
caregiv
requir
knowledg
symptom
inform
decid
seek
care
conveni
access
qualiti
medicin
aff
ordabl
cost
knowledg
motiv
skill
use
recommend
medicin
direct
prescrib
must
prescrib
clinic
appropri
costeff
ectiv
product
requir
diagnost
therapeut
decisionmak
skill
uptod
evidencebas
treatment
guidelin
consist
medicin
avail
reimburs
system
reliabl
valid
diagnost
tool
facil
profession
train
time
appropri
incent
act
interest
patient
caregiv
dispens
must
provid
highqual
product
sound
advic
aff
ordabl
price
requir
knowledg
correctli
order
purchas
store
sell
highqual
product
essenti
medicin
reimburs
list
consist
uptod
evidencebas
treatment
guidelin
facil
tool
process
correctli
order
purchas
receiv
store
sell
need
highqual
product
profession
train
time
appropri
incent
act
interest
patient
custom
profession
board
respons
set
standard
train
licens
care
provid
need
licens
continu
educ
requir
promot
compet
clinician
doctor
pharmacist
nurs
other
regulatori
oversight
power
enforc
profession
standard
consum
organis
pharmaceut
manufactur
provid
inform
health
profession
set
directli
public
requir
regulatori
oversight
provid
unbias
evidencebas
inform
public
sector
privat
sector
must
meet
demand
medicin
effi
cient
suppli
system
requir
govern
manag
structur
public
facil
must
function
account
effi
cientli
maximis
eff
ectiv
effi
cient
use
public
resourc
govern
standard
oversight
privat
sector
provid
medicin
lowincom
middleincom
countri
purchas
thirdparti
payer
increasingli
cover
care
cost
system
move
toward
univers
health
coverag
must
make
pharmaceut
coverag
decis
reimburs
arrang
public
privat
sector
provid
incentivis
appropri
use
medicin
requir
fi
nancial
resourc
technic
knowhow
fair
process
manag
tool
ensur
pay
right
medicin
cost
sustain
aff
ord
consid
popul
individu
patient
need
uptod
clinic
evid
routin
collect
inform
monitor
medicin
use
spend
negoti
skill
engag
valuefocus
contract
provid
pharmaceut
manufactur
regul
must
guarante
safe
effi
caciou
highqual
product
avail
market
regul
promot
activ
industri
requir
capac
resourc
review
decid
licens
origin
gener
biosimilar
product
time
manner
capac
resourc
ensur
licens
product
qualiti
independ
transpar
account
regulatori
process
manufactur
import
must
produc
sell
qualiti
medicin
need
work
public
procur
system
wholesal
distributor
establish
effi
cient
suppli
chain
need
regulatori
oversight
technolog
incent
ensur
manufactur
import
distribut
need
qualiti
product
manufactur
associ
establish
monitor
industri
code
conduct
eff
ectiv
regulatori
environ
within
high
standard
code
conduct
enforc
scientist
univers
compani
must
invent
new
molecul
formul
meet
popul
need
requir
societi
industri
philanthropi
fund
incent
conduct
need
research
develop
insulin
usa
increas
associ
increas
patient
outofpocket
cost
clear
evid
clinic
benefi
sinc
poverti
associ
poorer
health
need
medicin
inappropri
use
medicin
poor
could
exacerb
health
dispar
expand
coverag
without
address
medicin
use
harm
patient
wast
resourc
imped
reach
goal
uhc
increasingli
avail
target
therapiesveri
highli
price
highli
eff
ectiv
certain
patient
sub
groupsrepres
anoth
challeng
use
requir
extens
diagnost
test
care
monitor
patient
whose
genom
molecular
cellular
diseas
marker
target
inappropri
use
target
therapi
medicin
also
wast
substanti
resourc
commiss
recognis
three
main
reason
littl
progress
improv
use
medicin
fi
rst
access
medicin
domin
global
discours
fund
medicin
sinc
hiv
treatment
becam
avail
intens
focu
access
limit
focu
issu
appropri
use
potenti
benefi
ts
access
medicin
might
realis
second
reason
problem
inappropri
use
medicin
clear
owner
medicin
use
determin
combin
behaviour
mani
actor
local
nation
health
system
panel
health
direct
indirect
econom
cost
inappropri
use
often
born
individu
patient
household
pay
pocket
medicin
eff
ort
quantifi
systemwid
individu
health
econom
consequ
inappropri
use
larg
specul
reliabl
data
medicin
expenditur
use
individu
patient
scarc
model
link
clinician
patient
behaviour
longterm
health
fi
nancial
outcom
underdevelop
especi
lmic
systemwid
eff
ect
inappropri
use
popul
health
econom
develop
therefor
wide
recognis
final
interven
improv
medicin
use
challeng
wide
array
healthsystem
stakehold
legitim
diff
erent
object
function
incent
infl
uenc
medicin
use
one
driver
inappropri
use
econom
profi
ts
vendor
servic
provid
whose
incom
depend
sell
medicin
fragment
health
system
hinder
concert
systemfocus
eff
ort
improv
medicin
use
problem
exacerb
vertic
programm
access
medicin
focu
specifi
c
health
problem
coordin
sustain
attent
prioriti
medicin
use
problem
also
undermin
rang
factor
almost
singular
focu
part
mani
intern
donor
nongovernment
organis
develop
agenc
access
medicin
aid
tuberculosi
malaria
fragment
frequent
compet
prioriti
across
stakehold
oper
environ
weak
legal
regulatori
structur
lack
awar
problem
inadequ
polit
tackl
commiss
suggest
barrier
qualiti
use
medicin
could
address
explicit
systemwid
evidencebas
emphasi
medicin
use
relev
stakehold
countri
take
concret
step
toward
achiev
univers
coverag
time
right
design
implement
novel
approach
promot
qualiti
use
medicin
build
lesson
past
take
advantag
current
futur
system
opportun
technolog
innov
process
entail
develop
uhc
er
uniqu
opportun
engag
diff
erent
stakehold
gener
new
law
regul
institut
cultiv
informationdriven
organis
manag
coordin
benefi
packag
focus
invest
polici
deliveri
system
strategi
toward
achiev
popul
health
valueformoney
sustain
system
remaind
section
commiss
fi
rst
propos
taxonomi
inappropri
use
summaris
known
intervent
promot
qualiti
use
medicin
describ
nation
strategi
three
countri
improv
use
medicin
lastli
er
action
recommend
promot
qualiti
use
medicin
sinc
nairobi
confer
ration
use
drug
initi
focus
medicin
use
use
variou
terminolog
includ
ration
qualiti
respons
convey
concept
appropri
commiss
use
appropri
use
medicin
refer
use
medicin
consist
clinic
evid
econom
wise
gener
health
valu
money
spent
within
given
budget
phrase
qualiti
use
medicin
use
interchang
confus
focu
product
qualiti
medicin
inappropri
use
medicin
happen
use
much
littl
wrong
kind
medicin
facilit
explor
medicin
use
problem
commiss
classifi
es
inappropri
use
four
categori
unnecessari
use
overus
failur
use
need
medicin
underus
incorrect
use
misus
unnecessari
use
highli
price
medicin
tabl
type
inappropri
use
harm
individu
popul
health
directli
indirectli
wast
scarc
resourc
undermin
public
trust
provid
health
system
medicin
use
depend
behaviour
mani
stakehold
health
system
panel
particularli
diagnosi
prescrib
dispens
practic
provid
careseek
medicinestak
practic
patient
patient
jomkwan
prescrib
antidiabet
medicin
appropri
given
condit
suff
ere
advers
eff
ect
gain
weight
stakehold
involv
regul
fi
nanc
payment
organis
healthcar
deliveri
servic
infl
uenc
behaviour
provid
patient
panel
promot
particularli
relev
regard
panel
result
type
inappropri
use
multipl
contribut
factor
along
complex
chain
develop
licens
manufactur
procur
distribut
prescrib
dispens
buy
imburs
take
medicin
panel
jomkwan
stori
provid
salari
employe
prescrib
less
subject
infl
uenc
fi
nanc
incent
either
underprescrib
stay
within
limit
budget
overprescrib
gener
revenu
might
case
provid
payment
system
eff
ectiv
approach
promot
qualiti
use
reduc
inappropri
use
depend
type
medicin
use
problem
target
system
factor
actor
specifi
c
context
includ
health
system
econom
legal
societ
polit
environ
need
promot
qualiti
use
medicin
optimis
health
outcom
increas
effi
cienci
health
medicin
expenditur
long
recognis
use
wrong
medicin
target
indic
patient
wrong
use
right
medicin
broadspectrum
antibiot
narrowspectrum
antibiot
would
suffi
ce
teratogen
medicin
use
pregnant
women
coprescrib
absolut
contraind
medicin
prescrib
contraind
medicin
base
patient
characterist
eg
aspirin
children
adolesc
treatment
fever
medicin
dose
adjust
patient
age
weight
organ
function
inject
patient
swallow
oral
product
target
cancer
therapi
use
without
confi
rming
presenc
target
unnecessari
use
highli
price
medicin
use
medicin
costli
possibl
equal
eff
ectiv
safe
medicin
use
origin
brand
product
brand
gener
lowerpr
qualiti
intern
nonproprietari
name
gener
product
could
use
use
secondlin
thirdlin
medicin
fi
rstline
medicin
appropri
tri
fi
rst
use
new
highli
price
medicin
question
ad
valu
older
bettercharacteris
medicin
would
suffi
ce
eg
new
oral
inject
option
type
diabet
new
analogu
insulin
type
diabet
therapeut
group
antibiot
address
inappropri
use
requir
key
intervent
outsid
health
sector
eg
agricultur
describ
elsewher
ration
use
medicin
origin
drug
begin
pivot
role
nairobi
confer
sinc
nairobi
confer
member
state
endors
seri
world
health
assembl
resolut
relat
improv
use
essenti
medicin
appendix
resolut
cover
wide
rang
relat
topic
ere
approach
diff
erent
piec
complex
puzzl
among
strategi
urg
member
state
invest
suffi
cientli
human
resourc
provid
adequ
fi
nanc
strength
ene
institut
capac
may
member
state
also
commit
global
action
plan
tackl
antimicrobi
resist
cover
use
antimicrobi
human
health
anim
health
agricultur
mani
studi
assess
strategi
intend
improv
use
medicin
healthcar
provid
user
wide
rang
set
includ
public
privat
sector
healthcar
facil
pharmaci
drug
shop
commun
variou
intervent
target
broad
array
health
worker
commonli
physician
also
paramed
clinic
offi
cer
nurs
midwiv
pharmacist
dispens
shop
attend
commun
health
worker
patient
commun
member
intervent
focus
problem
practic
eg
antibiot
use
inject
use
polypharmaci
care
specifi
c
condit
eg
respiratori
infect
malaria
diarrhoea
hyper
tension
diabet
process
care
eg
diagnosi
laboratori
test
commun
treat
ment
decis
make
explan
medicin
howev
key
contextu
factor
detail
implement
often
poorli
describ
publish
report
summaris
research
eff
ectiv
mani
heterogen
intervent
done
divers
set
therefor
challeng
rx
chang
databas
maintain
canadian
agenc
drug
technolog
health
comprehens
sourc
inform
eff
ectiv
intervent
target
medicin
use
rx
chang
identifi
es
systemat
review
intervent
approach
summaris
result
highqual
review
use
rigor
studi
design
endors
cochran
collabor
eff
ectiv
practic
organ
care
group
use
rx
chang
intervent
classifi
cation
commiss
summaris
evid
eff
ectiv
diff
erent
type
intervent
target
health
profession
fi
gure
appendix
tabl
patient
consum
fi
gure
appendix
tabl
largescal
systemat
review
done
intervent
improv
consum
patient
behaviour
lmic
mani
studi
improv
medicin
use
lmic
focus
strategi
target
rel
small
group
clinician
health
facil
patient
geograph
limit
programm
littl
systemwid
work
done
bring
success
pilot
intervent
scale
assess
eff
ect
two
systemat
review
evid
intervent
improv
healthwork
behaviour
use
eff
ectiv
practic
organ
care
criteria
studi
qualiti
restrict
analys
studi
lmic
fi
rst
holloway
colleagu
summaris
studi
eff
ect
well
design
intervent
improv
treatment
paediatr
infect
gener
outpati
prescrib
median
improv
practic
across
type
intervent
lmic
set
modest
treatment
paediatr
infect
gener
outpati
prescrib
larger
median
eff
ect
tend
occur
multifacet
strategi
combin
sever
compon
exampl
educ
direct
provid
consum
medicin
use
issu
compar
singl
strategi
commun
case
manag
programm
commun
member
train
recognis
treat
common
ill
respiratori
infect
diarrhoea
provid
medicin
supervis
care
deliveri
consist
posit
eff
ect
notabl
higher
strategi
second
systemat
review
health
care
provid
perform
review
methodolog
rigor
largescal
systemat
review
studi
intervent
improv
healthwork
perform
includ
diagnosi
prescrib
dispens
lmic
preliminari
result
indic
highintens
train
day
interact
train
modal
combin
posttrain
supervis
particularli
eff
ectiv
median
improv
lic
mic
intervent
engag
healthwork
team
group
problem
solv
qualiti
improv
collabor
combin
lowintens
train
less
day
interact
train
modal
also
sizeabl
eff
ect
lic
median
improv
howev
studi
intervent
methodolog
limit
mic
support
intervent
patient
commun
member
combin
lowintens
train
health
worker
tend
larg
eff
ect
median
improv
eff
ectiv
increas
intervent
combin
manag
techniqu
strengthen
supervis
infrastructur
govern
median
improv
imci
involv
algorithmbas
symptombas
treatment
common
childhood
ill
extens
healthwork
train
supervis
commun
sensitis
improv
ill
recognit
care
seek
imci
type
multicompon
intervent
literatur
review
suggest
eff
ectiv
howev
nation
evalu
result
sober
countri
found
challeng
scale
strategi
maintain
fi
deliti
approach
commun
engag
gener
weak
essenti
programm
messag
eff
ectiv
commun
furthermor
programm
reach
suff
ere
implement
exclus
reli
public
sector
deliveri
system
fail
involv
sourc
care
assess
suggest
success
implement
larg
nation
programm
improv
use
medicin
requir
specifi
c
technic
design
element
polit
commit
dedic
human
fi
nancial
resourc
coordin
polici
programm
meaning
engag
variou
stakehold
equal
import
programm
one
core
element
heart
stop
tb
strategi
daili
supervis
therapi
often
specialis
tuberculosi
treatment
centr
burdensom
nevertheless
import
dot
frequent
defend
essenti
programm
success
howev
systemat
review
conclud
dot
provid
solut
low
level
adher
given
substanti
resourc
requir
implement
dot
review
conclud
tailor
treatment
model
local
circumst
might
better
address
fi
nancial
logist
barrier
care
well
patient
staff
motiv
issu
despit
sober
assess
result
describ
also
promis
intervent
comparison
three
longterm
nation
programmesfrom
australia
brazil
chinaillustr
diff
erent
prioriti
medicin
use
across
countri
well
multifacet
contextdriven
eff
ort
achiev
improv
coordin
polici
implement
australia
np
medicinewis
commit
ensur
qualiti
use
medicin
np
medicinewis
establish
implement
pillar
australia
nation
medicin
polici
commit
stakehold
ensur
qualiti
use
key
driver
inappropri
use
medicin
pharmaceut
promot
compani
deliber
seek
infl
uenc
sale
target
health
profession
patient
although
data
remain
poor
promot
appear
grow
middleincom
countri
grow
market
increas
number
local
manufactur
directtoconsum
advertis
lack
local
code
market
practic
weaker
regul
lessdevelop
consum
movement
compar
highincom
countri
new
pharmaceut
promot
subtlethey
might
even
immedi
recognis
product
advertis
instanc
receiv
consider
attent
direct
payment
medic
practition
china
global
problem
increasingli
hard
control
compani
transit
digit
method
includ
use
social
media
panel
number
sever
breach
nation
legisl
industri
code
relat
size
compani
extens
literatur
review
hai
found
promot
strongli
infl
uenc
prescrib
prescrib
underestim
infl
uenc
compani
fund
educ
event
research
eff
ectiv
intervent
counter
eff
ect
govern
regul
train
student
media
exposur
abus
promot
free
provis
noncommerci
therapeut
inform
profession
public
yet
regulatori
author
struggl
control
promot
mani
govern
consid
prioriti
enforc
often
poor
preapprov
advertis
ment
scarc
breach
identifi
ed
exposur
weak
penalti
deterr
govern
reli
industri
selfregul
strategi
often
insuffi
cientli
eff
ectiv
voluntari
code
creat
monitor
compani
necessarili
legal
enforc
ethic
criteria
medicin
drug
promot
remain
gold
standard
control
promot
advis
among
strategi
directtoconsum
advertis
prescript
medicin
public
explicitli
anticip
internet
advertis
social
media
ban
directtoconsum
advertis
enough
set
baselin
regul
method
regul
adapt
criteria
contemporari
context
us
sunshin
act
franc
loi
bertrand
dutch
transpar
regist
mandat
disclosur
fi
nancial
link
pharmaceut
compani
healthcar
profession
also
refl
ect
ethic
criteria
transpar
need
follow
independ
review
necessari
correct
action
stricter
regul
pharmaceut
promot
one
core
function
nation
regulatori
author
lack
fund
adequ
monitor
enforc
ment
remain
key
barrier
need
remov
govern
also
ensur
access
unbias
free
inform
medicin
treat
public
good
compani
increasingli
use
wide
rang
digit
market
approach
onlin
event
email
product
updat
webinar
healthcar
profession
use
websit
read
medic
news
connect
peer
obtain
continu
educ
creditsthes
often
incorpor
advertis
sponsor
discuss
forum
market
game
exampl
sermo
alzheim
challeng
invit
site
user
earn
cash
answer
question
clinic
trial
data
brand
product
compani
also
target
consum
app
search
engin
optimis
social
media
campaign
instagram
post
featur
kim
kardashian
promot
morn
sick
medicin
million
social
media
follow
appendix
us
food
drug
administr
order
manufactur
remov
post
ground
fals
mislead
time
decis
reach
post
receiv
nearli
half
million
like
comment
medicin
independ
organis
np
medicinewis
rang
multifacet
evidencebas
activ
intervent
includ
therapeut
behaviour
chang
programm
datadriven
qualiti
improv
ment
report
intervent
consum
awar
campaign
decisionsupport
tool
health
profession
consum
np
medicinewis
also
provid
profession
develop
activ
includ
onlin
learn
onlin
case
studi
clinic
eaudit
educ
visit
indepth
assess
strategi
incorpor
strong
qualit
element
regular
stakehold
survey
well
timeseri
analys
routin
prescrib
data
document
chang
stimul
programm
panel
tabl
fund
australian
govern
np
medicinewis
report
annual
achiev
qualiti
gain
cost
save
addit
save
area
np
medicinewis
programm
across
seven
therapeut
area
result
save
au
million
pharmaceut
benefi
scheme
revenu
report
million
compar
total
spend
billion
np
medicinewis
reach
broad
rang
health
profession
consum
total
health
profession
particip
np
medicinewis
programm
includ
regist
gener
practition
np
medicinewis
also
promin
internet
presenc
million
visit
websit
million
twitter
million
facebook
view
fi
nancial
year
fund
million
depart
health
australia
np
medicinewis
estim
save
pharmaceut
benefi
scheme
million
million
addit
save
medic
benefi
scheme
year
annual
return
invest
billion
sinc
incept
np
medicinewis
estim
deliv
save
australian
govern
million
key
featur
contribut
success
np
medicinewis
includ
independ
govern
coordin
rang
evidencebas
programm
infl
uenc
prescrib
consum
secur
longterm
fund
agre
upon
benchmark
use
ad
hoc
routin
data
evalu
success
increas
rate
antimicrobi
resist
major
public
health
issu
china
substanti
challeng
global
health
overprescript
antimicrobi
use
antibiot
infus
outpati
widespread
primari
health
care
still
emerg
chinaonli
outpati
visit
took
place
primari
care
facil
public
tertiari
care
hospit
main
healthcar
provid
patient
access
hospit
even
common
ill
spur
action
sever
acut
respiratori
syndrom
outbreak
chines
govern
adopt
number
polici
address
antimicrobi
use
fi
gure
ministri
health
china
launch
campaign
promot
appropri
use
antimicrobi
hospit
follow
consult
stakehold
govern
announc
multifacet
packag
polici
reform
hospit
meet
establish
target
risk
downgrad
dismiss
leadership
medic
staff
violat
regul
could
profession
qualifi
cation
revok
intervent
follow
immedi
substanti
reduct
inpati
outpati
antimicrobi
use
although
proport
overus
avail
product
lack
effi
caci
safeti
compar
eff
ectiv
busi
model
incentivis
aggress
market
product
lack
eff
ectiv
regul
limit
licens
ineff
ectiv
product
aggress
market
payment
model
incentivis
highvolum
prescrib
dispens
use
lack
qualifi
ed
prescrib
dispens
care
giver
patient
public
expect
percept
prefer
underus
lack
practic
aff
ordabl
reliabl
valid
diagnost
tool
lack
eff
ectiv
treatment
need
form
certain
condit
suppli
chain
problem
lead
stock
out
test
medicin
lack
qualifi
ed
diagnostician
prescrib
dispens
care
giver
lack
patient
knowledg
resourc
seek
care
purchas
take
medicin
payment
model
incentivis
lowvolum
prescrib
dispens
outofpocket
payment
result
underus
patient
public
expect
percept
prefer
lack
need
dosag
form
strength
lack
practic
aff
ordabl
reliabl
valid
diagnost
tool
therapeut
monitor
test
suppli
chain
problem
lead
stockout
medicin
test
materi
payment
model
incentivis
use
therapeut
drug
monitor
lack
qualifi
ed
prescrib
dispens
care
giver
lack
resourc
therapeut
drug
monitor
limit
time
knowledg
prescrib
dispens
patient
public
expect
percept
prefer
unnecessari
use
highli
price
medicin
ineff
ectiv
regul
guarante
lowcost
qualityassur
gener
product
market
ineff
ectiv
polici
process
encourag
price
qualiti
competit
gener
product
ineff
ectiv
polici
negoti
process
lower
price
medicin
payment
model
incentivis
use
highcost
product
payment
model
incentivis
use
lowcost
qualityassur
gener
product
lack
eff
ectiv
commun
qualiti
valu
lower
cost
highqual
gener
product
lack
commun
evid
guidelinebas
care
algorithm
provid
patient
public
expect
percept
prefer
key
featur
contribut
success
chang
antibiot
use
pattern
includ
sequenti
polici
aim
diff
erent
aspect
problem
avail
data
antibiot
clinic
use
resist
monitor
network
establish
clear
perform
target
threat
individu
institut
sanction
hospit
fail
meet
target
brazil
like
mani
lmic
experienc
demograph
health
transit
requir
increas
focu
strategi
enabl
patient
manag
chronic
ill
especi
diabet
hypertens
intervent
aim
prevent
neg
clinic
consequ
reduc
incid
costli
downstream
health
event
end
brazil
launch
farmacia
popular
fp
programm
fi
gure
fp
design
allevi
two
barrier
qualiti
use
medicin
shortag
medicin
public
sector
health
facil
high
medicin
price
privat
sector
programm
extend
coverag
select
privat
sector
pharmaci
licens
govern
fp
reduc
refer
price
paid
cover
medicin
result
increas
patient
outofpocket
cost
fp
made
medicin
diabet
hypertens
avail
free
patient
fi
prescript
either
public
affi
liat
privat
sector
pharmaci
expand
programm
includ
privat
retail
pharmaci
stimul
programm
growth
allow
patient
access
medicin
conveni
brazilian
ministri
health
data
indic
number
privat
pharmaci
particip
fp
increas
substanti
number
public
fp
pharmaci
also
grew
period
howev
particip
pharmaci
unequ
distribut
higher
coverag
wealthi
area
south
southeast
lower
coverag
mostli
rel
poorer
area
greater
need
improv
access
medicin
north
northeast
govern
took
addit
step
make
specifi
c
medicin
free
patient
privat
sector
alreadi
public
clinic
consequ
govern
expand
market
share
gave
greater
leverag
drive
prescrib
toward
guidelinerecommend
medicin
cover
programm
negoti
lower
price
help
contain
cost
addit
purchas
brazil
govern
access
privat
sector
dispens
data
usual
inaccess
govern
overal
total
patient
receiv
oral
hypoglycaem
patient
receiv
antihypertens
medicin
commiss
analysi
show
proport
day
cover
reach
overal
indic
good
adher
programm
medicin
ere
freeofcharg
govern
integr
use
medicin
data
patient
unifi
ed
data
system
although
outcom
data
yet
link
consum
profi
le
pharmaceut
practic
diff
er
fp
regular
privat
pharmaci
patient
use
fp
pharmaci
like
receiv
inform
regard
dispens
medicin
prescriptiononli
statu
respect
case
contrast
medicin
purchas
privat
pharmaci
occur
without
prescript
fp
experi
suggest
govern
privat
sector
partner
creativ
way
make
care
chronic
ill
conveni
aff
ordabl
patient
howev
programm
come
cost
govern
expenditur
diabet
medicin
reach
us
million
per
month
fi
gure
calcul
commiss
basi
data
brazilian
ministri
health
strateg
manag
use
convers
rate
us
brazil
central
bank
nevertheless
govern
see
privat
sector
partnership
fp
programm
key
compon
current
strategi
reduc
underus
medicin
three
exampl
sever
theme
emerg
inform
develop
programm
sustain
implement
resourc
need
achiev
longterm
qualiti
use
goal
increment
improv
govern
must
commit
coordin
polici
implement
time
medicin
use
problem
multifactori
multipl
stakehold
system
engag
includ
patient
consum
independ
govern
stakehold
could
advantag
australia
np
medicinewis
establish
brand
ident
abil
work
eff
ectiv
across
stakehold
stabil
across
success
polit
administr
polici
programm
need
address
econom
incent
includ
fi
nancial
barrier
face
patient
need
medicin
fi
nancial
incent
drive
prescrib
dispens
healthcar
institut
pharmaceut
industri
reliabl
data
essenti
build
nation
data
system
use
medicin
take
substanti
resourc
concert
longterm
eff
ort
maximis
clinic
valu
evalu
metric
need
focu
access
medicin
price
specifi
calli
appropri
qualiti
use
achiev
clinic
endpoint
resourc
longerstand
pharmaceut
system
develop
lic
lowerm
latter
countri
might
face
great
challeng
tri
mobilis
suffi
cient
resourc
implement
similar
programm
appropri
use
medicin
key
provid
highqual
highvalu
care
use
scarc
resourc
wiselythu
qualiti
use
medicin
key
achiev
goal
uhc
commiss
identifi
es
three
immedi
opportun
advanc
qualiti
use
medicin
uhc
health
system
encount
major
problem
perform
know
medicin
use
cost
detail
inform
analysi
medicin
use
therefor
essenti
inform
relev
assess
medicin
use
construct
data
collect
de
novo
dh
program
stat
compil
health
action
intern
actwatch
exampl
via
survey
household
member
patient
providersand
data
routin
exist
system
procur
prescrib
dispens
payment
record
gener
inform
routin
data
enorm
benefi
ts
routin
collect
data
allow
assess
past
current
practic
pattern
without
cost
time
constraint
denovo
prospect
data
collect
also
refl
ect
actual
practic
system
routin
data
relev
panel
improv
qualiti
use
medicin
australian
provid
consum
np
medicinewis
independ
notforprofi
evidencebas
organis
work
across
australian
health
sector
broader
commun
deliv
improv
medicin
use
better
health
outcom
effi
cient
health
care
np
medicinewis
involv
stakehold
develop
key
messag
produc
mix
public
product
intervent
design
achiev
specifi
c
outcom
inhous
evalu
team
assess
np
medicinewis
activ
part
evalu
process
np
medicinewis
conduct
regular
gener
practition
pharmacist
consum
survey
knowledg
attitud
awar
behaviour
around
medicin
use
np
programm
indic
base
pharmaceut
data
alon
help
focu
attent
key
issu
includ
highlight
variat
among
provid
expect
norm
tabl
data
across
dimens
link
detail
question
address
conclus
indic
valid
import
limit
measur
deter
focus
import
issu
valid
limit
system
focusingand
actingonli
indic
easili
measur
could
skew
resourc
alloc
detriment
either
prioriti
medicin
use
issu
patient
group
less
data
stakehold
whose
behaviour
infl
uenc
use
medicin
includ
govern
ministri
health
fi
nanc
social
secur
offi
ce
privat
payer
nongovernment
organis
civil
societi
organis
local
intern
pharmaceut
manufactur
pharmaceut
distributor
retail
well
medic
nurs
pharmaci
healthcar
profession
academ
patient
citizen
panel
stakehold
relationship
pharmaceut
sector
frequent
characteris
misunderstand
confl
ict
diff
erent
stakehold
legitim
diff
erent
perspect
diff
erent
data
could
use
gener
better
qualiti
inform
medicin
use
identifi
pattern
medicin
use
integr
data
regulatori
procur
deliveri
reimburs
system
well
industri
sale
would
lead
creation
increasingli
sophist
data
system
metric
measur
qualiti
care
health
outcom
meet
inform
need
diff
erent
stakehold
health
system
move
toward
uhc
opportun
emerg
establish
new
stakehold
collabor
act
analys
medicin
inform
chang
use
medicin
system
level
requir
dialogu
role
qualiti
use
medicin
achiev
diff
erent
stakehold
object
enabl
sustain
qualiti
health
care
fi
nanc
system
medicin
transpar
allianc
pilot
meaning
stakehold
engag
seven
countri
howev
project
success
mani
hope
key
lesson
learn
medicin
transpar
allianc
engag
stakehold
requir
build
trust
confi
denc
time
creat
neutral
environ
stakehold
work
togeth
multistakehold
engag
alon
insuffi
cient
creat
chang
care
disclosur
data
essenti
undertak
concert
action
establish
prioriti
implement
nation
intervent
appropri
use
medicin
might
individu
behaviour
must
enabl
core
system
function
pharmaceut
system
continu
chang
new
product
enter
market
evid
best
practic
evolv
inform
move
medic
social
network
clinician
patient
choic
chang
respons
factor
chang
turn
determin
qualiti
care
effi
cienci
health
spend
achiev
posit
health
outcom
ultim
whether
peopl
abl
engag
global
develop
agenda
systemat
coher
process
involv
multipl
stakehold
promot
qualiti
use
medicin
could
develop
follow
concret
activ
data
adapt
permiss
sun
colleagu
comprehens
antibiot
stewardship
programm
hospit
target
outpati
antibiot
prescrib
rate
patient
inpati
antibiot
prescrib
rate
patient
antibiot
prophylaxi
given
incis
continu
h
total
inpati
antibiot
consumpt
defi
ned
daili
dose
per
inpati
day
decemb
antibiot
consumpt
drop
half
highest
level
use
parenter
antibiot
outpati
begun
declin
prioritis
medicin
use
problem
base
estim
health
econom
harm
exampl
follow
assess
trend
valu
volum
top
medicin
provid
public
privat
sector
focu
treat
preval
sever
acut
chronic
health
problem
determin
appropri
use
medicin
respons
highest
cost
volum
especi
use
treat
import
health
problem
determin
appropri
use
highalert
medicin
narrow
therapeut
spectra
thu
high
potenti
fatal
outcom
harm
review
theprob
interrelatedcontribut
system
actor
panel
identifi
key
stakehold
prioriti
problem
identifi
ed
develop
complementari
multifacet
strategi
engag
diff
erent
stakehold
address
prioritis
medicin
use
problem
reach
diff
erent
level
system
build
exist
evid
intervent
impact
fi
gure
appendix
tabl
defi
ning
target
outcom
chang
agre
monitor
assess
indic
implement
com
plementari
programm
implement
research
monitor
strategi
assess
eff
ect
desir
undesir
strategi
use
routin
data
solicit
diff
erent
stakehold
perspect
invest
develop
highimpact
programm
system
potenti
promot
qualiti
use
medicin
provid
consum
long
term
commiss
conclud
promot
appropri
qualiti
use
medicin
explicit
key
object
nation
institut
pharmaceut
clinic
educ
health
fi
nanc
polici
programm
countri
basi
exist
inform
experi
commiss
suggest
acceler
progress
toward
appropri
qualiti
use
medicin
requir
explicit
systemwid
evidenceinform
focu
among
relev
stakehold
therefor
commiss
propos
three
recommend
govern
main
public
privat
payer
operationalis
focu
implement
health
system
reform
toward
uhc
govern
main
public
privat
payer
establish
independ
pharmaceut
analyt
unit
equival
focu
gener
inform
action
promot
qualiti
use
conjunct
object
system
work
toward
uhc
invest
independ
local
institut
produc
policyrelev
pharmaceut
analyt
countri
context
infl
uenc
appropri
structur
resourc
base
support
independ
medicinesfocus
analyt
unit
pharmaceut
analyt
unit
must
collabor
multipl
stakehold
relev
system
increas
engag
account
qualiti
use
medicin
interven
jointli
use
medicin
problem
analyt
unit
independ
public
privat
sector
stakehold
posit
interact
multipl
stakehold
whose
diverg
object
behaviour
might
contribut
appropri
inappropri
use
medicin
engag
inform
gener
analysi
intervent
design
implement
monitor
assess
engag
stakehold
group
led
data
produc
pharmaceut
analyt
unit
identifi
prioritis
local
medicin
use
problem
identifi
contribut
factor
across
system
develop
implement
sustain
longterm
multifacet
intervent
process
multistakehold
engag
prioriti
set
nation
activ
promot
qualiti
use
medicin
result
better
understand
stakehold
underli
assumpt
motiv
object
succeed
must
tangibl
benefi
ts
construct
engag
stakehold
bina
singl
mother
three
children
youngest
born
bina
test
posit
pulmonari
tuberculosi
month
treatment
felt
better
stop
treatment
year
later
began
cough
diagnos
drugresist
tuberculosi
follow
need
daili
inject
least
month
well
mani
pill
bina
terrifi
ed
sure
keep
treatment
continu
support
children
time
beg
doctor
anoth
medicin
easier
use
less
toxic
told
medicin
exist
consid
lucki
live
area
hospit
could
treat
drugresist
tuberculosi
present
system
develop
new
medicin
crisi
larg
fail
produc
muchneed
product
address
health
need
million
peopl
new
essenti
medicin
develop
market
exclus
patent
mechan
allow
price
potenti
make
unaff
ordabl
even
hic
mani
case
miss
essenti
medicin
even
develop
even
though
earli
stage
r
medicin
larg
public
invest
process
take
market
larg
carri
forprofi
compani
pharmaceut
compani
sharehold
typic
reluct
invest
develop
medicin
patient
popul
repres
profi
tabl
market
diseas
predominantli
aff
ect
lmic
problem
high
price
section
miss
essenti
medicin
relat
di
proportion
aff
ect
peopl
lmic
section
present
summari
complex
polit
problem
ingrain
current
patentbas
innov
data
polici
fi
rst
increas
patient
cost
share
made
medicin
avail
free
patient
essenti
medicin
hypertens
diabet
asthma
began
provid
public
privat
pharmaci
zero
copay
patient
chang
led
dramat
rise
particip
programm
patient
diabet
million
prescript
fi
lled
per
month
proport
day
cover
measur
adher
increas
consid
close
optimum
valu
chronic
ill
care
particip
farmacia
popular
proport
day
cover
b
system
examin
initi
address
system
defi
cienci
propos
concert
global
action
public
polici
intervent
lay
foundat
sustain
approach
essenti
medicin
develop
key
problem
current
innov
system
key
exampl
gap
paediatr
treatment
million
children
live
hiv
subsaharan
africa
statist
attract
suffi
cient
commerci
r
invest
alarm
crisi
antimicrobi
develop
anoth
exampl
marketdriven
r
system
invest
new
lifesav
antimicrobi
use
ration
start
prevent
resist
failur
respond
ebola
viru
outbreak
showcas
anoth
exampl
clinic
test
ebola
viru
vaccin
shown
promis
result
took
death
extens
polit
mobilis
take
vaccin
candid
shelf
sit
year
initi
develop
public
health
agenc
canada
extens
r
activ
start
outbreak
threaten
richer
popul
octob
molecul
ebola
viru
treatment
commerci
develop
issu
miss
essenti
medicin
discuss
decad
billion
billion
spent
annual
health
research
orient
need
lmic
wide
quot
studi
san
new
medicin
develop
tropic
diseas
tuberculosi
account
global
diseas
burden
newli
approv
product
neglect
diseas
new
formul
combin
exist
medicin
similarli
decemb
nearli
regist
clinic
trial
neglect
diseas
octob
product
activ
develop
list
neglect
diseas
commiss
analysi
data
work
done
cover
part
need
failur
marketdriven
r
go
beyond
neglect
diseas
analysi
new
medicin
approv
europ
reveal
real
breakthrough
occur
new
medicin
ere
advanc
possibl
help
newli
market
medicin
modifi
ed
version
exist
medicin
ad
littl
treatment
armamentarium
nowaday
r
eff
ort
therefor
yield
truli
innov
product
respond
essenti
public
health
need
new
essenti
medicin
unaff
ordabl
peopl
also
consid
miss
high
price
direct
result
relianc
market
monopoli
grant
patent
system
fi
nanc
r
high
price
new
pharmaceut
product
long
aff
ect
lmic
increasingli
felt
hic
well
medic
specialist
usa
uk
start
protest
section
sever
notfor
profi
product
develop
partnership
neglect
diseas
establish
recent
year
product
develop
partnership
approach
r
invest
fund
upfront
philanthrop
public
fi
nanc
compani
need
recoup
full
cost
r
afterward
high
medicin
price
exampl
includ
drug
neglect
diseas
initi
dndi
medicin
malaria
ventur
global
allianc
tb
drug
develop
intern
aid
vaccin
initi
foundat
innov
new
diagnost
aera
global
tb
vaccin
foundat
program
appropri
technolog
health
govern
major
philanthrop
actor
bill
melinda
gate
foundat
commit
substanti
fund
initi
new
industri
r
platform
creat
new
incent
industri
involv
develop
initi
start
bear
fruit
tabl
exampl
dndi
develop
six
new
treatment
sinc
expect
complet
addit
new
treatment
dndi
expand
scope
neglect
diseas
hiv
hepat
c
antimicrobi
resist
initi
also
provid
import
insight
true
cost
r
panel
yet
research
agenda
initi
larg
follow
prioriti
donor
govern
foundat
transpar
priorityset
process
miss
result
import
therapeut
area
hardli
cover
diabet
cancer
ncd
mental
disord
commiss
conclud
intern
agreement
sought
global
list
miss
essenti
medicin
due
regard
need
lmic
r
list
diseas
support
dedic
fund
list
regularli
updat
past
decad
half
new
push
pull
incent
mechan
establish
new
donor
unitaid
japanes
global
health
innov
technolog
fund
includ
privat
compani
among
other
increas
fund
r
miss
essenti
medicin
longitud
prize
establish
prize
fund
million
develop
pointofcar
diagnost
test
determin
whether
antibiot
appropri
given
case
initi
new
show
defi
nitiv
result
yet
signal
public
privat
interest
new
way
incentivis
innov
commiss
support
assess
altern
incent
new
initi
un
prequalifi
cation
programm
manag
section
ema
articl
adapt
regulatori
activ
global
health
purpos
articl
ema
provid
scientifi
c
assess
coordin
medicin
product
human
use
market
outsid
eu
sinc
us
feder
legisl
allow
prioriti
review
voucher
prv
howev
prv
criticis
provis
product
made
avail
aff
ordabl
prv
also
use
product
alreadi
regist
outsid
usa
compani
invest
r
market
antituberculosi
medicin
bedaquilin
ere
price
around
mic
lic
yet
usa
market
per
treatment
despit
receiv
prv
fasttrack
approv
us
food
drug
administr
eff
ort
underway
includ
access
novelti
requir
legisl
new
regul
encourag
paediatr
medicin
develop
introduc
usa
eu
new
applic
eu
must
includ
data
children
year
unless
specifi
c
waiver
approv
increas
new
paediatr
formul
possibl
yet
cost
societi
might
becom
higher
actual
r
invest
whether
innov
meet
prioriti
need
primarili
use
extend
market
exclus
product
predominantli
adult
indic
remain
unclear
eu
initi
review
r
incent
mechan
includ
paediatr
r
strengthen
balanc
pharmaceut
system
europ
regulatori
approv
new
essenti
medicin
pose
great
challeng
exampl
oner
studi
need
new
paediatr
formul
assess
new
medicin
neglect
diseas
preval
countri
stringent
regulatori
author
commiss
assert
assess
new
medicin
neglect
diseas
led
regulatori
author
aff
ect
area
institut
probabl
need
strengthen
review
enhanc
collabor
stringent
regulatori
author
whoun
prequalifi
cation
programm
section
region
regulatori
initi
within
zone
similar
diseas
pattern
also
support
high
price
medicin
justifi
ed
pharmaceut
industri
compens
cost
r
high
failur
rate
howev
real
cost
r
well
known
panel
industrysupport
estim
set
averag
cost
medicin
develop
billion
per
new
product
tabl
although
direct
comparison
possibl
lack
compar
datapoint
r
cost
data
notforprofi
develop
show
substanti
innov
possibl
much
less
especi
small
molecul
exampl
dndi
real
cost
develop
new
chemic
entiti
includ
cost
failur
estim
million
industri
fi
gure
commiss
argu
transpar
cost
r
enabl
eff
ectiv
dialogu
decis
make
aff
ordabl
price
new
essenti
medicin
fair
return
r
invest
initi
pharmaceut
research
often
larg
fund
public
fund
us
nation
institut
health
european
horizon
programm
childhood
cancer
virtual
research
fund
come
nation
cancer
institut
privat
foundat
philanthrop
sourc
howev
fi
nal
commercialis
step
develop
process
usual
done
forprofi
pharmaceut
compani
obtain
intellectu
properti
right
publicli
fund
research
institut
thu
control
technolog
includ
decis
commercialis
price
medicin
price
public
pay
twice
innov
fi
rst
governmentfund
scientifi
c
research
high
medicin
price
un
special
rapporteur
right
health
paul
hunt
note
b
ecaus
critic
social
function
patent
lifesav
medicin
place
import
righttohealth
respons
patent
holder
respons
reinforc
patent
lifesav
medicin
benefi
ted
r
undertaken
publicli
fund
laboratori
student
movement
univers
alli
essenti
medicin
lobbi
respons
licens
univers
commiss
recognis
need
activ
manag
protect
public
interest
proce
statefund
research
direct
result
global
strategi
plan
action
public
health
innov
intellectu
properti
unitaid
establish
mpp
hiv
medicin
mpp
initi
focus
patent
relat
hiv
medicin
promot
lowcost
gener
product
develop
fi
xeddos
combin
paediatr
formul
mpp
expand
mandat
cover
hepat
c
tuberculosi
novemb
mpp
sign
agreement
bristolmy
squibb
allow
suppli
gener
daclatasvir
lmic
separ
mpp
gilead
scienc
inc
licens
patent
hepat
c
viru
medicin
use
lmic
unfortun
mic
exclud
licenc
must
continu
reli
trip
fl
exibl
access
lowpric
gener
appendix
gener
compani
produc
hepat
c
viru
hiv
medicin
licenc
agreement
mpp
gilead
scienc
inc
mostli
allow
suppli
gener
product
countri
make
use
trip
fl
exibl
year
oper
mpp
million
peopl
benefi
ted
impress
fi
nancial
save
achiev
panel
commiss
conclud
great
potenti
expand
access
new
essenti
medicin
licens
patent
patent
pool
patent
present
substanti
challeng
medicin
avail
howev
fl
exibl
patent
law
use
number
countri
secur
access
gener
medicin
frequent
deploy
fl
exibl
compulsori
licens
medicin
govern
use
patent
waiver
allow
ldc
postpon
grant
enforc
medicin
patent
test
data
protect
option
use
wide
usual
assum
new
fi
gure
real
cost
pharmaceut
research
develop
r
often
kept
trade
secret
industrysupport
estim
set
averag
cost
medicin
develop
us
billion
per
new
product
industryfund
studi
offi
ce
health
econom
came
estim
billion
develop
cost
per
new
product
fi
gure
use
pharmaceut
industri
justifi
high
medicin
price
challeng
other
even
industri
express
sceptic
glaxosmithklin
chief
execut
offi
cer
sir
andrew
witti
call
billion
fi
gure
one
great
myth
industri
light
warburton
estim
net
invest
industri
discov
import
new
medicin
amount
sale
tabl
summaris
r
cost
estim
publish
sinc
global
allianc
tuberculosi
drug
develop
estim
cost
success
develop
new
chemic
entiti
treat
tuberculosi
approxim
million
exclud
cost
failur
cost
cover
preclin
develop
million
pharmaceut
develop
million
phase
clinic
develop
million
includ
cost
unsuccess
project
would
increas
total
cost
million
drug
neglect
diseas
initi
estim
r
expenditur
improv
treatment
ie
combin
product
use
exist
molecul
would
million
drug
neglect
diseas
initi
cost
develop
new
chemic
entiti
estim
million
basi
real
cost
product
develop
product
develop
partnership
includ
cost
failur
estim
includ
inkind
contribut
industri
mpp
see
http
wwwmedicinespatentpoolorg
aboutunitaid
improv
access
medicin
exampl
thailand
cl
erlotinib
docetaxel
letrozol
clopidogrel
save
healthcar
system
million
per
year
past
decad
half
countri
amend
patent
law
refl
ect
health
concern
exampl
india
reward
innov
prevent
trivial
patent
socal
evergreen
patent
south
africa
propos
introduc
patent
examin
limit
number
inappropri
patent
decemb
organis
africain
de
la
intellectuel
amend
bangui
agreement
allow
ldc
member
postpon
grant
patent
protect
regulatori
test
data
howev
plethora
trade
agreement
tripsplu
provis
seriou
threat
polici
legal
space
trip
provid
exampl
provis
patent
linkag
data
exclus
extens
patent
term
scope
restrict
ground
compulsori
licens
parallel
import
provis
appear
variou
trade
agreement
world
trade
organ
access
agreement
china
cambodia
tran
pacifi
c
partnership
agreement
intellectu
properti
chapter
promot
new
standard
global
trade
rule
inform
patent
system
trip
fl
exibl
tripsplu
provis
given
appendix
commiss
believ
govern
must
make
full
use
avail
trip
fl
exibl
enabl
effi
cient
use
nation
legisl
govern
stop
make
tripsplu
demand
trade
agreement
resist
pressur
includ
tripsplu
provis
nation
law
commiss
believ
drive
everhigh
level
intellectualproperti
protect
trade
agreement
stem
probabl
requir
intervent
multilater
level
globalis
norm
patent
protect
high
price
new
product
make
success
pharmaceut
busi
model
thu
satisfi
need
investor
howev
increasingli
clear
approach
endang
progress
realis
global
health
equiti
object
human
right
global
commun
laid
vision
health
care
human
right
treati
intern
coven
econom
social
cultur
right
enshrin
right
health
ratifi
ed
countri
right
essenti
medicin
key
compon
right
health
also
impli
certain
human
right
oblig
pharmaceut
compani
pharmaceut
compani
fail
acknowledg
uniqu
role
societi
provid
lifesav
medicin
one
assess
fi
larg
pharmaceut
compani
show
corpor
social
respons
approach
inconsist
appli
case
offi
cial
compani
credo
fact
refl
ect
compani
action
exampl
johnson
johnson
publicli
commit
strive
reduc
cost
maintain
reason
price
yet
compani
licens
hiv
medicin
patent
mpp
one
hiv
medicin
darunavir
price
per
patient
per
year
certain
lmic
market
mg
dose
declin
usa
price
novarti
imatinib
treatment
chronic
myeloid
also
vigor
defend
patent
lmic
strive
access
imatinib
abbvi
charg
mic
per
patient
per
year
lopinavirritonavir
twice
price
per
patient
per
year
ldc
price
chang
sinc
price
per
patient
per
year
quot
lopinavir
ritonavir
malaysia
investor
profi
tseek
blame
compani
fail
arrang
access
price
pharmaceut
manufactur
lmic
also
expect
contribut
public
health
need
howev
mani
fail
produc
essenti
medicin
produc
accord
accept
qualiti
standard
panel
academ
institut
seek
increas
commerci
valu
research
also
insuffi
cient
focu
develop
miss
essenti
medicin
initi
focu
r
neglect
diseas
develop
countri
driven
mani
intern
polici
develop
area
howev
simplist
dichotomi
develop
develop
countri
longer
appropri
lmic
experienc
epidemiolog
transit
increas
preval
ncd
certain
neglect
tropic
diseas
emerg
diseas
also
pose
threat
hic
due
climat
chang
intern
travel
therefor
high
price
patent
newli
develop
essenti
medicin
aff
ect
everyon
set
lack
privat
sector
invest
develop
medicin
diseas
aff
ect
peopl
without
purchas
power
small
patient
popul
often
describ
market
failur
commiss
disagre
reli
profi
tdriven
r
model
respond
public
health
need
repres
public
polici
failur
nobel
laureat
sir
john
sulston
said
recogn
free
market
good
servant
bad
master
take
import
global
decis
basi
free
market
alon
inadequ
regul
busi
sector
protect
promot
human
right
also
public
polici
failur
commiss
conclud
govern
intervent
includ
intern
level
need
ensur
market
respond
public
health
need
hold
privat
sector
partner
account
includ
regard
respons
protect
promot
human
right
imper
govern
act
press
global
market
pharmaceut
product
almost
trillion
expect
reach
trillion
market
share
lmic
particularli
asia
latin
america
grow
rapid
pace
global
medicin
market
repres
money
public
spend
either
pocket
health
insur
social
secur
scheme
taxbas
governmentprovid
health
care
yet
previous
describ
industri
invest
r
neglect
diseas
remain
low
public
privat
invest
r
neglect
diseas
billion
pharmaceut
corpor
contribut
million
latter
amount
repres
total
industri
r
spend
billion
notforprofi
r
initi
compens
defi
cienci
current
system
provid
perman
solut
underli
fundament
problem
innov
system
reli
market
exclus
commiss
believ
govern
need
proactiv
set
public
healthbas
research
prioriti
socal
essenti
r
leav
prioriti
pharmaceut
manufactur
govern
also
need
fi
nanc
new
model
biomed
innov
address
access
earli
stage
develop
global
health
innov
technolog
base
japan
massiv
spend
pharmaceut
increasingli
higher
price
medicin
repurpos
shape
new
r
framework
countri
requir
intern
agreement
regul
concept
delink
cost
price
base
premis
cost
risk
associ
r
reward
incent
r
provid
mean
price
product
r
cost
new
medicin
recoup
high
price
medicin
would
free
market
exclus
could
made
wide
avail
aff
ordabl
price
better
competit
commiss
support
propos
progress
delink
cost
r
prioriti
medicin
price
product
develop
new
way
share
cost
burden
innov
intern
jame
love
suggest
hear
un
high
level
panel
access
medicin
march
let
outcompet
patentbas
innov
exampl
countri
could
contribut
develop
miss
essenti
medicin
amount
pro
portion
econom
develop
contribut
would
refl
ect
r
essenti
medicin
global
public
good
would
help
ensur
fruit
r
eff
ort
access
state
access
drug
depend
decis
privat
compani
also
govern
respons
intens
negoti
member
adopt
global
strategi
plan
action
public
health
innov
intellectu
properti
gspa
gspa
encourag
needsdriven
research
rather
pure
marketdriven
research
contain
mani
practic
recommend
sever
propos
made
new
polici
framework
particular
new
intern
agreement
medic
r
achiev
two
object
innov
access
fi
rst
propos
made
hubbard
love
year
propos
receiv
support
increas
number
govern
scientist
nobel
laureat
civil
societi
organis
expert
repres
research
intern
organis
also
call
global
biomed
r
fund
mechan
innov
public
health
import
separ
global
fi
nanc
mechan
innov
discuss
neglect
diseas
antimicrobi
ebola
viru
lack
suffi
cient
commerci
market
opportun
prioriti
lic
mic
hic
alik
medic
tool
address
consid
global
public
good
r
need
reconcil
within
global
umbrella
framework
fund
coordin
r
emphasis
innov
also
secur
access
need
new
global
approach
reinforc
un
secretarygener
ban
kimoon
call
new
deal
establish
highlevel
panel
access
medicin
novemb
scope
panel
investig
review
assess
propos
recommend
solut
remedi
polici
incoher
justifi
abl
right
inventor
intern
human
right
law
trade
rule
public
health
context
health
technolog
member
state
continu
discuss
monitor
coordin
fi
nanc
health
r
take
account
report
un
panel
consult
expert
work
group
research
develop
financ
co
ordin
recommend
establish
biomed
r
treati
panel
talk
new
r
framework
like
intens
polit
negoti
gspa
import
clear
r
prioriti
inform
process
necessari
practic
detail
new
medic
r
framework
need
negoti
global
discuss
r
prioriti
provid
opportun
nation
govern
un
fulfi
l
oblig
present
bold
new
global
framework
achiev
dual
object
healthne
driven
r
equit
access
product
pool
patent
new
essenti
medicin
promot
univers
access
innov
basi
posit
outcom
mpp
commiss
conclud
wide
scope
patent
pool
essenti
medicin
defi
ned
nation
committe
end
current
mpp
could
expand
essenti
mpp
empp
expans
would
creat
opportun
compani
licens
patent
purpos
creat
competit
gener
market
essenti
medicin
line
respons
protect
promot
human
right
patent
medicin
develop
new
research
agreement
new
fi
nanc
mechan
could
also
licens
empp
use
tier
royalti
system
remuner
patent
holder
contribut
r
expenditur
level
proportion
economi
countri
medicin
use
commiss
note
patent
owner
refus
licens
essenti
medicin
empp
would
satisfi
condit
grant
compulsori
licenc
trip
articl
requir
grante
made
eff
ort
obtain
authoris
right
holder
reason
commerci
term
condit
requir
case
nation
emerg
extrem
urgenc
public
noncommerci
use
govern
also
ensur
nation
patent
legisl
allow
easi
deploy
trip
fl
exibl
eff
ectiv
automat
licens
essenti
medicin
absenc
voluntari
agreement
regulatori
rule
protect
test
data
provid
necessari
fl
exibl
regist
product
submit
license
see
also
section
pharmaceut
industri
live
special
respons
instanc
import
achiev
industri
open
collabor
appar
exampl
includ
mpp
collabor
research
vaccin
neglect
diseas
research
recent
year
panel
intern
agreement
research
develop
r
sever
propos
made
intern
agreement
medic
r
achiev
two
object
fi
nanc
need
innov
equit
access
innov
key
featur
agreement
includ
r
prioriti
driven
health
need
rather
commerci
potenti
bind
oblig
govern
invest
r
equit
distribut
contribut
across
countri
measur
improv
regulatori
environ
measur
ensur
aff
ordabl
end
product
accessmaximis
licens
practic
deal
intellectu
properti
issu
innov
approach
promot
r
delink
cost
ultim
sale
price
agreement
could
craft
auspic
whose
constitut
allow
member
state
negoti
formal
intern
law
formal
inform
norm
guidelin
global
strategi
infl
uenc
behaviour
state
actor
bind
intern
law
er
sever
potenti
advantag
import
preced
set
framework
convent
tobacco
control
fi
rst
public
health
agreement
negoti
within
contribut
signifi
cantli
global
tobacco
control
eff
ort
fi
rm
made
list
patent
avail
glaxosmithklin
announc
fi
le
enforc
patent
lic
licens
patent
lmic
make
patent
landscap
transpar
commit
futur
oncolog
medicin
patent
patent
pool
hope
develop
might
set
import
preced
yet
deep
chang
impli
new
global
r
framework
also
requir
gener
cultur
chang
industri
among
investor
detail
descript
would
expect
industri
formul
sinc
exampl
un
special
rapporteur
human
right
council
defi
ned
human
right
respons
pharma
ceutic
compani
respons
includ
refrain
action
limit
access
pursu
stronger
intellectu
properti
protect
also
take
reason
step
make
new
medicin
access
need
within
viabl
busi
model
compani
violat
human
right
principl
give
nation
govern
strong
justifi
cation
impos
correct
measur
compulsori
licenc
domest
product
import
atm
index
independ
review
mechan
polici
practic
larg
pharmaceut
compani
regard
lmic
assess
everi
year
atm
index
strongli
base
human
right
principl
refi
ned
time
collabor
industri
commiss
believ
move
away
exclus
profi
torient
approach
toward
patientcentr
publiccentr
sociallyrespons
open
collabor
enterpris
would
improv
global
health
reput
pharmaceut
industri
result
special
natur
product
pharmaceut
industri
uniqu
role
societi
live
special
respons
seen
access
new
essenti
medicin
key
compon
uhc
progress
realis
right
health
develop
describ
section
repres
real
progress
help
bring
new
essenti
medicin
market
certain
diseas
bring
medicin
price
yet
recommend
polici
often
restrict
certain
therapeut
area
eg
hiv
neglect
diseas
paediatr
formul
sustain
larg
depend
charit
contribut
repair
excess
partial
solut
leav
exist
system
place
current
patentbas
innov
system
feasibl
achiev
maintain
uhc
serious
risk
commiss
therefor
believ
busi
usual
resolv
problem
r
concert
global
action
way
forward
new
global
r
polici
framework
need
drastic
adapt
current
model
reduc
relianc
market
exclus
main
driver
innov
commiss
conclud
public
healthori
r
system
need
recognis
countri
tackl
issu
intern
public
polici
play
much
greater
role
set
r
prioriti
fi
nanc
coordin
new
approach
promot
access
new
essenti
medicin
practic
commiss
conclud
govern
need
defi
ne
list
miss
essenti
medicin
provid
uhc
scheme
govern
nongovernment
organis
need
make
necessari
r
fi
nanc
mechan
avail
identifi
ed
need
price
new
essenti
medicin
delink
develop
cost
product
made
wide
avail
aff
ordabl
nonexclus
licens
agreement
result
decreas
price
provid
fi
nancial
space
directli
fi
nanc
identifi
ed
prioriti
r
commiss
analysi
show
challeng
access
new
essenti
medicin
directli
associ
failur
current
r
system
develop
much
need
new
medicin
commiss
make
follow
recommend
stronger
public
polici
r
includ
intern
level
govern
must
take
intern
public
leadership
prioriti
set
essenti
r
due
regard
public
health
need
lmic
includ
develop
list
miss
essenti
medicin
within
context
global
health
r
observatori
close
connect
model
list
essenti
medicin
mechan
identifi
miss
essenti
medicin
develop
involv
relev
stakehold
govern
must
lead
process
toward
global
r
polici
framework
agreement
includ
new
fi
nanc
mechan
ensur
miss
essenti
medicin
develop
made
aff
ordabl
mechan
base
transpar
estim
real
cost
r
might
includ
pool
fund
global
health
r
prize
fund
target
research
partnership
advanc
market
agreement
licens
relat
patent
lead
increas
number
new
prioriti
product
aff
ordabl
price
delink
r
cost
known
progress
delink
indic
measur
progress
essenti
medicin
polici
persist
promin
gap
exist
current
situat
access
aff
ordabl
qualityassur
essenti
medicin
ideal
equit
access
essenti
medicin
previou
section
commiss
made
seri
recommend
basi
evid
crucial
analysi
intend
guid
countri
toward
progress
close
gap
panel
commiss
recognis
implement
recommend
posit
essenti
medicin
integr
part
uhc
major
contribut
sustain
develop
requir
adapt
local
circumst
fi
nal
section
address
challeng
account
propos
set
indic
panel
measur
implement
recommend
describ
criteria
use
select
indic
indic
tie
strategi
outlin
recommend
well
crosscut
theme
set
indic
intend
help
nation
govern
intern
commun
establish
system
review
correct
action
essenti
medicin
polici
move
world
toward
account
equit
access
essenti
medicin
system
would
hold
stakehold
includ
govern
multilater
agenc
account
steadi
progress
toward
eff
ectiv
implement
essenti
medicin
polici
compon
uhc
final
section
propos
next
step
toward
creat
stakehold
agreement
indic
defi
ning
global
nation
target
appropri
establish
ing
independ
review
mechan
enabl
measur
progress
ultim
correct
action
three
theme
cut
across
prioriti
area
action
essenti
medicin
polici
discuss
commiss
prioritis
equiti
access
appropri
avail
aff
ordabl
qualiti
essenti
medicin
import
peopl
diffi
cult
achiev
among
poor
otherwis
marginalis
popul
within
nation
promot
equiti
access
essenti
medicin
must
key
prioriti
throughout
report
commiss
note
special
import
essenti
medicin
polici
contribut
achiev
equiti
disaggreg
data
ensur
diff
erent
strata
societi
well
repres
compar
measur
eff
ect
polici
strengthen
institut
throughout
report
commiss
identifi
ed
rang
specialis
knowledg
skill
requir
implement
essenti
medicin
polici
well
collect
analys
data
decis
make
account
capac
rest
sole
singl
person
countri
sustain
account
institut
structur
process
must
creat
support
develop
administ
implement
assess
polici
one
key
structur
process
independ
review
mechan
identifi
correct
action
necessari
capac
variou
institut
carri
task
must
strengthen
establish
explicit
mandat
assur
independ
provis
dedic
fund
promot
account
account
refer
respons
meet
specifi
c
oblig
actor
answer
one
anoth
public
transpar
process
ultim
aim
uhcimprov
health
statu
protect
fi
nancial
catastroph
due
ill
achiev
patient
satisfactionrequir
commit
concert
action
govern
partner
govern
must
demonstr
citizen
polici
institut
administr
mechan
implement
polici
accomplish
goal
increasingli
govern
also
agre
demonstr
progress
intern
commun
sdg
track
chang
data
must
collect
analys
share
stakehold
account
requir
transpar
decis
make
result
independ
assess
intervent
stakehold
particip
process
decis
make
also
promot
account
benefi
ciari
must
repres
whenev
decis
made
behalf
civil
societi
particip
key
repres
public
larg
well
protect
particular
subgroup
crosscut
theme
align
broader
global
agenda
sdg
uhc
strengthen
health
system
progress
realis
human
right
health
core
indic
commiss
recommend
intend
complement
develop
sdg
includ
core
health
indic
initi
medicin
transpar
allianc
good
govern
medicin
approach
made
substanti
insuffi
cient
contribut
increas
transpar
relat
medicin
eff
ort
need
expand
inform
medicin
price
avail
qualiti
pay
basket
essenti
medicin
govern
nation
health
system
must
provid
adequ
fi
nanc
ensur
inclus
essenti
medicin
benefi
packag
provid
public
sector
health
insur
scheme
govern
nation
health
system
must
implement
polici
reduc
amount
outofpocket
spend
medicin
intern
commun
must
fulfi
l
human
right
oblig
support
govern
lowincom
countri
fi
nanc
basic
packag
essenti
medicin
unabl
domest
govern
nation
health
system
must
invest
capac
accur
track
expenditur
medicin
especi
essenti
medicin
public
privat
sector
disaggreg
prepaid
outofpocket
expenditur
among
import
key
popul
make
essenti
medicin
aff
ordabl
govern
health
system
must
creat
maintain
inform
system
routin
monitor
data
aff
ordabl
essenti
medicin
well
price
avail
public
privat
sector
govern
must
implement
comprehens
set
polici
achiev
aff
ordabl
price
essenti
medicin
govern
health
system
must
develop
nation
capac
creat
medicin
benefi
packag
guid
procur
reimburs
aff
ordabl
essenti
medicin
govern
nation
health
system
pharmaceut
industri
must
promot
transpar
share
health
medicin
inform
assur
qualiti
safeti
essenti
medicin
global
eff
ort
must
made
promot
harmonis
qualiti
assur
eff
ort
use
intern
standard
regulatori
dossier
cover
format
content
evolv
whoun
prequalifi
cation
programm
maintain
move
focu
new
essenti
medicin
payer
procur
agenc
must
adopt
good
procur
practic
incorpor
eff
ectiv
transpar
qualiti
assur
mechan
govern
must
redirect
activ
nation
regulatori
agenc
toward
add
valu
reduc
duplic
eff
ort
engag
system
independ
public
assess
perform
nmra
regulatori
agenc
must
encourag
involv
stakehold
gener
public
promot
qualiti
safeti
essenti
medicin
nation
govern
must
establish
concret
target
public
account
mechan
perform
nation
regulatori
author
promot
qualiti
use
essenti
medicin
govern
main
public
privat
payer
establish
independ
pharmaceut
analyt
unit
equival
focu
gener
inform
action
promot
qualiti
use
conjunct
object
pharmaceut
analyt
unit
must
collabor
multipl
stakehold
relev
system
increas
engag
account
qualiti
use
medicin
interven
jointli
use
medicin
problem
engag
stakehold
group
led
data
produc
pharmaceut
analyt
unit
identifi
prioritis
local
medicin
use
problem
identifi
contribut
factor
across
system
develop
implement
sustain
longterm
multifacet
intervent
develop
miss
essenti
medicin
govern
must
take
intern
public
leadership
prioriti
set
essenti
r
due
regard
public
health
need
lowincom
middleincom
countri
govern
must
lead
process
toward
global
research
develop
polici
framework
agreement
includ
new
fi
nanc
mechan
ensur
miss
essenti
medicin
develop
made
aff
ordabl
intern
commun
must
creat
gener
essenti
medicin
patent
pool
govern
nation
stakehold
must
develop
implement
comprehens
nation
action
plan
guarante
equit
access
new
essenti
medicin
pharmaceut
industri
must
better
align
research
develop
prioriti
set
global
health
need
develop
access
strategi
make
medic
import
innov
avail
need
use
gener
nation
intern
level
contribut
countri
health
system
polici
consid
global
public
good
similar
price
inform
medicin
made
avail
manag
scienc
health
share
hta
result
clinic
trial
registri
commiss
acknowledg
gener
inform
requir
upfront
invest
public
good
respect
cost
case
recoup
longer
term
commiss
understand
access
good
qualiti
inform
necessari
suffi
cient
condit
improv
access
goodqual
essenti
medicin
mani
factor
need
mobilis
assur
eff
ectiv
adopt
implement
necessari
essenti
medicin
polici
commiss
recognis
enough
done
establish
coordin
global
approach
strengthen
essenti
medicinesrel
institut
hold
accountablethi
key
aim
commiss
recommend
indic
commiss
propos
follow
indic
measur
progress
recommend
key
area
pay
essenti
medicin
total
pharmaceut
expenditur
percentag
total
health
expenditur
per
capita
total
pharmaceut
expenditur
public
sector
expenditur
pharmaceut
percentag
total
pharmaceut
expenditur
household
expenditur
pharmaceut
percentag
total
household
expenditur
outofpocket
expenditur
pharmaceut
percentag
total
pharmaceut
expenditur
aff
ordabl
essenti
medicin
median
avail
basket
essenti
medicin
public
privat
sector
percentag
median
consum
price
ratio
basket
essenti
medicin
public
privat
sector
median
public
sector
procur
reimburs
price
essenti
medicin
percentag
intern
refer
price
market
share
multisourc
medicin
brand
unbrand
gener
product
volum
valu
public
privat
sector
exist
independ
nation
programm
institut
promot
scientifi
calli
sound
costeff
ectiv
use
medicin
yesno
stakehold
represent
includ
civil
societi
patient
repres
independ
programm
institut
specifi
calli
provid
yesno
qualiti
prescrib
public
privat
sector
adher
nation
standard
treatment
guidelin
common
condit
public
privat
sector
legal
enforc
code
market
practic
place
implement
yesno
develop
miss
essenti
medicin
number
licenc
agreement
concern
essenti
medicin
conclud
patent
pool
stratifi
ed
inlic
outlic
number
product
produc
essenti
medicin
patent
pool
licenc
authoris
least
one
follow
intern
council
harmonis
pharmaceut
inspect
convent
pharmaceut
inspect
cooper
scheme
member
whoun
prequalifi
cation
programm
nation
law
includ
patent
medicin
regul
law
contain
eff
ectiv
provis
applic
traderel
aspect
intellectu
properti
right
compat
fl
exibl
yesno
share
research
pipelin
refl
ect
new
molecul
diseas
within
scope
atm
index
per
compani
equiti
data
stratifi
ed
follow
variabl
gender
ethnic
educ
place
resid
wealth
quintil
market
share
essenti
medicin
volum
measur
addit
medicin
gener
indic
requir
valid
individu
indic
prescript
includ
antimicrobi
desir
threshold
polypharmaci
prescript
desir
threshold
prescript
includ
inject
desir
threshold
medicin
prescrib
gener
name
desir
threshold
medicin
prescrib
essenti
medicin
list
reimburs
list
desir
threshold
refer
grant
licenc
patent
pool
patent
holder
outlicens
refer
licens
gener
produc
patent
pool
accord
provis
origin
licenc
pool
eg
geograph
scope
limit
specifi
c
type
dosag
form
paediatr
dosag
form
pharmaceut
sector
long
characteris
lack
transpar
exacerb
lack
account
meet
global
health
essenti
medicin
goal
demonstr
com
munic
progress
crucial
increas
transpar
also
enabl
identifi
cation
good
practic
eff
ectiv
implement
essenti
medicin
polici
progress
track
independ
agenc
govern
multilater
organis
might
confl
ict
interest
commiss
propos
core
indic
panel
expect
govern
health
author
stakehold
use
creat
baselin
measur
assess
essenti
medicin
polici
develop
implement
share
data
countri
would
help
refi
ne
instrument
repeat
measur
time
would
reveal
progress
demonstr
eff
ectiv
medicin
polici
correct
action
document
progress
essenti
medicin
polici
would
help
direct
resourc
eff
ectiv
programm
health
institut
set
appropri
target
indicatora
crucial
compon
continu
develop
processremain
done
action
requir
activ
involv
relev
stakehold
contextspecifi
c
need
past
perform
must
taken
consider
defi
ning
target
prioriti
area
improv
sinc
propos
core
indic
alreadi
well
establish
valid
countri
begin
immedi
use
assess
current
perform
formul
target
exist
data
appropri
disaggreg
addit
eff
ort
need
address
defi
cit
propos
new
indic
urgent
need
valid
set
target
measur
indic
alon
drive
eff
ectiv
chang
propos
set
indic
meant
steppingston
toward
account
system
eff
ectiv
essenti
medicin
polici
implement
continu
process
mechan
must
establish
incentivis
improv
implement
correct
action
desir
multipl
independ
institut
includ
academ
centr
studi
essenti
medicin
avail
price
consumpt
key
nongovernment
organis
long
play
import
role
collect
dissemin
inform
health
system
perform
relat
essenti
medicin
hold
diff
erent
actor
account
exampl
health
action
intern
taken
lead
measur
avail
price
medicin
transpar
intern
assess
govern
transpar
pharmaceut
sector
identifi
corrupt
implement
prevent
strategi
likewis
privat
busi
nongovernment
organis
sector
undertak
medicin
qualiti
measur
mission
essenti
drug
suppli
kenya
gather
intellig
market
dynam
im
health
data
sourc
limitationseg
market
intellig
inform
might
includ
inform
small
countri
specifi
c
geograph
regionsbut
mani
set
might
sourc
type
inform
nongovernment
actor
need
continu
play
part
measur
progress
substitut
nation
global
government
leadership
stewardship
dedic
fund
necessari
state
percentag
medicin
procur
reimburs
budget
australia
np
medicineswis
demonstr
possibl
obtain
return
small
invest
medicin
budget
fi
nancial
year
save
medicin
expenditur
commiss
recommend
countri
establish
support
independ
institut
programm
fulfi
l
key
function
includ
collect
analys
di
semin
inform
price
medicin
avail
aff
ordabl
qualiti
use
coordin
hta
valuebas
analysi
new
exist
essenti
medicin
improv
use
medicin
commiss
use
sever
criteria
select
propos
indic
first
commiss
gave
prefer
use
exist
valid
indic
rather
creat
new
one
use
exist
valid
indic
mean
histor
data
avail
baselin
benchmark
furthermor
indic
advantag
proven
feasibl
data
collect
howev
exist
indic
cover
recommend
made
commiss
thu
commiss
also
includ
new
indic
requir
valid
second
instead
input
indic
eg
physic
resourc
staff
materi
fi
nancial
resourc
commiss
prioritis
output
indic
avail
essenti
medicin
public
sector
import
note
propos
indic
measur
ultim
goal
health
system
health
statu
patient
satisfact
indic
howev
contribut
inform
measur
progress
fi
core
area
address
report
pay
essenti
medicin
guarante
aff
ordabl
qualiti
safeti
assur
improv
use
develop
miss
essenti
medicin
rather
assign
specifi
c
indic
recommend
attempt
measur
recommend
comprehens
indic
select
serv
sensit
fl
ag
progress
exampl
indic
relat
market
share
gener
medicin
gaug
extent
progener
polici
implement
promot
aff
ordabl
howev
indic
measur
extent
full
rang
price
polici
implement
third
emphasi
place
select
indic
measur
progress
three
theme
increas
equiti
strengthen
institut
promot
account
final
eff
ect
commiss
recommend
measur
com
pre
hensiv
use
set
multipl
indic
howev
stage
commiss
elect
focu
small
set
core
indic
indic
one
two
specifi
c
aspect
exampl
would
take
sever
indic
demonstr
progress
made
relat
establish
mpp
howev
one
core
indic
two
com
plementari
indic
chosen
repres
sever
other
mani
instanc
measur
disaggreg
essenti
versu
nonessenti
medicin
feasibl
eg
countri
pharmaceut
expenditur
although
commiss
focus
essenti
medicin
measur
medicin
mani
indic
desir
sinc
medicin
consid
essenti
chang
time
likewis
product
qualiti
improv
also
focu
medicin
essenti
medicin
continu
develop
indic
requir
ongo
consult
process
full
rang
relev
stakehold
indic
propos
intermedi
step
longer
process
develop
global
consensu
fi
nal
set
key
indic
particularli
commiss
recognis
need
set
target
nation
level
addit
overarch
target
relat
essenti
medicin
sdg
intern
commun
alreadi
settl
target
diseasespecifi
c
area
exampl
countri
agre
aim
avail
aff
ordabl
basic
technolog
essenti
medicin
includ
gener
requir
treat
major
ncd
panel
summaris
suggest
core
indic
section
addit
list
propos
complementari
indic
present
appendix
fi
indic
select
fi
nanc
essenti
medicin
panel
well
establish
still
lack
compar
comprehens
data
analysi
pharmaceut
expenditur
lmic
nation
health
account
inform
collect
provid
recent
inform
pharmaceut
spend
countri
likewis
world
health
statist
provid
inform
overal
health
expenditur
pharmaceut
expenditur
latest
comprehens
analysi
global
pharmaceut
expenditur
present
data
alreadi
least
year
old
oecd
publish
expenditur
pharmaceut
expenditur
select
countri
given
gener
diffi
culti
measur
pharmaceut
expenditur
countri
unlik
abl
disaggreg
expenditur
essenti
medicin
spend
medicin
percentag
public
expenditur
pharmaceut
could
use
proxi
indic
assum
public
fi
nanc
medicin
prioritis
item
nation
essenti
medicin
list
financ
essenti
medicin
infl
uenc
organis
arrang
ultim
aff
ect
fi
nancial
protect
one
key
goal
health
system
cardin
featur
uhc
one
indic
includ
sethousehold
expenditur
pharmaceut
percentag
total
household
expenditurei
measur
fi
nancial
protect
measur
progress
reduc
dispar
relat
fi
nanc
essenti
medicin
household
expenditur
pharmaceut
percentag
total
household
expenditur
disaggreg
incom
ethnic
educ
geographi
relev
characterist
household
member
live
ncd
sinc
household
data
expenditur
often
separ
data
health
statu
household
member
diffi
cult
meaning
measur
equiti
exist
dataset
indic
fi
nanc
depend
household
survey
obtain
data
household
expenditur
pharmaceut
includ
outofpocket
expenditur
yet
mani
countri
still
lack
routin
collect
nation
repres
household
data
measur
progress
toward
uhc
provid
opportun
integr
indic
wider
sdgmonitor
framework
estim
aff
ordabl
given
set
aggreg
medicin
price
per
time
period
divid
household
incom
per
equival
time
period
eg
wage
lowestpaid
govern
worker
indic
requir
inform
price
pharma
ceutic
data
notori
diffi
cult
captur
lack
transpar
invest
monitor
three
indic
measur
compar
inform
price
medicin
avail
alreadi
use
extens
includ
two
standard
indic
world
health
statist
ensur
inform
price
avail
depend
sever
prerequisit
price
essenti
medicin
must
monitor
regularli
sever
point
along
suppli
chain
procur
price
public
privat
sector
includ
hospit
retail
consumpt
price
individu
product
collect
report
provid
mean
price
ratio
combin
maxim
minim
valu
individu
product
rare
hospit
procur
price
openli
avail
health
insur
fund
play
key
part
collect
publicis
reimburs
price
inform
current
indic
exist
measur
transpar
decis
make
regard
inclus
essenti
medicin
reimburs
procur
list
work
need
done
area
develop
valid
indic
complementari
indic
appendix
includ
relat
transpar
exist
mechan
reveal
confl
ict
interest
member
involv
reimburs
decis
sever
other
measur
degre
inform
result
clinic
trial
inform
reimburs
decis
made
publicli
avail
greater
inform
share
across
institut
would
allow
greater
effi
cienci
avoid
duplic
assess
safeti
effi
caci
howev
action
would
requir
global
nation
standardis
format
report
inform
assur
qualiti
safeti
essenti
medicin
two
core
indic
qualiti
safeti
well
establish
sinc
includ
pharmaceut
countri
profi
le
fi
rst
third
indic
qualiti
safeti
essenti
medicin
section
panel
depend
part
transpar
nmra
provid
data
perform
measur
perform
nmra
hold
account
often
prove
challeng
increas
transpar
nmra
data
includ
provid
access
data
use
nmra
decis
make
safeti
eg
market
intellig
con
sumption
often
proprietari
publicli
access
addit
indic
use
bolster
account
system
nmra
includ
appendix
second
indic
qualiti
safeti
essenti
medicin
section
panel
measur
evolut
whoun
prequalifi
cation
programm
third
indic
section
provid
inform
promot
qualiti
product
procur
ideal
composit
indic
com
prise
diff
erent
dimens
procur
per
formanc
would
use
measur
perform
measur
extent
adher
standard
treatment
guidelin
common
condit
well
establish
indic
qualiti
use
essenti
medicin
addit
wide
use
set
indic
measur
qualiti
prescrib
primari
care
includ
one
standard
indic
includ
set
measur
proport
patient
prescrib
antimicrobi
key
global
prioriti
past
latter
indic
emphasis
acut
condit
condit
taken
consider
futur
expand
includ
chronic
noncommunic
condit
hypertens
diabet
cancer
palli
care
data
medicin
consumpt
disaggreg
sex
age
educ
incom
insur
benefi
ts
among
local
relev
variabl
captur
dispar
access
expert
suggest
use
composit
indic
measur
qualiti
prescrib
could
use
futur
fi
rst
indic
use
medicin
section
panel
relat
crosscut
theme
institut
strengthen
measur
structur
compon
exist
independ
nation
programm
institut
promot
scientifi
calli
sound
costeff
ectiv
use
medicin
second
indic
section
measur
aspect
relat
account
stakehold
represent
fi
rst
two
indic
section
new
would
need
valid
addit
complementari
indic
includ
appendix
measur
commit
transpar
eg
exist
polici
confl
ict
interest
measur
aim
protect
public
knowledg
necessari
restrain
infl
uenc
privatesector
actor
major
interest
develop
public
polici
relat
chang
use
medicin
common
goal
fi
recommend
section
promot
acceler
develop
essenti
medicin
address
crucial
unmet
health
need
two
indic
suggest
measur
progress
develop
miss
essenti
medicin
new
fi
rst
two
recommend
correspond
indic
would
need
develop
institut
howev
institut
atm
foundat
alreadi
use
indic
develop
miss
essenti
medicin
eg
similar
fourth
indic
develop
miss
essenti
medicin
section
panel
atm
index
publish
everi
year
atm
foundat
cover
lead
pharmaceut
compani
measur
perform
compani
yet
includ
atm
index
addit
resourc
requir
expand
scope
index
creat
new
organis
similar
mission
method
howev
secur
longterm
sustain
fi
nanc
independ
organis
must
assur
intern
health
commun
commiss
confi
dent
new
endeavour
creat
independ
account
system
support
global
commun
ensur
crucial
action
taken
protect
invest
made
essenti
medicin
invest
translat
health
develop
without
essenti
medicin
health
system
ensur
popul
serv
progress
realis
right
health
yet
essenti
medicin
polici
receiv
insuffi
cient
attent
sinc
nairobi
confer
report
commiss
present
practic
recommend
enabl
new
era
equiti
strengthen
institut
account
ensur
essenti
medicin
polici
support
uhc
sustain
develop
centuri
contributor
vjw
hvh
alg
develop
propos
commiss
drew
object
commiss
met
three
occas
groningen
london
amsterdam
commission
coauthor
contribut
identifi
cation
key
problem
select
fi
main
topic
review
cochair
commiss
hvh
vjw
alg
plan
coordin
activ
commiss
develop
review
variou
draft
report
prepar
extern
peer
review
vjw
hvh
alg
mrr
review
edit
section
report
commission
review
variou
stage
report
approv
fi
nal
version
introduct
section
hvh
alg
vjw
wrote
fi
rst
subsequ
draft
introduct
input
mrr
section
alg
vjw
wrote
fi
rst
subsequ
draft
section
fi
nanc
essenti
medicin
input
hvh
mrr
cost
model
develop
py
ar
cm
vjw
section
cost
model
draft
cm
input
py
vjw
pn
section
yt
wrote
fi
rst
draft
section
aff
ordabl
essenti
medicin
input
alg
efmth
mae
mrr
alg
substanti
revis
follow
draft
addit
input
vjw
hvh
efmth
mrr
section
lr
hvh
wrote
fi
rst
subsequ
draft
section
qualiti
essenti
medicin
input
vjw
alg
mae
mrr
section
akw
drd
wrote
fi
rst
subsequ
draft
section
promot
qualiti
use
medicin
contribut
sj
vll
pn
hvh
alg
vjw
mrr
provid
input
draft
panel
promot
draft
hvh
substanti
input
mae
section
efmth
hvh
wrote
fi
rst
subsequ
draft
section
r
essenti
medicin
input
bp
alg
mrr
vjw
section
section
written
vjw
substanti
input
mb
mrr
alg
hvh
vjw
hvh
alg
formul
fi
rst
version
propos
indic
account
framework
substanti
input
commission
cpdj
director
essenti
medicin
health
product
april
alg
member
expert
panel
drug
polici
manag
south
african
medicin
control
council
south
african
nation
essenti
medicin
list
committe
hvh
report
person
fee
health
action
intern
access
medicin
index
outsid
submit
work
drd
report
person
fee
access
medicin
research
networkoswaldo
cruz
studi
grant
im
institut
use
fund
novarti
indonesia
poverti
commiss
use
fund
ausaid
univers
indonesia
hacettep
univers
use
fund
novarti
fsg
german
intern
develop
organ
giz
collabor
world
bank
institut
person
fee
nation
univers
singapor
outsid
submit
work
pn
report
pharmaceut
compani
govern
academ
institut
grant
donorsmultilater
organis
outsid
submit
work
efmth
report
person
fee
drug
neglect
diseas
initi
conduct
studi
akw
report
person
fee
geneva
myanmar
countri
offi
ce
grant
univers
indonesia
hacettep
univers
acibadem
univers
use
fund
novarti
grant
im
institut
use
fund
novarti
indonesia
poverti
commiss
use
fund
ausaid
fsg
nation
univers
singapor
giz
world
bank
allianc
health
polici
system
research
global
task
forc
cancer
care
control
harvard
school
public
health
use
fund
pfi
zer
outsid
submit
work
addit
akw
patent
tuft
medic
center
licens
johnson
johnson
topiram
royalti
paid
tuft
medic
center
vjw
report
grant
bill
melinda
gate
foundat
conduct
studi
grant
sandoz
intern
gmbh
manag
scienc
health
outsid
submit
work
py
report
grant
bill
melinda
gate
foundat
conduct
studi
nonfi
nancial
support
merck
mother
merck
serono
outsid
submit
work
author
declar
compet
interest
thought
opinion
express
individu
contributor
alon
necessarili
refl
ect
view
employ
affi
liat
organis
